




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/02, A61K 38/05, 38/06 // C07K 14/60		A1	(11) International Publication Number: WO 96/22997
			(43) International Publication Date: 1 August 1996 (01.08.96)
(21) International Application Number: PCT/DK96/00045		(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).	
(22) International Filing Date: 26 January 1996 (26.01.96)			
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
0099/95 27 January 1995 (27.01.95) DK 0100/95 27 January 1995 (27.01.95) DK 1083/95 28 September 1995 (28.09.95) DK 1084/95 28 September 1995 (28.09.95) DK 1372/95 4 December 1995 (04.12.95) DK			
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).		Published With international search report.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): LAU, Jesper [DK/DK]; Rosenvænget 3, DK-3520 Farum (DK). PESCHKE, Bernd [DE/DK]; Eskebjerggård 56, DK-2760 Måløv (DK). HANSEN, Thomas, Kruse [DK/DK]; Tibbevænget 78, DK-2730 Herlev (DK). JOHANSEN, Nils, Langeland [DK/DK]; Niels W. Gadesgade 45, DK-2100 Copenhagen Ø (DK). ANKERSEN, Michael [DK/DK]; Dalgas Have 34, 1. th., DK-2000 Frederiksberg (DK).			

(54) Title: **COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES**

(57) Abstract

There are disclosed novel synthetic peptides of general formula (I), where the abbreviations A, B, D, E, F, G, J and m, n, p are further defined in the description. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient thereof, methods of stimulating the release of growth hormone as well as use of such compounds of formula (I) are also disclosed.



BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES

FIELD OF INVENTION

The present invention relates to novel compounds, compositions containing them, and their use for treating medical disorders 5 resulting from a deficiency in growth hormone.

BACKGROUND OF THE INVENTION

Growth hormone is a hormone which stimulates growth of all tissues capable of growing. In addition, growth hormone is known to have 10 a number of effects on metabolic processes, e.g., stimulation of protein synthesis and free fatty acid mobilization and to cause a switch in energy metabolism from carbohydrate to fatty acid metabolism. Deficiency in growth hormone can result in a number of severe medical disorders, e.g., dwarfism.

15

Growth hormone is released from the pituitary. The release is under tight control of a number of hormones and neurotransmitters either directly or indirectly. Growth hormone release can be stimulated by growth hormone releasing hormone (GHRH) and 20 inhibited by somatostatin. In both cases the hormones are released from the hypothalamus but their action is mediated primarily via specific receptors located in the pituitary. Other compounds which stimulate the release of growth hormone from the pituitary have also been described. For example arginine, 25 L-3,4-dihydroxyphenylalanine (L-Dopa), glucagon, vasopressin, PACAP (pituitary adenylyl cyclase activating peptide), muscarinic receptor agonists and a synthetic hexapeptide, GHRP (growth hormone releasing peptide) release endogenous growth hormone either by a direct effect on the pituitary or by affecting the 30 release of GHRH and/or somatostatin from the hypothalamus.


In disorders or conditions where increased levels of growth hormone is desired, the protein nature of growth hormone makes anything but parenteral administration non-viable. Furthermore, other directly acting natural secretagogues, e.g., GHRH and PACAP, are longer polypeptides for which reason oral administration of them is not viable.

The use of certain compounds for increasing the levels of growth hormone in mammals has previously been proposed, e.g. in EP 18 072, EP 83 864, WO 89/07110, WO 89/01711, WO 89/10933, WO 88/9780, WO 83/02272, WO 91/18016, WO 92/01711, WO 93/04081, WO 95/17422, WO 95/17423 and WO 95/14666.

The composition of growth hormone releasing compounds is important for their growth hormone releasing potency as well as their bioavailability. It is therefore the object of the present invention to provide compounds with growth hormone releasing properties which have improved properties relative to known peptides of this type.

SUMMARY OF THE INVENTION

Accordingly, the present invention relates to a compound of general formula I




Wherein

n is 0 or 1;

m is 1 or 2;

p is 0, 1 or 2;


5 A is



wherein R¹ is hydrogen or C₁₋₆-alkyl,



W is =O or =S;

B is



wherein R^2 is hydrogen or C_{1-6} -alkyl,
 W' is =O or =S;

D is




5 wherein R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and

10 U is -O-, -S- or a valence bond;

M is -O-, -S-, -CH=CH-,





optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

15 o, r and t are independently 0, 1, 2, 3 or 4;


q and s are independently 0 or 1;

and $r+s+t$ is 1, 2, 3 or 4;

E is hydrogen,




or




wherein L is hydrogen, $-\text{OR}^9$, $-\text{CONR}^9\text{R}^{10}$, C_{1-6} -alkyl optionally substituted with hydroxy or C_{1-6} -alkoxy,

5 or L is



or



wherein R^9 and R^{10} are independently hydrogen, C_{1-6} -alkyl or together form $-(\text{CH}_2)_k-\text{U}'-(\text{CH}_2)_l-$,

wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5 10 or 6,

U' is $-\text{O}-$, $-\text{S}-$ or a valence bond;

X is $-\text{N}(\text{R}^{11})-$, $-\text{O}-$ or $-\text{S}-$,


V is $-\text{C}(\text{R}^{12})=$ or $-\text{N}=$,

Y is $-\text{C}(\text{R}^{13})=$ or $-\text{N}=$,

15 Z is $-\text{C}(\text{R}^{14})=$ or $-\text{N}=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-\text{COOR}^{15}$, $-\text{CONR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_v\text{NR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_u\text{OR}^{15}$, halogen, hydroxy, branched or linear C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl, R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or branched or 20 linear C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is hydrogen or



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} 5 optionally forming $-(\text{CH}_2)_{k'}-\text{Z}-(\text{CH}_2)_{l'}-$ where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;

Z is $-\text{O}-$, $-\text{S}-$ or a valence bond;

b is 0 or 1;


a and d are independently 0, 1, 2, 3 or 4;

10 and $a+b$ is 1 to 4;

Q is $>\text{CR}^{22}-$ or $>\text{N}-$,

wherein R^{22} is hydrogen or C_{1-6} -alkyl,



F is



15 wherein R^{23} is hydrogen or C_{1-6} -alkyl,


W' is $=\text{O}$ or $=\text{S}$;

G is hydrogen,



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

J is




optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

Regarding the above compounds of the general formula I preferred substituents are mentioned in the dependent claims. Furthermore, especially preferred substituents are those mentioned below.

15 Preferred groups of A are




wherein R^1 and W are as defined above.

Preferred groups of R^1 is C_{1-6} -alkyl, and more preferred C_{1-3} -alkyl such as methyl, ethyl, cyclopropyl and isopropyl.

Preferably m is 1 and/or p is 1.


5 Preferred groups of B are



wherein R^2 and W are as defined above.

Preferably R^2 is C_{1-6} -alkyl, and more preferred C_{1-3} -alkyl such as methyl, ethyl, cyclopropyl and isopropyl.


Preferably D is



10 wherein R^5 , R^6 , R^7 , R^8 , M, s, t, q and o are as defined above. Preferably R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 are optionally forming $\text{—}(\text{CH}_2)_i\text{—U—}(\text{CH}_2)_j\text{—}$, wherein U, i and j are as defined above.

Preferably U is a valence bond.

Preferably M is -O-, -CH=CH- or




Preferably o, r and t are independently 0, 1, 2 or 3.


Specifically preferred D is 4-piperidinyl, 3-piperidinyl, 3-aminomethylphenyl, 3-amino-3-methyl-butenyl or 4-amino-4-methyl-pentenyl.

Preferably K is hydrogen.

Preferably F is





or




wherein R²³ is as defined above.

10 Preferably G is




or




The meanings of the above preferred substituents should in no way be construed as limiting the invention to such substituents. Representative compounds of the present invention include the following:


15 3-Aminomethyl-N-((1R, 2E, 4S)-4-carbamoyl-5-(2-naphthyl)-1-(2-naphthyl)methylpent-2-enyl)benzamide:




Piperidine-4-carboxylic acid ((1R,2E,4S)-4-carbamoyl-5-(2-naphthyl)-1-(2-naphthyl)methylpent-2-enyl) amide:




5 N-((1R)-1-((1R)-1-((1S)-5-Amino-1-(dimethylcarbamoyl)pentylcarbamoyl)-2-phenylethoxy)methyl-2-(2-naphthyl)ethyl)-3-aminomethylbenzamide:




N-((1R,4S)-4-(((1S)-5-Amino-1-(dimethylcarbamoyl)pentyl)carbamoyl)-1-((2-naphthyl)methyl)-2-oxo-5-phenylpentyl)-3-aminomethylbenzamide:




N-((1R,2R,4S)-4-(((1S)-5-Amino-1-(dimethylcarbamoyl)pentyl)carbamoyl)-2-hydroxy-1-((2-naphthyl)methyl)-5-phenylpentyl)-3-aminomethylbenzamide:




Piperidine-3-carboxylic acid ((1R, 2R, 4S)-4-(((1S)-5-amino-1-(dimethylcarbamoyl)pentyl)carbamoyl)-2-hydroxy-1-(2-naphthyl)methyl)-5-phenylpentyl)amide:




5 5-((1R)-1-(N-Methyl-N-((2R)-3-(2-naphthyl)-2-(piperidine-4-carbonylamino)propionyl)amino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester:



5-((1R)-1-(N-((2R)-2-(3-Aminomethylbenzoylamino)-3-(2-10 naphthyl)propionyl)-N-methylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester:



5-((1R)-1-(N-((2R)-2-(3-Aminomethylbenzoylamino)-3-(2-naphthyl)propionyl)-N-methylamino)-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid amide:



It is believed that compounds of formula I exhibit an improved resistance to proteolytic degradation by enzymes because they are non-natural, in particular because the natural amide bonds are replaced by non-natural amide bond mimetics. The increased resistance to proteolytic degradation combined with the reduced size of the compounds of the invention in comparison with known growth hormone releasing peptides is expected to improve their bioavailability compared to that of the peptides suggested in the prior literature.

In the above structural formulas and throughout the present specification, the following terms have the indicated meanings:

The C₁₋₆-alkyl groups specified above are intended to include those alkyl groups of the designated length in either a linear or
5 branched or cyclic configuration. Examples of linear alkyl are methyl, ethyl, propyl, butyl, pentyl and hexyl. Examples of branched alkyl are isopropyl, sec-butyl, tert.-butyl, isopentyl and isohexyl. Examples of cyclic alkyl are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

- 10 Especially preferred C₁₋₆-alkyl groups are the C₁₋₃-alkyl groups. Preferred C₁₋₃-alkyl groups are methyl, ethyl, isopropyl and cyclopropyl.

The C₁₋₆-alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a linear
15 or branched or cyclic configuration. Examples of linear alkoxy are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, ter.-butoxy, isopentoxy and isohexoxy. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

- 20 Especially preferred C₁₋₆-alkoxy groups are the C₁₋₃-alkoxy groups. Preferred C₁₋₃-alkoxy groups are methoxy, ethoxy, isopropoxy and cyclopropoxy.

The C₁₋₆-alkylamino groups specified above are intended to include those alkylamino groups of the designated length in either a
25 linear or branched or cyclic configuration. Examples of linear alkylamino are methylamino, ethylamino, propylamino, butylamino, pentylamino and hexylamino. Examples of branched alkylamino are isopropylamino, sec-butylamino, tert.-butylamino, isopentylamino

and isohexylamino. Examples of cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino and cyclohexylamino.

Especially preferred C₁₋₆-alkylamino groups are the C₁₋₃-alkylamino groups. Preferred C₁₋₃-alkylamino groups are methylamino, ethylamino, isopropylamino and cyclopropylamino.


In the present context, the term "aryl" is intended to include aromatic rings, such as carbocyclic and heterocyclic aromatic rings selected from the group consisting of phenyl, naphthyl, pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, quinoline, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxalyl, thiopheneyl, quinolinyl, pyrazinyl or isothiazolyl, optionally substituted by one or more C₁₋₆-alkyl, C₁₋₆-alkoxy, aminohalogen or aryl. Aryl is preferably phenyl, thienyl, imidazolyl, pyridyl, indolyl or naphthyl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy. The term "halogen" is intended to include Cl, F, Br and I.

The compounds of the present invention may have one or more asymmetric centres and it is intended that stereoisomers, as separated, pure or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the invention.

Compounds of the present invention may be prepared from natural and unnatural amino acid residues as described in the following general methods A to E, and where the starting amino acids can be prepared as known in the art:

General Method A


Reaction Scheme I:



Compounds of formula I may be prepared as shown in reaction scheme I starting with an appropriate N-protected amino acid which can be converted to sulfone 1 using a known procedure (e.g. Spaltenstein, J. Org. Chem. 1987, 52, 3759). The other starting material 2 may be prepared from dimethyl malonate and an aromatic alkyl halide followed by reduction by LiAlH_4 , monosilylation with TBDMS and oxidation to aldehyde 2 under Swern conditions according to a known procedure (e.g. Jenmalm, J. Org. Chem 1994, 59, 1139). The reaction between 2 and 1 may be effected by strong base e.g. BuLi in an appropriate solvent e.g. THF followed by reductive conditions (e.g. sodium amalgam) and removal of the silyl protecting group by methods known in the art (e.g. T. W. Greene, Protective Groups in Organic Synthesis, 2nd Ed. John Wiley and Sons 1991) to give alkene 3. These steps can either be carried out one-pot or sequentially. The intermediate 3 may be oxidized by e.g. Jones reagent to a carboxylic acid 4 which may be converted to an amide 5 by treatment with e.g. thionyl chloride and ammonia. Compound 5 may finally be reacted with a protected amino acid using a suitable condensing agent (e.g. DCC) and deprotected by methods which are described by e.g. T.W. Greene (Protective Groups in Organic Chemistry, 2.ed. John Wiley and Sons, 1991) to form compound 6 which is a compound of formula I.

General Method B


Reaction Scheme II



Compound of formula I may be prepared as shown in reaction scheme II starting with the synthesis of intermediate 10 using the procedure of e.g. A. E. DeCamp et al. (Tetrahedron Letters, 1991, 32, 1867 - 1870.): The titanium-homoenolate 9 may be generated 5 from 3-iodopropionic acid 8 and added onto a suitable aldehyde 7. A cyclization in e.g. acetic acid may furnish the lactone 11. Alkylation of the lactone may be done as described by e.g. A. H. Fray et al. (J. Org. Chem., 1986, 51, 4828 - 4833). The enolate may be generated by treatment with base such as lithium 10 hexamethyldisilazane (LHDS) or Lithium diisopropylamide (LDA) and reacted with a suitable alkylating reagent such as alkylchloride to give a compound of type 12. The lactone may be transferred into a silyl-protected hydroxy acid 13 as described by e.g. A. H. Fray et al (J. Org. Chem., 1986, 51, 4828 - 4833). Coupling with an 15 amine, which may contain amino protective groups as e.g. phthalimido or FMOC, by reaction with EDAC and HOBT may give an amide of type 14. Deprotection of the amino group using procedures known in the art (e.g. T.W. Greene, Protective Groups in Organic Chemistry, 2.ed. John Wiley and Sons 1991) is followed by coupling 20 to a suitable acid, which may include a protection group, by reaction with e.g. EDAC and HOBT to give a compound of type 16. Finally, protection groups on the variable fragments may be removed by methods described in the art (e.g. T. W. Greene, Protective Groups in Organic Synthesis, 2nd. edition, John Wiley 25 and Sons, New York 1991.) to give the final product 17 which is a compound of formula I.

General Method C


Reaction Scheme III:



Compounds of formula I may be prepared as shown in scheme III starting with deprotection of an amide of type 14 by reaction with e.g. tetrabutylammonium fluoride and subsequent oxidation with a suitable reagent such as PCC or PDC to give a compound 19. The amino group may be deprotected with e.g. hydrochloric acid in ethyl acetate followed by coupling with a suitable acid which may contain a protection group. Finally, protection groups on the variable fragments may be removed by methods described in the art (e.g. T. W. Greene, Protective Groups in Organic Synthesis, 2nd. edition, John Wiley and Sons, New York 1991.) to give the final product 20 which is a compound of formula I.

General Method D

Reaction Scheme IV:



Compounds of formula I may be prepared as shown in scheme IV starting with an amino-alcohol of type 21 which may be reacted with chloroacetyl chloride as described in the literature by e.g. E. D. Nicolaides et al. (J. Med. Chem. 1986, 29, 959 - 971.).

5 Reaction with a base such as sodium hydride in THF may furnish a morpholinone 23 which can be alkylated by using a base such as LDA or LHDS and subsequent addition of a suitable alkylating reagent such as alkyl chloride. After separation of diastereoisomeres, the ring can be opened by reaction with acid as described by e.g. R.


10 E. TenBrink (J. Org. Chem. 1987, 52, 418 - 422.) and the amino-group can be protected to give a compound 25. The E-fragment, that may contain protected functionalities, can be attached by reaction of a suitable amine using e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) and 1-hydroxybenzotriazole

15 (HOBt). The amino group in 26 can be deprotected by suitable conditions, such as hydrogen chloride in ethyl acetate, and reacted with a suitable acid, that may contain protection groups, EDAC, and HOBt. Removal of all protection groups by methods described in the art (e.g. T. W. Greene, Protective Groups in

20 Organic Synthesis, 2nd. edition, John Wiley and Sons, New York 1991.), may yield the final product 28 which is a compound of general formula I.

General Method E

Reaction Scheme V:




Compounds of formula I may be prepared as shown in reaction scheme 5 V starting with an N-protected amino acid **29** which may be activated with, e.g. EDAC and then reacted with an amido oxime **30** in e.g. pyridine using a known procedure (e.g. J. Heterocyclic Chem. 1989, 26, 125) to give 1,2,4-oxadiazole derivative **31**. After deprotection of the amino group using methods known in the art and 10 described by e.g. T.W. Greene (Protective Groups in Organic

Synthesis, 2. ed. John Wiley and Sons 1991) the compound can be reductive alkylated using an aldehyde and a mild reducing reagent, such as sodium cyanoborohydride to give the desired intermediate 33. Further reaction of 33 with an N-protected natural or 5 unnatural amino acid 34 using peptide coupling methodologies as described in the art (e.g. DCC coupling in DMF) can give intermediate 35, which after deprotection with e.g. hydrochloric acid in an appropriate solvent, such as ethyl acetate can be coupled with another N-protected aminoacid 37 using a known 10 peptide coupling methodology such as DCC coupling in DMF to give an intermediate which after deprotection of the amino group with e.g. hydrochloric acid in an appropriate solvent, such as ethyl acetate can give the desired product 38 which is a compound of formula I. When R^{12} is a functional group (e.g. an ester) this 15 group may be derivatized at an appropriate step in the reaction sequence.

General method F:

Scheme VI




A compound of formula I may be prepared as shown in scheme V 5 starting with lactone **40** which may be reacted with ammonia to give the amide **41**. A reaction under Mitsunobu conditions as described by M. S. Manhas et al. (J. Chem. Soc. Perkin Trans I, 1975, 461 - 463.) may give an ether **42** which may be deprotected under acidic conditions. Coupling with a suitable acid, that might contain a 10 protected functionality, may give a compound of type **43**, which may be deprotected by methods described in the art (e.g. T. W. Greene, Protective Groups in Organic Synthesis, 2nd. edition, John

Wiley and Sons, New York 1991.) to give the final product **44** which is a compound of formula I.

General Method G

Scheme VII



A compound of formula I may be prepared as shown in scheme VII, starting with an amino acid 45, which may be acylated with e.g. an acid anhydride and - after work up - may be subsequently reduced with e.g. diborane, sodium borohydride/iodine or lithium aluminumhydride as described by e.g. M. J. McKennon et. al. (J. Org. Chem, 1993, 58, 3568 - 3571) in an appropriate solvent such as THF, diethylether, dioxane or hydrocarbons to give an aminoalcohol 46. It may be protected with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991), with e.g. di-tert-butoxy dicarbonate or benzoylcarbonyl chloride to give the protected alcohol 47. A reaction with ethyl diazoacetate under rhodium acetate catalysis (preferentially 0.01 - 15%) as described by e.g. J. Hlaváček and V. Král (Collect. Czech. Chem. Commun., 1992, 57, 525 - 530) may furnish the ester 48. The ester may be saponified with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) with bases such as lithium hydroxide or potassium hydroxide to give the acid 49, which may be activated by e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogenchloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogenchloride and 1-hydroxy-benzotriazole or 1-hydroxy-7-azabenzotriazole and reacted with an amine 50 to give an amide 51. The amino group in 51 may be deprotected by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) e.g. hydrogen chloride in ethyl acetate or trifluoroacetic acid. An acid 34a may be activated by e.g. 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrogenchloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogenchloride and 1-hydroxy-benzotriazole or 1-hydroxy-7-azabenzotriazole and reacted in an appropriate solvent such as e.g. DMF or dichloromethane with 52 to give the amide 53. The

amine-protection group may be removed by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) such as e.g. hydrogenchloride in ethyl acetate or trifluoroacetic acid.


5 A protected acid 37 may be activated by e.g. 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrogenchloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogenchloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole and may be reacted with the amine 54 in an

10 appropriate solvent such as DMF or dichloromethane to give - after deprotection by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) such as e.g. hydrogen chloride in ethyl acetate or trifluoroacetic acid - 55, which is a compound of

15 formula I.

General Method H
Scheme VIII

31




A compound of formula I may be prepared as shown in scheme VIII, starting with an amino acid 56. As described by e.g. S. Borg et al. (J. Org. Chem. 1995, 60, 3112 - 3120.) 56 may be transformed into an ester 57 by e. g. reaction with ethanol in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 4-dimethylaminopyridine, which may be subsequently reacted with hydrazine hydrate to give the hydrazide 58. The ester 60 may be obtained from 58 by reaction with ethyl oxalyl chloride (59) in the presence of a base such as e.g. triethylamine. The ring closure may proceed e.g. with thionyl chloride/pyridine and subsequent heat, furnishing and [1,3,4]oxadiazole 61. The amide 62 may be obtained by aminolysis of the ester moiety in e.g. liquid ammonia. Deprotection of the amino group by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991.) e. g. hydrogen chloride in ethyl acetate or trifluoroacetic acid may furnish the amine 63. A suitable protected amino acid 34a may be coupled to 63 using a coupling reagent known in the art such as e.g. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride or a combination of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to give 64. A deprotection, carried out with a method known in the art and described by e.g. T. W. Green (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991.) e. g. hydrogen chloride in ethyl acetate or trifluoroacetic acid, may furnish the amine 65. This may be coupled with a coupling reagent known in the art such as e.g. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride or a combination of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole with a suitable protected amino acid 37 to give - after deprotection with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991.) e. g. hydrogen chloride

in ethyl acetate or trifluoroacetic acid - 66, which is a compound of formula I.

General Method J

Scheme IX




A compound of formula I may be prepared as shown in scheme IX, starting with a suitable protected amino alcohol e.g. 47, which may be oxidized by methods known in the art with reagents such as e.g. DMSO/oxalyl chloride/triethylamine (A. E. DeCamp, A. T. Kawaguchi, R. P. Volante, I. Shinkai, Tetrahedron Letters, 1991, 32, 1867 - 1870; J. R. Luly, J. F. Dellaria, J. J. Plattner, J. L. Soderquist, N. Yi, J. Org. Chem. 1987, 52, 1487 - 1492.) or DMSO/sulfur(IV)oxide pyridinium complex/triethylamine (J. S. Ng, C. A. Przybyla, C. Liu, J. C. Yen, F. W. Muellner, C. L. Weyker, Tetrahedron 1995, 51, 6397 - 6410; P. L. Beaulieu, D. Wernic, J.-S. Duceppe, Y. Guindon, Tetrahedron Letters, 1995, 36, 3317 - 3320.) to give the aldehyde 67. The aldehyde might be reacted with a Grignard reagent, e.g. allylmagnesium bromide to give an unsaturated compound 68. A hydroboration with e.g. 9-borabicyclo[3.3.1]nonane and subsequent treatment with hydrogen peroxide and sodium hydroxide may furnish the diol 69. The amino group may be deprotected with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) by reaction with e.g. hydrogen chloride in ethyl acetate or trifluoro acetic acid to give 70. A suitable protected amino acid 34a may be coupled to 70 using a coupling reagent known in the art such as e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole in an appropriate solvent such as e.g. DMF or dichloromethane to give 71. A deprotection carried out with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) e.g. trifluoro acetic acid may furnish the amine 72. A suitable protected amino acid 37 may be coupled to 72 with a coupling reagent known in the art such as e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride or a combination

of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole in an appropriate solvent such as e.g. DMF or dichloromethane to give - after deprotection with a method known in the art and described 5 by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) by reaction with e.g. trifluoro acetic acid - 73. 73 may be saponified by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) 10 by reaction with e.g. potassium hydroxide or sodium hydroxide to give 74, which is a compound of formula I.

General Method K


Scheme X



The ether 48 may be reduced with a method known in the art e.g. lithium boronhydride, sodium borohydride, or diisobutylaluminum hydride to give an alcohol 75. The amino group may be deprotected by a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) by reaction with e.g. hydrogen chloride in ethyl acetate or trifluoro acetic acid to give the amine 76. A suitable protected amino acid 34a may be coupled to 76 using a coupling reagent known in the art such as e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole in an appropriate solvent such as e.g. DMF or dichloromethane to give 77. A deprotection carried out with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) e.g. trifluoro acetic acid or hydrogen chloride in ethyl acetate may furnish the amine 78. A suitable protected amino acid 37 may be coupled to 78 with a coupling reagent known in the art such as e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid hydrochloride and 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole in an appropriate solvent such as e.g. DMF or dichloromethane to give - after deprotection with a method known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) by reaction with e.g. trifluoro actic acid - 79, which is a compound of formula I. To enhance the yield, it may be feasible to subject the crude product to a saponification with reagents known in the art and described by e.g. T. W. Greene (Protective Groups in Organic Synthesis, 2. ed., John Wiley and Sons, New York 1991) such as e.g. potassium hydroxide in methanol to cleave esters, that may have formed during the amide coupling steps.

General Method L


Scheme XI



Thioamides **81** can be incorporated by the same methods as in method K. They can be made from the corresponding amides **80** by the action of Lawesson's reagent (LR). This methodology is described in S. Scheiby, B. S. Pedersen, S.O. Lawesson, Bull. Chim. Soc. Belg., 1978, 229-38.


General Method M

10 Scheme XII



Tetrazole analogs 83 of amides 82 can be incorporated by much the same methods as in method K. They may be prepared by the action of triphenylphosphine, diethylazodicarboxylate and trimethylsilylazide on amides like 82. This methodology is 5 described in J. V. Dunica, M. E. Pierce, J. B. Santella III, J. Org. Chem. 1991, 56, 2395-2400.

General Method N
Scheme XIII



Thiazoles **89** may be incorporated by the same methodology as in
 5 method F. **89** may be synthesized by acylation of the imine **84** using
 a strong base such as potassium tert butoxide or lithium
 diisopropylamide and an acylating reagent such as an acid chloride
85. The resulting 3-keto-aminoacid **86** could be coupled to the
 dipeptide **88** by known methods such as the asymmetrical anhydride
 10 method using a reagent such as isobutylchloroformate as coupling
 agent. The dipeptide **88** could be cyclised by a number of methods
 e.g. with Lawessons reagent (LR) to give the desired thiazoles **89**.
 This methodology has been described in T. D. Gordon, J. Singh, P.
 H. Hansen, B. A. Morgan, Tett. Lett., 1993, 1901-1904.

Pharmaceutically acceptable acid addition salts of compounds of formula I include those prepared by reacting the compound with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, acetic, phosphoric, lactic, maleic, phthalic, citric, 5 glutaric, gluconic, methanesulfonic, salicylic, succinic, tartaric, toluenesulfonic, trifluoroacetic, sulfamic or fumaric acid.

In another aspect, the present invention relates to a pharmaceutical composition comprising, as an active ingredient, 10 a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as 15 described in Remington's Pharmaceutical Sciences, 1985. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

20 The pharmaceutical carrier or diluent employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, 25 peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.

Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate 30 or glyceryl distearate, alone or mixed with a wax.

If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatin capsule in

powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, 5 soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet which may be prepared by conventional tableting techniques may contain:

10 Core:

Active compound (as free compound or salt thereof)	100mg
Colloidal silicon dioxide (Aerosil)	1.5mg
Cellulose, microcryst. (Avicel)	70mg
Modified cellulose gum (Ac-Di-Sol)	7.5mg

15 Magnesium stearate

Coating:

HPMC approx.	9mg
*Mywacett 9-40 T approx.	0.9mg

20 *Acylated monoglyceride used as plasticizer for film coating.

For nasal administration, the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. 25 propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.

Generally, the compounds of the present invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient

together with a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is suitably 0.1-500 mg/day, e.g. from about 5 to about 50 mg, such as about 10 mg per dose, when administered to patients, e.g. humans, as a drug.

It has been demonstrated that compounds of the general formula I possess the ability to release endogenous growth hormone in vivo. The compounds may therefore be used in the treatment of conditions which require increased plasma growth hormone levels such as in growth hormone deficient humans or in elderly patients or livestock.

Thus, in a particular aspect, the present invention relates to a pharmaceutical composition for stimulating the release of growth hormone from the pituitary, the composition comprising, as an active ingredient, a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

In a further aspect, the present invention relates to a method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula I or a pharmaceutically acceptable salt thereof.

In a still further aspect, the present invention relates to the use of a compound of the general formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulating the release of growth hormone from the pituitary.

To those skilled in the art, it is well known that the current and potential uses of growth hormone in humans are varied and multitudinous. Thus, compounds of formula I can be administered for purposes stimulating release of growth hormone from the
5 pituitary and would then have similar effects or uses as growth hormone itself. The uses of growth hormone may be summarized as follows: stimulation of growth hormone release in the elderly; prevention of catabolic side effects of glucocorticoids, prevention and treatment of osteoporosis, stimulation of the
10 immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting from growth retardation, treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic
15 illness, treatment of obesity and growth retardation associated with obesity, treating growth retardation associated with the Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients; treatment of intrauterine growth retardation, skeletal dysplasia,
20 hypercortisolism and Cushing's syndrome; induction of pulsatile growth hormone release; replacement of growth hormone in stressed patients, treatment of osteochondrodysplasias, Noonan's syndrome, schizophrenia, depressions, Alzheimer's disease, delayed wound healing and psychosocial deprivation, treatment of pulmonary
25 dysfunction and ventilator dependency, attenuation of protein catabolic responses after major surgery, reducing cachexia and protein loss due to chronic illness such as cancer or AIDS; treatment of hyperinsulinemia including nesidioblastosis, adjuvant treatment for ovulation induction; to stimulate thymic development
30 and prevent the age-related decline of thymic function, treatment of immunosuppressed patients, improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal homeostasis in the frail elderly, stimulation of osteoblasts, bone remodelling and cartilage growth, stimulation

of the immune system in companion animals and treatment of disorder of aging in companion animals, growth promoter in livestock and stimulation of wool growth in sheep.

For the above indications the dosage will vary depending on the compound of formula I employed, on the mode of administration and on the therapy desired. However, generally dosage levels between 0.0001 and 100 mg/kg body weight daily are administered to patients and animals to obtain effective release of endogenous growth hormone. Usually, dosage forms suitable for oral, nasal, 10 pulmonal or transdermal administration comprise from about 0.0001 mg to about 100 mg, preferably from about 0.001 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.

15 The compounds of formula I may be administered in pharmaceutically acceptable acid addition salt form or, where appropriate, as a alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.

20 Optionally, the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more compounds exhibiting a different activity, e.g., an antibiotic or other pharmacologically active material.

25 The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral, the oral route being preferred.

Apart from the pharmaceutical use of the compounds of formula I, 30 they may be useful in vitro tools for investigating the regulation of growth hormone release.

Compounds of formula I may also be useful in vivo tools for evaluating the growth hormone releasing capability of the pituitary. For example, serum samples taken before and after 5 administration of these compounds to humans can be assayed for growth hormone. Comparison of the growth hormone in each serum sample would directly determine the ability of the patients pituitary to release growth hormone.

10 Compounds of formula I may be administered to commercially important animals to increase their rate and extent of growth, and to increase milk production.

A further use of growth hormone secretagogue compounds of formula 15 I is in combination with other secretagogues such as GHRP (2 or 6), GHRH and its analogues, growth hormone and its analogues or somatomedins including IGF-1 and IGF-2.

Pharmacological Methods

20 Compounds of formula I may be evaluated in vitro for their efficacy and potency to release growth hormone in rat pituitary primary cultures.

The isolation of rat pituitary cells is a modification of O. Sartor et al., Endocrinology 116, 1985, pp. 952-957. Male albino 25 Sprague-Dawley rats (250 +/- 25 grams) were purchased from Møllegaard, Lille Skensved, Denmark. The rats were housed in group cages (four animals/cage) and placed in rooms with 12 hour light cycle. The room temperature varied from 19-24°C and the humidity from 30 - 60%.

30 The rats were decapitated and the pituitaries dissected. The neurointermediate lobes were removed and the remaining tissue was immediately placed in icecold isolation buffer (Gey's medium

(Gibco 041-04030) supplemented with 0.25% D-glucose, 2% non-essential amino acids (Gibco 043-01140) and 1% bovine serum albumine (BSA) (Sigma A-4503)). The tissue was cut into small pieces and transferred to isolation buffer supplemented with 3.8 5 mg/ml of trypsin (Worthington #3707 TRL-3) and 330 µg/ml of DNase (Sigma D-4527). This mixture was incubated at 70 rotations/min for 35 min at 37°C in a 95/5% atmosphere of O₂/CO₂. The tissue was then washed three times in the above buffer. Using a standard pasteur pipet, the tissue was then aspirated into single cells. After 10 dispersion, cells were filtered through a nylon filter (160 µm) to remove undigested tissue. The cell suspension was washed 3 times with isolation buffer supplemented with trypsin inhibitor (0.75 mg/ml, Worthington #2829) and finally resuspended in culture medium; DMEM (Gibco 041-01965) supplemented with 25 mM HEPES 15 (Sigma H-3375), 4 mM glutamine (Gibco 043-05030H), 0.075% sodium bicarbonate (Sigma S-8875), 0.1% non-essential amino acid, 2.5% fetal calf serum (FCS, Gibco 011-06290), 3% horse serum (Gibco 034-06050), 10% fresh rat serum, 1 nM T₃ (Sigma T-2752) and 40 µg/L dexamethasone (Sigma D-4902) pH 7.3, to a density of 2 x 10⁵ 20 cells/ml. The cells were seeded into microtiter plates (Nunc, Denmark), 200 µl/well, and cultured for 3 days at 37°C and 8% CO₂.

Compound testing

After culturing, the cells were washed twice with stimulation buffer (Hanks Balanced Salt Solution (Gibco 041-04020) 25 supplemented with 1% BSA (Sigma A-4503), 0.25% D-glucose (Sigma G-5250) and 25 mM HEPES (Sigma H-3375) pH 7.3) and preincubated for 1 hour at 37°C. The buffer was exchanged with 90 µl stimulation buffer (37°C). Ten µl test compound solution was added and the plates were incubated for 15 min at 37°C and 5% CO₂. The 30 medium was decanted and analyzed for GH content in an rGH SPA test system.

All compounds were tested in doses ranging from 10 pM to 100 μ M. A dose-response relation was constructed using the Hill equation (Fig P, Biosoft). The efficacy (maximal GH released, E_{max}) was expressed in % of the E_{max} of GHRP-6. The potency (EC_{50}) was determined as the concentration inducing half maximal stimulation of the GH release.

Compounds of formula I may be evaluated for their metabolic stability.

Compounds were dissolved at a concentration of 1 μ g/ μ l in water. 10 25 μ l of this solution is added to 175 μ l of the respective enzyme-solution (resulting in an enzyme:substrate ratio (w/w) of approximately 1:5). The solution is left at 37°C overnight. 10 μ l of the various degradation solutions is analyzed against a corresponding zero-sample using flow injection electrospray mass spectrometry (ESMS) with selected ion monitoring of the molecular ion. If the signal has decreased more than 20% compared to the zero-sample, the remainder of the solution is analyzed by HPLC and mass spectrometry in order to identify the extent and site(s) of degradation precisely.

20 Several standard peptides (ACTH 4-10, Angiotensin 1-14 and Glucagon) have been included in the stability tests in order to verify the ability of the various solutions to degrade peptides.

Standard peptides (angiotensin 1-14, ACTH 4-10 and glucagon) were purchased from Sigma, MO, USA)

25 Enzymes (trypsin, chymotrypsin, elastase aminopeptidase M and carboxypeptidase Y and B) were all purchased from Boehringer Mannheim GmbH (Mannheim, Germany)

Pancreatic enzyme mix: trypsin, chymotrypsin and elastase in 100 mM ammoniumbicarbonate pH 8.0 (all concentrations 0.025 μ g/ μ l).

Carboxypeptidase mix: carboxypeptidase Y and B in 50 mM ammoniumacetate pH 4.5 (all concentrations 0.025 $\mu\text{g}/\mu\text{l}$).

Aminopeptidase M solution: aminopeptidase M (0.025 $\mu\text{g}/\mu\text{l}$) in 100 mM ammoniumbicarbonate pH 8.0

- 5 Mass spectrometric analysis was performed using two different mass spectrometers. A Sciex API III triple quadrupole LC-MS instrument (Sciex instruments, Thornhill, Ontario) equipped with an electrospray ion-source and a Bio-Ion 20 time-of-flight Plasma Desorption instrument (Bio-Ion Nordic AB, Uppsala, Sweden).
- 10 Quantification of the compounds (before and after degradation) was done on the API III instrument using single ion monitoring of the molecular ion in question with flow injection of the analyte. The liquid flow (MeOH:water 1:1) of 100 $\mu\text{l}/\text{min}$ was controlled by an ABI 140B HPLC unit (Perkin-Elmer Applied Biosystems Divisions,
- 15 Foster City, CA). The instrument parameters were set to standard operation conditions, and SIM monitoring was performed using the most intense molecular ion (in most cases this corresponded to the doubly charged molecular ion).

- Identification of degradation products furthermore involved the
- 20 use of plasma desorption mass spectrometry (PDMS) with sample application on nitrocellulose coated targets and standard instrumental settings. The accuracy of the hereby determined masses is generally better than 0.1%.

- Separation and isolation of degradation products was done using
- 25 a HY-TACH C-18 reverse phase 4.6x105 mm HPLC column (Hewlett-Packard Company, Palo Alto, CA) with a standard acetonitril: TFA separation gradient. The HPLC system used was HP1090M (Hewlett-Packard Company, Palo Alto, CA).

5

Peptide derivative	MW/SIM ion (amu)	Carboxy-peptidase mix	Pen. enzyme mix
Standards			
ACTH 4-10	1124.5/562.8	+	-
Glucagon	3483/871.8	-	-
Insulin (B23-29)	859.1/430.6		
Angiotensin 1-14	1760.1/881.0	-	-
GHRP-2	817.4/409.6	-	-
GHRP-6	872.6/437.4	-	-

10 +: Stable (less than 20% decrease in SIM signal after 24 h in degradation solution)

-: Unstable (more than 20% decrease in SIM signal after 24 h in degradation solution)

Any novel feature or combination of features described herein is considered essential to this invention.

EXAMPLES:

The process for preparing compounds of formula I and preparations containing them is further illustrated in the following examples, which however, are not to be construed as limiting.

5 The structures of the compounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (δ) are given in parts per million (ppm) and only selected peaks are given. mp is melting point and is given in °C. Column chromatography was carried out using the
10 technique described by W.C. Still et al, J. Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.

Abbreviations:

15 TLC: thin layer chromatography
DMSO: dimethylsulfoxide
min: minutes
h: hours

ESMS = Electro Spray Mass Spectrometry

20 PDMS = Plasma Desorption Mass Spectrometry

HPLC-Analysis:

Method a.

The RP-HPLC analysis was performed using UV detection at 254nm and a Lichrosorp RP-18 5 μ M column, which was eluted at 1ml/minute. Two

25 solvent systems were used:

Solvent system I: 0.1% Trifluoroacetic acid in acetonitrile.

Solvent system II: 0.1% Trifluoroacetic acid in water.

The column was equilibrated with a mixture composed of 20% of solvent system I and 80% of solvent system II. After injection of


the sample a gradient of 20% to 80% of solvent system I in solvent system II was run over 30 min. The gradient was then extended to 100% of solvent system I over 5 min. followed by isocratic elution with 100% of this system for 6 min.

5 Method b.

The RP-analysis was performed using UV detections at 214, 254, 276, and 301 nm on a 218TP54 4.6 mm x 250 mm 5 μ C-18 silica column (The Separations Group, Hesperia), which was eluted at 1 mL/min at 42°C. The column was equilibrated with 5% acetonitrile in a 10 buffer consisting of 0.1 M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid. After injection the sample was eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min.


15 Example 1

(3R)-Piperidine 3-carboxylic acid [(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]amide:



20 Prepared according to method E.

(R) [1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamic acid tertbutyl ester:



1,3-Dicyclohexylcarbodiimide (10.1g, 49mmol) was dissolved in 5 dichloromethane (100ml) and added to a solution of (R) N-tert-butoxycarbonyl-phenylalanine (10.0g, 37.7mmol) in dichloromethane (250ml) at 0-5°C. The reaction mixture was heated to 20°C and stirred at this temperature for 1h. Acetamide oxime (3.63g, 49mmol) was suspended in pyridine (200ml) and N,N-10 dimethylformamide (40ml) and added to the reaction mixture. The dichloromethane was evaporated and the reaction mixture was heated at reflux temperature for 18h. The reaction mixture was cooled to 0°C and filtered. The filtrate was diluted with ethyl acetate (100ml) and washed with aqueous citric acid (10%, 3x50ml) and 15 water (3x50ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and crystallized from ethyl acetate and heptane to give 5.48g of (R) [1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamic acid tertbutyl ester.


20 mp 94-98°C

¹H-NMR (DMSO-d₆) δ 1.30(s, 9H); 2.32(s, 3H); 4.90-5.10(m, 1H); 7.15-7.30(m, 5H).

HPLC: R_t = 26.7 min (Method a)

(R) 1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylamine

hydrochloride:




(R) [1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamic acid tertbutyl ester (2.4g, 7.9mmol) was dissolved in a saturated solution of hydrogen chloride in ethyl acetate (40ml). After 5h at 20°C the reaction mixture was concentrated in vacuo. The residue was crystallized from ethyl acetate to give 2.05g of (R) 1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylamine hydrochloride.

10 m.p. 144-148°C.

¹H-NMR (DMSO-d₆) δ 2.35(s, 3H); 3.21(dd, 1H); 3.49(dd, 1H); 5.05(dd, 1H); 7.13-7.35(m, 5H).

HPLC: R_t = 9.2 min (Method a)

((1R)-1-((1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbonyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (6.3g, 32.9mmol) and 1-hydroxybenzotriazole monohydrate (5.0g, 32.9mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)-alanine (10.4g, 32.9mmol) in N,N-dimethylformamide (140ml). After 1h at 20°C a mixture of 1-(3-methyl-[1,2,4]oxadiazole-5-yl)-2-phenylethylamine hydrochloride (5.6g, 23.5 mmol) and triethylamine (2.37g, 23.5mmol) in N,N-dimethylformamide (100ml) were added. After 18h at 20°C the reaction mixture was poured onto water (1.4L) and extracted several times with ethyl acetate (total 1.4L). The combined organic phases were washed with aqueous citric acid (10%, 200ml), a saturated solution of sodium hydrogencarbonate (200ml) and water (3x200ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and crystallized from ethyl acetate and heptane to give 9.45g of ((1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbonyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester.

m.p. 148-150°C.

¹H-NMR (DMSO-d₆) δ 1.25(s, 9H); 2.29(s, 3H); 4.25-4.35(m, 1H); 5.25-5.35 (s, 1H); 7.15-7.85 (m, 12H).


HPLC: R_t = 29.6 min (Method a)

Calculated for C₂₉H₃₂N₄O₄:

C, 69.58; H, 6.44; N, 11.19%; found:

C, 69.40; H, 6.65; N, 10.93%.

(2R)-2-Amino-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide hydrochloride:



((1R)-1-((1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester (4.5g, 8.99mmol) was suspended in ethyl acetate (50ml) and a saturated mixture of hydrogen chloride in ethyl acetate (45ml) was added. After 3h at 20°C, the reaction mixture was filtered to give 3.17g of (2R)-2-amino-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide hydrochloride.

mp 197-199°C.

¹H-NMR (DMSO-d₆) δ 2.28(s, 3H); 3.15-3.35(m, 4H); 4.15(t, 1H); 5.35(q, 1H); 7.20-7.90(m, 12H).


15 HPLC: R_t = 18.5 min (Method a)

Calculated for C₂₄H₂₄N₄O₂·HCl:

C, 65.97; H, 5.77; N, 12.82%; found:

C, 66.20; H, 5.90; N, 12.57%.

(3R)-3-((1R)-1-((1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tertbutyl ester:



5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.42g, 2.18mmol) and 1-hydroxybenzotriazole monohydrate (0.33g, 2.18mmol) were added to a solution of (R)-N-tertbutoxycarbonyl-3-piperidine carboxylic acid (0.50g, 2.18mmol) in N,N-dimethylformamide (7ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-3-(2-naphthyl)propionamide hydrochloride (0.68g, 1.56mmol) and triethylamine (0.16g, 1.56mmol) in N,N-dimethylformamide (8ml) was added. After 18h at 20°C the reaction mixture was poured on ice water (90ml) and extracted several times with ethyl acetate (total 15 90ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash chromatography on silica gel (90g) using ethyl 20 acetate and heptane (3:2) as eluent to give 0.83g of (3R)-3-((1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tertbutyl ester.

¹H-NMR (DMSO-d₆) δ 1.37(s, 9H); 2.30(s, 3H); 4.60-4.70(m, 1H); 5.25-5.35(m, 1H); 7.15-7.85(m, 12H).

HPLC: R_t = 31.6 min (Method a)

3-((1R)-[(1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tertbutyl ester (0.80g, 1.31mmol) was dissolved in ethyl acetate (20ml) and a saturated solution of hydrogen chloride in ethyl acetate (20ml) was added. After 2h at 20°C the reaction mixture was concentrated in vacuo. The compound was
10 crystallized from a mixture of methanol and ethyl acetate to give 0.66g of the title compound.

m.p. 198-200°C

¹H-NMR (DMSO-d₆) δ 1.10-1.80(m, 4H); 2.30(s, 3H); 4.60-4.70(m, 1H); 5.25-5.35(m, 1H); 7.20-7.90(m, 12H).

15 HPLC: R_t = 20.9 min (Method a)


Calculated for C₃₀H₃₃N₅O₅·HCl:

C, 65.74; H, 6.25; N, 12.78%; found:

C, 65.57; H, 6.35; N, 12.46%.

Example 2:


4-Amino-4-methyl-pent-2-enoic acid [(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]amide:



5

Prepared according to method E.

N-2-Hydroxy-1,1-dimethylethyl carbamic acid tert-butyl ester:




10 2-Amino-2-methylpropan-1-ol (10.0 g, 112 mmol) was dissolved in tetrahydrofuran (100 ml). A 1N solution of sodium hydroxide in water (112 ml, 112 mmol) was added. A solution of di-tert-butyl dicarbonate (29.3 g, 134 mmol) in tetrahydrofuran (100 ml) was added over a period of 15 min. The solution was stirred at 20°C
15 for 16 h. Water (100 ml) was added. The phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 150 ml) and the combined organic phases were dried (magnesium sulfate). The solvent was removed in vacuo and the crude product was chromatographed on silica gel (180 g) with ethyl acetate/heptane

1:1 as eluent to give 19.6g of N-2-hydroxy-1,1-dimethylethyl carbamic acid tert-butyl ester.

mp 53°C

¹H-NMR (CDCl₃): δ 1.22 (s, 6 H); 1.45 (s, 9 H); 3.58 (d, 2 H); 4.05 (br, 1 H); 4.65 (br, 1 H).

2-tert-Butoxycarbonylamino-2-methylpropanal:




DMSO (12.4 ml, 174.4 mmol) was dissolved in dichloromethane (240 ml) and the solution was cooled to -78 °C. Oxalyl chloride (7.6 ml, 87 mmol) was added dropwise. The solution was stirred at -78 °C for 15 min. A solution of N-2-hydroxy-1,1-dimethylethyl carbamic acid tert-butyl ester in dichloromethane (30 ml) was added dropwise. The solution was stirred for 30 min at -78 °C. Triethylamine (55.23 ml, 396.3 mmol) was added slowly. After 5 min at -78 °C the solution was allowed to warm to 20°C, diluted with dichloromethane (300 ml) and washed with 1N hydrochloric acid (3 x 200 ml). The combined aqueous phases were extracted with dichloromethane (2 x 200 ml). The combined organic layers were washed with a saturated solution of sodium hydrogencarbonate (2 x 200 ml) and dried (magnesium sulfate). The solvent was removed in vacuo and the crude product was chromatographed on silica gel (180 g) with ethyl acetate/heptane 1:4 as eluent to give 13.4g of 2-tert-butoxycarbonylamino-2-methylpropanal.

mp 84 - 85°C

¹H-NMR (CDCl₃) δ 1.35 (s, 6 H); 1.45 (s, 9 H); 5.00 (br, 1H); 9.45 (s, 1 H).

(2E)-4-tert-Butoxycarbonylamino-4-methylpent-2-enoic acid ethyl ester:




Triethyl phosphonoacetate (9.6ml, 48mmol) was added slowly to a suspension of potassium tert-butoxide (5.39g, 48mmol) in tetrahydrofuran (140ml). After 30min at 20°C 2-tert-butoxycarbonylamino-2-methylpropanal (5.0g, 26mmol) was added. After 2.5h at 20°C 1N hydrochloric acid (80ml) was added slowly. The mixture was extracted with ethyl acetate (120ml, 2 x 50ml) and the combined organic layers were washed with a saturated solution of sodium hydrogencarbonate (100ml) and dried (magnesium sulfate). The solvent was removed in vacuo and the crude product was chromatographed on silica gel (100g) with ethyl acetate/heptane 1:4 as eluent to give 5.7g of (2E)-4-tert-butoxycarbonylamino-4-methylpent-2-enoic acid ethyl ester.

mp 40 - 41°C (Heptane)

¹H-NMR (CDCl₃): δ 1.29 (t, 3 H); 1.41 (s, 6 H); 1.43 (s, 9H); 4.19 (q, 2 H); 4.65 (br, 1H); 5.84 (d, J = 15.9 Hz, 1 H); 6.99 (d, J = 16.0 Hz, 1 H).

20 (2E)-4-tert-Butoxycarbonylamino-4-methylpent-2-enoic acid:




(2E)-4-tert-Butoxycarbonylamino-4-methylpent-2-enoic acid ethyl ester (5.0g, 19.4mmol) was dissolved in dioxane (50ml). A solution of lithium hydroxide (0.61 g, 25.3 mmol) in water (25 ml) was added. The solution was stirred for 16 h at 20°C. Ethyl acetate

(75 ml) and water (20 ml) were added. The phases were separated, and the aqueous phase was extracted with ethyl acetate (20 ml). The combined organic phases were extracted with 1N sodium hydroxide solution (30 ml). The combined aqueous phases were acidified with 1N sodium hydrogensulfate solution until pH = 2. The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (magnesium sulfate) and the solvent removed in vacuo. The crude (2E)-4-tert-butoxycarbonylamino-4-methylpent-2-enoic acid was used for further syntheses.

¹H-NMR (CDCl₃): δ 1.39 (s, 6 H); 1.43 (s, 9 H); 4.79 (br, 1 H); 5.75 (d, 1 H); 7.12 (d, 1 H); 9.50 - 11.50 (br, 1 H).

(1,1-Dimethyl-3-[(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl]-15 allyl)carbamic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.42g, 2.18mmol) and 1-hydroxybenzotriazole monohydrate (0.33g, 2.18mmol) were added to a solution of 4-tert-butoxycarbonylamino-4-methylpent-2-enoic acid (0.50g, 2.18mmol) in N,N-dimethylformamide

(7ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide hydrochloride (0.68g, 1.56mmol) and triethylamine (0.16g, 1.56mmol) in N,N-dimethylformamide (8ml) were added. After 18h at 20°C the reaction mixture was poured on ice water (90ml) and extracted several times with ethyl acetate (total 90ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash chromatography on silica gel (95g) using ethyl acetate and heptane (1:1) as eluent to give 0.90g of (1,1-dimethyl-3-[(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl]allyl)carbamic acid tertbutyl ester.

¹H-NMR (DMSO-d₆) δ 1.22(s, 3H); 2.28(s, 3H); 4.70-4.80(m, 1H); 5.72-5.82(m, 1H); 5.89(d, 1H); 6.72(d, 1H); 7.15-7.85(m, 12H).

HPLC: R_t = 30.3 min (Method a)

(1,1-Dimethyl-3-[(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl]allyl)carbamic acid tertbutyl ester (0.90g, 1.47mmol) was dissolved in ethyl acetate (10ml) and a saturated solution of hydrogen chloride in ethyl acetate (20ml) was added. After 3h at 20°C the reaction mixture was concentrated in vacuo to give 0.70g of the title compound.

mp 161-167°C

¹H-NMR (DMSO-d₆) δ 1.32(s, 3H); 1.34(s, 3H); 2.28(s, 3H); 4.75-4.83(m, 1H); 5.23-5.33(m, 1H); 6.12(d, 1H); 6.61(d, 1H); 7.15-7.88(m, 12H).

HPLC: R_t = 20.6 min (Method a)


Calculated for C₃₀H₃₃N₅O₅, HCl, 0.75H₂O:

C, 64.16; H, 6.45; N, 12.47%; found:

C, 64.42; H, 6.43; N, 12.03%.


Example 3:

3-Aminomethyl-N-[(1R)-1-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethyl]benzamide:



Prepared according to method E.

(3-[(1R)-1-[(1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl]-benzyl)carbamic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
(0.92g, 4.82mmol) and 1-hydroxybenzotriazole monohydrate (0.74g,

4.83mmol) were added to a solution of N-tertbutoxycarbonyl-3-aminobenzoic acid (1.21g, 4.82mmol) in N,N-dimethylformamide (15ml). After 1h at 20°C a mixture of (2R)-2-amino-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide hydrochloride (1.50g, 3.43mmol) and triethylamine (0.35g, 3.46mmol) in N,N-dimethylformamide (15ml) were added. After 18h at 20°C the reaction mixture was poured on ice water (180ml) and extracted several times with dichloromethane (total 180ml). The organic phases were collected and washed with aqueous citric acid (10%, 25ml), a saturated solution of sodium hydrogencarbonate (3x25ml) and water (3x25ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and 1.80g of (3-((1R)-1-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl)-benzyl)carbamic acid tertbutyl ester was isolated from ethyl acetate.

mp = 176-178°C

¹H-NMR (DMSO-d₆) δ 1.39(s, 9H); 2.30(s, 3H); 4.70-4.80(m, 1H); 5.29-5.39(m, 1H); 7.15-7.85(m, 17H).

HPLC: R_t = 31.4 min (Method a)

Calculated for C₃₇H₃₉N₅O₅:

C, 70.12; H, 6.20; N, 11.05%; found:

C, 70.20; H, 6.34; N, 10.86%.

(3-((1R)-1-[(1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl)-benzyl)carbamic acid tertbutyl ester (5.51g, 2.38mmol) was suspended in ethyl acetate (20ml) and a saturated solution of hydrogen chloride in ethyl acetate (30ml) was added. After 4h at 20°C the reaction mixture was concentrated in vacuo and crystallized from ethyl acetate to give 1.26g of the title compound.

mp 240-241°C

$^1\text{H-NMR}$ (DMSO- d_6) δ 2.31(s, 3H); 4.03(s, 2H); 4.75-4.85(m, 1H); 5.38-5.48(m, 1H); 7.15-7.90(m, 16H).

HPLC: R_t = 24.6 min (Method a)


Calculated for $\text{C}_{32}\text{H}_{31}\text{N}_5\text{O}_3, \text{HCl}$:

5 C, 67.42; H, 5.66; N, 12.28%; found:

C, 67.26; H, 5.76; N, 12.00%.


Example 4:

Piperidine 4-carboxylic acid N-[(1R)-1-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethyl]amide:



Prepared according to method E.

4-[(1R)-1-[(1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl]piperidine-1-carboxylic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.92g, 4.82mmol) and 1-hydroxybenzotriazole monohydrate (0.74g, 4.83mmol) were added to a solution of N-tertbutyloxycarbonyl-4-
 5 piperidine carboxylic acid (1.10g, 4.80mmol) in N,N-dimethylformamide (15ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide hydrochloride (1.50g, 3.43mmol) and triethylamine (0.35g, 3.46mmol) in N,N-
 10 dimethylformamide (15ml) were added. After 18h at 20°C the reaction mixture was poured on ice water (180ml) and extracted several times with ethyl acetate (total 180ml). The organic phases were collected and washed with aqueous citric acid (10%, 25ml), a saturated solution of sodium hydrogencarbonate (3x25ml) and
 15 water (3x25ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and crystallized from ethyl acetate to give 1.84g of 4-((1R)-1-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl]-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tertbutyl
 20 ester.

mp 152-155°C

¹H-NMR (DMSO-d₆) δ 1.35(s, 9H); 2.29(s, 3H); 4.60-4.70(m, 1H); 5.25-5.35(m, 1H); 7.15-7.85(m, 12H).

HPLC: R_t = 31.3 min (Method a)

25 Calculated for C₃₅H₄₁N₅O₅:

C, 68.72; H, 6.76; N, 11.45%; found:

C, 68.65; H, 6.95; N, 11.34%.

4-((1R)-1-((1R)-1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-5 carboxylic acid tertbutyl ester (1.57g, 2.57mmol) was dissolved in ethyl acetate (20ml) and a saturated solution of hydrogen chloride in ethyl acetate (30ml) was added. After 4h at 20°C the reaction mixture was filtered affording 1.34g of the title compound.

10 mp 238-241°C

¹H-NMR (DMSO-d₆) δ 2.30(s, 3H); 4.60-4.70(m, 1H); 5.25-5.35(m, 1H); 7.20-7.85(m, 12H).

HPLC: R_t = 23.7 min (Method a)


Calculated for C₃₀H₃₃N₅O₅·HCl:

15 C, 64.74; H, 6.25; N, 12.78%; found:

C, 65.91; H, 6.39; N, 12.42%.


Example 5:

5-((1R)-1-((2R)-2-(3-Aminomethylbenzoylamino)-3-(2-naphthyl)propionylamino)-2-phenylethyl)-[1,2,4]oxadiazole-3-20 carboxylic acid ethyl ester, trifluoroacetic acid:



Prepared according to method E.

(R) 5-(1-tert-Butoxycarbonylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester.




5 1,3-Dicyclohexylcarbodiimide (2.1g, 10mmol) was dissolved in dichloromethane (25ml) and added to a solution of (R) N-tert-butoxycarbonylphenylalanine (2.2g, 10mmol) in dichloromethane (50ml) at 0-5°C. The reaction mixture was heated to 20°C and
10 stirred at this temperature for 30 min. Ethyl 2-amino-2-(hydroxyimino)acetate (1.3g, 10mmol) was dissolved in pyridine (50ml) and added to the reaction mixture. The dichloromethane was evaporated and the reaction mixture was heated at reflux temperature for 18h. The reaction mixture was cooled to 0°C and
15 filtered. The filtrate was diluted with ethyl acetate (25ml) and washed with aqueous citric acid (10%, 3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash chromatography on silica gel (90g) using ethyl acetate and heptane (1:1) to give 1.68g of (R) 5-(1-
20 tert-butoxycarbonylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester.

mp 72-76°C

¹H-NMR (DMSO-d₆) δ 1.30(s, 9H); 1.32(t, 3H); 3.10-3.30(m, 2H); 4.41(q, 2H); 5.10(q, 1H); 7.20-7.50(m, 5H).


25 (R) 5-(1-Amino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride:



(R) 5-(1-tert-Butoxycarbonylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (1.5g, 4.2mmol) was dissolved in a saturated solution of hydrogen chloride in 5 ethyl acetate (40ml). After 5h at 20°C the reaction mixture was concentrated in vacuo to give 1.2g of (R) 5-(1-amino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride.

¹H-NMR (DMSO-d₆) δ 1.32(t, 3H); 4.41(q, 2H), 5.20(dd, 1H); 7.10-7.30(m, 5H).


5-[(1R)-1-[(2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionylamino]-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



15 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.77g, 4.03mmol) and 1-hydroxybenzotriazole monohydrate (0.62g, 32.9mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (1.27g, 4.03mmol) in N,N-dimethylformamide

(20ml). After 30min at 20°C a solution of (R) ethyl 5-(1-amino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylate hydrochloride (1.20g, 4.03mmol) in N,N-dimethylformamide (15ml) was added. The reaction mixture was heated to 50°C for 3h, poured on water (400ml) and 5 extracted several times with dichloromethane (total 350ml). The combined organic phases were washed with a saturated solution of sodium hydrogencarbonate (2x50ml) and dried (magnesium sulfate). The solution was concentrated in vacuo and purified by flash chromatography on silica gel (40g) using ethyl acetate and heptane 10 (3:7) to give 0.41g of 5-[(1R)-1-[(2R)-2-tert-butoxycarbonylamino-3-(2-naphthyl)propionylamino]-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester. ¹H-NMR (DMSO-d₆) δ 1.23(s, 9H); 1.32(t, 3H); 4.25-4.35(m, 1H), 4.38-4.45(q, 2H); 5.38-5.48(m, 1H); 7.20-7.85(m, 12H).


15 5-[(1R)-1-[(2R)-2-Amino-3-(2-naphthyl)propionylamino]-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride:



5-[(1R)-1-[(2R)-2-tert-Butoxycarbonylamino-3-(2-
20 naphthyl)propionylamino]-2-phenylethyl]-[1,2,4]oxadiazole-3-
carboxylic acid ethyl ester (0.41g, 0.7mmol) was suspended in a
saturated mixture of hydrogen chloride in ethyl acetate (10ml).
After 18h at 20°C, the reaction mixture was filtered to give 0.39g
of 5-[(1R)-1-[(2R)-2-amino-3-(2-
25 naphthyl)propionylamino]-2-phenylethyl]-[1,2,4]oxadiazole-3-
carboxylic acid ethyl ester hydrochloride.

$^1\text{H-NMR}$ (DMSO-d_6) δ 1.32(t, 3H); 4.10-4.20(m, 1H); 4.40-4.45(m, 2H); 5.40-5.50(m, 1H).

5-[(1R)-1-((2R)-2-((3-tert-Butoxycarbonylamino-methyl)benzoylamino)-3-(2-naphthyl)propionylamino)-2-phenylethyl]-5 [1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.23g, 1.20mmol) and 1-hydroxybenzotriazole monohydrate (0.18g, 1.2mmol) were added to a solution of 3-(tert-butoxycarbonylamino-methyl)benzoic acid (0.30g, 1.2mmol) in N,N-dimethylformamide (8ml). After 1h at 20°C a mixture of 5-[(1R)-1-((2R)-2-amino-3-(2-naphthyl)propionylamino)-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride (0.39g, 0.79mmol) and triethylamine (0.08g, 0.79mmol) in N,N-dimethylformamide (2ml) were added. After 18h at 20°C the reaction mixture was poured on water (70ml) and extracted several times with ethyl acetate (total 80ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (10ml) and water (3x10ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and crystallized from a mixture of ethyl acetate and heptane to give 0.44g of 5-[(1R)-1-((2R)-2-((3-tert-butoxycarbonylamino-methyl)benzoylamino)-3-(2-naphthyl)propionylamino)-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester.
mp =170-176°C

¹H-NMR (DMSO-d₆) δ 1.30-1.40 (m, 12H); 4.42(q, 2H), 4.80-4.90(m, 1H); 5.40-5.50(m, 1H).

5-[(1R)-1-((2R)-2-((3-tert-Butoxycarbonyl-aminomethyl)benzoylamino)-3-(2-naphthyl)propionylamino)-2-phenylethyl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (0.40g, 0.58mmol) was suspended in a saturated solution of hydrogen chloride in ethyl acetate (10ml). After 5h at 20°C the reaction mixture was concentrated in vacuo. The compound was purified by flash chromatography with silica gel (40g) using a mixture of dichloromethane and 10% ammonia in ethanol (9:1) as eluent to give 0.14g of the title compound. The compound was further purified by semipreparative HPLC in three runs on a 25mm x 250 mm column packed with 7μ C-18 silica which was preequilibrated with 30% acetonitrile in a 0.5M solution of ammonium sulfate, which was adjusted to pH 2.5 with sulfuric acid (4M). The column was eluted with a gradient of 24% to 50% acetonitrile in 0.5M ammonium sulfate, pH 2.5 at 10ml/min during 47min at 40°C and the fractions corresponding to the major peak were collected, diluted with three volumes of water and applied to a Sep-Pak C-18 cartridge (Waters part # WAT036915). After preequilibration with 0.1% TFA, the compound was eluted from the Sep-Pak cartridge with 70% TFA and isolated from the eluate by lyophilisation.

¹H-NMR (DMSO-d₆) δ 1.35(t, 3H); 4.40(q, 2H); 4.85-4.95(m, 1H); 5.35-5.45(m, 1H); 7.10-7.85(m, 16H).

HPLC: R_t = 28.4 min (method: 0-90% 0.1% TFA in acetonitrile over 50 min)

Calculated for C₃₄H₃₃N₅O₅·TFA·1.5H₂O:


C, 59.01; H, 5.09; N, 9.56%; found:

30 C, 68.89; H, 5.10; N, 9.74%.

Example 6:


5-{1-[2-(3-Aminomethylbenzoyl)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl}-[1,2,4]oxadiazol-3-carboxylic acid ethyl ester:

5



Prepared according to method E.

(R)-3-(2-Naphthyl)alanine methyl ester.




Thionyl chloride (5 ml) was added dropwise over 15 min. to a suspension of (R)-3-(2-naphthyl)alanine (5.0 g) in methanol (50 ml) at 35°C. After addition the mixture was heated at 60°C for 1 h, cooled and the solvent removed in vacuo. Water (75 ml) and ethyl acetate (125 ml) were added and pH was adjusted to 8.5 with sodium carbonate. The organic phase was separated and dried (magnesium sulfate) to afford 4.86 g of (R)-3-(2-naphthyl)alanine methyl ester.

¹H-NMR (CDCl₃) δ 1.50 (s(br), 2H); 3.03 (dd, 1H); 3.27 (dd, 1H); 3.71 (s, 3H); 3.84 (dd, 1H); 7.30-7.82 (m, 7H).

(R)-2-(3-(tert-Butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)-propionic acid methyl ester:

15




3-(tert-Butoxycarbonylaminomethyl)benzoic acid (5.32 g; 21.2 mmol) was dissolved in N,N-dimethylformamide (20 ml). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (4.06 g, 21.2 mmol) was added and the mixture was stirred for 20 min. A solution of (R)-3-(2-naphthyl)alanine methyl ester (4.85 g, 21.2 mmol) in N,N-dimethylformamide (20 ml) and triethylamine (4.4 ml) was added

and stirring was continued for 18h. The mixture was diluted with ethyl acetate (400 ml) and the organic phase was washed with water (200 ml), 10% aqueous sodium hydrogensulfate (50 ml), 5 % aqueous sodium hydrogencarbonate (100 ml) and water (100 ml). The phases were separated and the organic phase was dried (magnesium sulfate) and the solvent removed in vacuo to afford 8.9g of (R)-2-(3-(tert-butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionic acid methyl ester.

$^1\text{H-NMR}$ (CDCl_3) δ 1.44 (s, 9H); 3.40 (t, 2H); 3.76 (s, 3H) 4.28 (d, 2H); 5.00 (s(br), 1H); 5.18 (q, 1H); 6.75 (d, 1H); 7.20-7.80 (m, 11H)

(R)-2-(3-(tert-Butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionic acid:




15 (R)-2-(3-(tert-Butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionic acid methyl ester (8.8 g, 19.1 mmol) was dissolved in methanol (100 ml) and lithium hydroxide (0.55 g, 22.2 mmol) was added. After 2 h dichloromethane (200 ml), water (200 ml) and 3 M sodium hydrogen sulfate (50 ml) were added. The
20 organic phase was separated and washed with water (100 ml). The organic phase was dried (magnesium sulfate) and the solvent removed in vacuo to yield 7.9g of (R)-2-(3-(tert-

butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionic acid.

$^1\text{H-NMR}$ (DMSO) δ 1.38, 1.39 (two s, 9H); 3.30 (m, 2H); 4.12 (d, 2H); 4.71 (m, 1H); 6.10 (s(br), 1H); 7.30-7.90 (m, 11 H); 8.75 (d, 5 1H); 12.80 (s(br), 1H).

(R)-5-(1-(N-Methyl-tert-butoxycarbonylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:




10 1,3-Dicyclohexylcarbodiimide (1.88g, 9.1mmol) was dissolved in dichloromethane (25ml) and added to a solution of (R) N-tert-butoxycarbonyl-(2-naphthyl)alanine (3.0g, 9.1mmol) in dichloromethane (50ml) at 0-5°C. The reaction mixture was heated to 20°C and stirred at this temperature for 30 min. Ethyl 2-amino-15 2-(hydroxyimino)acetate (1.2g, 9.1mmol) was dissolved in pyridine (50ml) and added to the reaction mixture. The dichloromethane was evaporated and the reaction mixture was heated at reflux temperature for 18h. The reaction mixture was cooled to 0°C and filtered. The eluent was concentrated in vacuo, redissolved in 20 ethyl acetate (25ml) and washed with aqueous citric acid (10%,

3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash chromatography on silica gel (90g) using ethyl acetate and heptane (1:4) to give 1.59g of (R) 5-(1-(N-methyl-tert-butoxycarbonylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester.

mp 99-102°C

¹H-NMR (DMSO-d₆) δ 1.30-1.40(m, 3H); 4.40-4.50(m, 2H); 5.70-5.90(m, 1H); 7.45-7.90(m, 7H).

10 (R) 5-(1-Methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride:




(R) 5-(1-(N-Methyl-tert-butoxycarbonylamino)-2-(2-naphthyl)-ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (0.77g, 15 1.8mmol) was dissolved in a saturated solution of hydrogen chloride in ethyl acetate (15ml). After 5h at 20°C the reaction mixture was concentrated in vacuo to give 0.72g of (R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride.

20 ¹H-NMR (DMSO-d₆) δ 1.32(t, 3H); 2.71(s, 3H); 4.40(q, 2H); 5.45(q, 1H); 7.30-7.90(m, 7H).

HPLC: R_t = 19.7 min (Method a)

5-(1-[2-(3-(tert-Butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.51g, 2.6mmol) and 1-hydroxy-7-azabenzotriazole (0.36g, 2.6mmol) were added to a solution of 2-(3-(tert-butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionic acid (1.18g, 2.6mmol) in N,N-dimethylformamide (15ml). After 30min
10 at 20°C a mixture of (R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride (0.69g, 1.9mmol) and triethylamine (0.19g, 1.9mmol) in N,N-dimethylformamide (10ml) were added. After 18h at 20°C the reaction mixture was poured onto water (175ml) and extracted
15 several times with ethyl acetate (total 175ml). The combined organic phases were washed with aqueous citric acid (10%, 20ml), a saturated solution of sodium hydrogencarbonate (25ml), water (3x25ml) and dried (magnesium sulfate). The solution was concentrated in vacuo and purified by flash chromatography on
20 silica gel (80g) using ethyl acetate and heptane (2:3) to give 0.8g of a 1:1 mixture of two diastereoisomers of 5-(1-[2-(3-(tert-butoxycarbonylamino-
methyl)benzoylamino)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl
25 ester.

$^1\text{H-NMR}$ (DMSO-d_6) δ 1.30-1.42(m, 12H), 4.40-4.48(m, 2H); 4.90-5.20(m, 1H); 6.00-6.10(m, 1H).

HPLC: diastereoisomer I ; R_t = 25.6 min (Method a)
diastereoisomer II; R_t = 30.81min (Method a)

5 5-(1-[2-(3-(tert-Butoxycarbonylaminomethyl)benzoylamino)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (0.34g, 0.5mmol) was suspended in a mixture of trifluoroacetic acid and dichloromethane (1:1, 20ml). After 10min at 20°C, the reaction
10 mixture was concentrated in vacuo and purified by flash chromatography on silica gel (40g) using dichloromethane and a 10% mixture of ammonia in ethanol (85:15) to give 0.14g of two diastereoisomers of the title compound.

$^1\text{H-NMR}$ (DMSO-d_6) δ 1.35-1.50(m, 3H); 4.40-4.50(m, 2H); 5.00-5.20(m, 15 1H); 5.98-6.13(m, 1H).


HPLC: diastereoisomer I ; R_t = 26.9 min (Method a)
diastereoisomer II; R_t = 37.7min (Method a)

Calculated for $\text{C}_{39}\text{H}_{37}\text{N}_5\text{O}_5$:

C, 71.43; H, 5.69; N, 10.68%; found:
20 C, 71.05; H, 5.54; N, 10.41%.

Example 7:


5-((1R)-1-[(2R)-2-(piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



5


Prepared according to method E.

5-((1R)-1-[(2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)-propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.54g, 2.8mmol) and 1-hydroxy-7-azabenzotriazole (0.38g, 2.8mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (0.88g, 2.8mmol) in N,N-dimethylformamide (15ml). After 30min at 20°C a solution of (R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride (0.7g, 2.0mmol) in N,N-dimethylformamide (15ml) was added. The reaction mixture was heated to 50°C for 3h, poured on water (180ml) and extracted several times with ethyl acetate (total 200ml). The combined organic phases were washed with aqueous citric acid (10%, 25ml), a saturated solution of sodium hydrogencarbonate (30ml), water (3x30ml) and dried (magnesium sulfate). The solution was concentrated in vacuo to give 1.3g of 5-((1R)-1-[(2R)-2-tert-butoxycarbonylamino-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester. ¹H-NMR (DMSO-d₆) δ 1.00-1.40(m, 12H); 4.45(q, 2H); 5.90-6.20(m, 1H).


5-((1R)-1-[(2R)-2-Amino-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester:



5-((1R)-1-[(2R)-2-tert-butoxycarbonylamino-3-(2-naphthyl)-propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (1.3g, 2.0mmol) was suspended in a saturated mixture of trifluoroacetic acid and 5 dichloromethane (1:1, 50ml). After 10min at 20°C, the reaction mixture was concentrated in vacuo and purified by flash chromatography on silica gel (100g) using dichloromethane and a mixture of 10% ammonia in ethanol (95:5) as eluent to give 0.9g of 5-((1R)-1-[(2R)-2-amino-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester.

¹H-NMR (DMSO-d₆) δ 1.35(i, 3H); 4.45(q, 2H); 5.88-6.20(m, 1H).

4-((1R)-1-([(1R)-1-(3-Ethoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.40g, 2.1mmol) and 1-hydroxybenzotriazole monohydrate (0.32g, 2.1mmol) were added to a solution of N-tert-butoxycarbonyl-4-

piperidinecarboxylic acid (0.48g, 2.1mmol) in N,N-dimethylformamide (10ml). After 1h at 20°C a solution of 5-((1R)-1-[(2R)-2-amino-3-(2-naphthyl)propionyl]-N-methylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester (0.73g, 1.4mmol) in N,N-dimethylformamide (2ml) was added. After 18h at 20°C the reaction mixture was poured on water (120ml) and extracted several times with ethyl acetate (total 140ml). The organic phases were combined and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (15ml) and water (3x20ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash chromatography on silica gel (40g) using ethyl acetate and heptane (1:1) to give 0.9g of 4-((1R)-1-[(1R)-1-(3-ethoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester.

¹H-NMR (DMSO-d₆) δ 1.30-1.45(m, 9H); 6.00-6.15(m, 1H).

HPLC: R_t = 33.9 min (Method a)

4-((1R)-1-[(1R)-1-(3-Ethoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.21g, 0.29mmol) was dissolved in a mixture trifluoroacetic acid and dichloromethane (1:1, 12ml). After 10 min at 20°C the reaction mixture was concentrated in vacuo. The compound was purified by flash chromatography with silica gel (40g) using a mixture of dichloromethane and 10% ammonia in ethanol (4:1) as eluent to give 0.12g of the title compound.

¹H-NMR (DMSO-d₆) δ 1.30-1.40(m, 3H); 2.80-2.90(2s, 3H), 4.40-4.50(m, 2H); 5.98-6.20(m, 1H).

HPLC: R_t = 25.0 min (Method a)


Calculated for C₃₇H₃₉N₅O₅, H₂O:

C, 68.19; H, 6.34; N, 10.75%; found:

C, 68,23; H, 6.25; N, 10.60%.


Example 8 :

Piperidine-4-carboxylic acid (1-([1-(3-carbamoyl-
5 [1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(
2-naphthyl)ethyl)amide:



Prepared according to method E.

4-(1-([1-(3-Carbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl]methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert butyl ester:



5 4-((1R)-1-([1-(3-Ethoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.67g, 0.91mmol) was suspended in refluxing liquid ammonia at 1 atm. After 18h the reaction mixture was concentrated in vacuo
10 to give 0.58g of two diastereoisomers of 4-(1-([1-(3-carbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl]methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert butyl ester.

15 ¹H-NMR (DMSO-d₆) δ 1.30-1.40(m, 9H); 4.80-4.95(m, 1H); 6.00-6.13(m, 1H).

HPLC: diastereoisomer I: R_t = 28.9 min (Method a)
diastereoisomer II: R_t = 29.4 min (Method a)


The diastereomer mixture of 4-(1-(1-(3-carbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)-piperidine-1-carboxylic acid tert butyl ester (0.58g, 0.29mmol) was dissolved in a mixture trifluoroacetic acid and dichloromethane (1:1, 12ml). After 5min at 20°C the reaction mixture was concentrated in vacuo. The compound was purified by flash chromatography with silica gel (80g) using a mixture of dichloromethane and 10% ammonia in ethanol (7:3) as eluent to give 0.44g of two diastereoisomers of the title compound.

¹H-NMR (DMSO-d₆) δ 2.88-2.92(2s, 3H); 4.79-5.00(m, 1H); 6.00-6.13(m, 1H).

HPLC: diastereoisomer I: R_t = 21.2 min (Method a)
diastereoisomer II: R_t = 22.1 min (Method a)


15 Example 9:

3-Aminomethyl-N-((1R,2E)-4-(hydroxymethyl)-1-((2-naphthyl)-methyl-5-phenylpent-2-enyl)benzamide:



Prepared according to method A.

((1R,2E)-4-(tert-Butyldimethylsilanyloxymethyl)-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert-butyl ester:




5 A solution of diisopropylaluminium methoxide was prepared by placing diisobutylaluminium hydride (17.9ml of a 25% solution in toluene; 26.6mmol) under nitrogen, cooling in an icebath and slowly treating with dry methanol (1.1ml, 26.6mmol). ((1R)-1-Benzenesulfonylmethyl-2-(2-naphthyl)ethyl)carbamic acid tert-butyl
 10 ester (2.14g; 5.0mmol) (prepared by the method of Spaltenstein et al., J. Org. Chem., 52, 3759-66, 1987) was refluxed in dry tetrahydrofuran (250ml). The reaction mixture was cooled to -70°C. n-Butyllithium (3.92 ml; 2.5M solution in hexane, 9.8mmol) was added over 10 min and the solution was left with stirring for 30
 15 min. A solution of racemic 2-(tert-butyldimethylsilanyloxymethyl)-3-phenylpropionaldehyde (2.1g; 7.6mmol) (prepared as in Jenmalm et al. J. Org. Chem., 59, 1139-48, 1994) in dry tetrahydrofuran (10 ml) under nitrogen was cooled to -70°C and treated with the previously prepared solution of diisopropylaluminium methoxide
 20 (5.4ml; 7.6mmol). Immediately after the addition, the aluminium complex was added via cannula to the sulfone-anion solution.

Cooling was maintained for 30 min. Then aqueous ammonium chloride (40 ml; 10%), water (200 ml) and dichloromethane (200 ml) were added. The phases were separated, the organic phase was dried (magnesium sulfate) and the solvent removed in vacuo to give 5.50g of an oil. On suspension of this oil in methanol (150 ml) a solid precipitated, was filtered off and discarded. Disodium hydrogenphosphate (1.7g) was added to the methanol solution, cooled to 5°C and treated with sodium amalgam (150g; 2%). After 4h at 20°C the solvent was removed in vacuo and the residue was chromatographed on silica (80g) using diethylether/heptane (1:6) as eluent. This afforded 0.85g of a mixture of isomers of ((1R,2E)-4-(tert-butyldimethylsilyloxymethyl)-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert-butyl ester which was used in the next step without further purification.

¹H-NMR (CDCl₃) δ -0.02-0.08 (four s, 6H); 0.85-0.90 (four s, 9H); 1.40-1.45 (four s, 9H); 2.40-3.60 (m, 7H); 4.45 (s(br), 2H); 5.20-5.46 (m, 2H); 7.02-7.82 (m, 12H).

R_f: 0.2 diethylether/heptane (1:6)


((1R,2E)-4-Hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert butyl ester:



((1R,2E)-4-(tert-Butyldimethylsilanyloxymethyl)-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert-butyl ester (0.75g, 1.38 mmol) was dissolved in 2% hydrogen fluoride in acetonitrile (50 ml) and stirred at room temperature for 3h. The solvent was removed in vacuo and the residue was chromatographed on silica (80g) using dichloromethane/heptane/methanol (4/10/1) as eluent. Three fractions were isolated containing compounds with R_f 0.1-0.2. The major fraction (eluting second) was concentrated in vacuo to give 0.35g of ((1R,2E)-4-hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert butyl ester as a mixture of diastereomers.

$^1\text{H-NMR}$ (CDCl_3) δ 1.38, 1.40 (two s, 9H); 2.46-3.55 (m, 7H); 4.35 (m, 1H); 4.55 (s(br), 1H); 5.28-5.43 (m, 2H); 7.01-7.82 (m, 12H).

(3E,5R)-5-Amino-2-benzyl-6-(2-naphthyl)hex-3-en-1-ol:



15

((1R,2E)-4-Hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)carbamic acid tert butyl ester (350mg, 0.81mmol) was dissolved in dichloromethane and trifluoroacetic acid (5 ml) was added. After 90 min the solvent was removed in vacuo and the residue was dissolved in dichloromethane (5 ml) and reevaporated. Finally the mixture was lyophilized in water acidified with 4 M HCl (2 ml) to afford 0.3g of two diastereoisomers of (3E,5R)-5-amino-2-benzyl-6-(2-naphthyl)hex-3-en-1-ol as a hydrochloride which were taken to the next step without further purification.

¹H-NMR (CDCl₃) δ 1.8 (s(br), 2H); 2.45-3.70 (m, 7H); 4.35 (m, 1H); 5.32-5.60 (m, 2H); 7.03-7.72 (m, 12 H).

3-(tert-Butoxycarbonylaminomethyl)benzoic acid (407mg) was dissolved in dichloromethane (6 ml) and then converted to the symmetrical anhydride by stirring with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (155mg) for 10 min. A solution of (3E,5R)-5-amino-2-benzyl-6-(2-naphthyl)hex-3-en-1-ol hydrochloride (149 mg) and N,N-diisopropylethylamine (70 µl) in dichloromethane (3 ml) was added to the mixture and then reacted for 20 h at 20°C. The reaction mixture was then concentrated to an oil and redissolved in ethyl acetate (50 ml). The solution was extracted successively with 5% aqueous sodium hydrogen carbonate (100 ml) and with water (2 X 100 ml). The combined organic phases were dried (sodium sulfate) and concentrated in vacuo to an oil. The oil was dissolved in dichloromethane / trifluoroacetic acid 1:1 (6 ml) and stirred. After 10 min the mixture was concentrated by a stream of nitrogen and the resulting oil was redissolved in acetic acid (1 ml). Then water (40ml) and acetonitrile (12 ml) were added. The solution of crude product of the title compound was then purified by semipreparative HPLC in five runs on a 25 mm x 250 mm column packed with 7µ C-18 silica. The column was preequilibrated with 30% acetonitrile in 0.05M ammonium sulfate, and was adjusted to pH 2.5 with 4M sulfuric acid.

25 The column was eluted with a gradient of 30% - 45% acetonitrile in 0.05M ammonium sulfate, pH 2.5 (using 4M sulfuric acid) at 10 ml/min during 47 min at 40 °C and the fractions corresponding to the two major components were each collected, diluted with 3 volumes of water and applied to two Sep-Pak® C18 cartridges connected in series (Waters part. #:51910) which were preequilibrated with 0.1% trifluoroacetic acid . The compounds were eluted from the Sep-Pak® cartridges with 70% acetonitrile

0.1% trifluoroacetic acid and isolated from the eluate by lyophilisation after dilution with water.

The final products obtained were characterised by analytical RP-HPLC (retention time) and by plasma desorption mass spectrometry (molecular mass). The molecular masses for isomer I and isomer II were found to 464.1 and 464.5 respectively which is in agreement with the expected structure within the experimental error of the method (± 0.9 amu).

The RP-HPLC analysis was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5 μ C-18 silica column (The Separations Group, Hesperia) which was eluted at 1 ml/min at 42 °C. Two different elution conditions were used:


A1: The column was equilibrated with 5% acetonitrile in a buffer consisting of 0.1M ammonium sulphate, which was adjusted to pH 2.5 with 4M sulfuric acid and eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min.

B1: The column was equilibrated with 5% acetonitrile / 0.1% trifluoroacetic acid / water and eluted by a gradient of 5% acetonitrile / 0.1% trifluoroacetic acid / water to 60% acetonitrile / 0.1% trifluoroacetic acid / water during 50 min.

The retention time using elution conditions A1 and B1 was found to be 32.97 min and 34.52 min, respectively for isomer I and 33.67 min and 33.67 min, respectively for isomer II.

Example 10:

(3R) Piperidine-3-carboxylic acid ((1R,2E)-4-hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)amide:




5 Prepared according to method A.

(3R) Piperidine-3-carboxylic acid ((1R,2E)-4-hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)amide was prepared and characterized using similar procedures as in example 10. The 10 molecular masses for isomer I and isomer II were found to 442.6 and 442.5 respectively which is in agreement with the expected structure within the experimental error of the method (± 0.9 amu).

The RP-HPLC retention time using elution conditions A1 and B1 were found to be 30.02 min and 31.30 min, respectively for isomer I and 15 30.56 min and 31.95 min, respectively for isomer II.


Example 11:

(2E)-5-Amino-5-methylhex-2-enoic acid ((1R)-1-[N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl)carbamoyl]-2-(2-naphthyl)ethyl) amide:



5 Prepared according to method E.

3-Hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester:




10 At 0 °C, ethyl chloroformate (1.10 ml, 11.5 mmol) was given dropwise to a solution of 3-tert-butoxycarbonylamino-3-methylbutanoic acid (2.50 g, 11.5 mmol) and triethylamine (1.92 ml, 13.8 mmol) in THF (10 ml). The solution was stirred for 40 min at 0 °C. The obtained precipitate was filtered off and washed with
 15 THF (20 ml). The liquid was immediately cooled to 0 °C. A 2M solution of lithium boronhydride in THF (14.4 ml, 28.8 mmol) was added dropwise. The solution was stirred at 0 °C for 2 h, and then warmed to room temp. over a period of 4 h. It was cooled to 0 °C. Methanol (5 ml) was added carefully. 1N Hydrochloric acid (100 ml)
 20 was added. The solution was extracted with ethyl acetate (2 x 100 ml, 3 x 50 ml). The combined organic layers were washed with

saturated solution of sodium hydrogencarbonate (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was chromatographed on silica (110 g) with ethyl acetate/heptane 1:2 to give 1.84 g of 3-hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester.

400 MHz-¹H-NMR (CDCl₃): 1.33 (s, 6 H); 1.44 (s, 9 H); 1.88 (t, 2 H); 1.94 (br, 1 H); 3.75 (q, 2 H); 4.98 (br, 1 H).


3-(tert-Butoxycarbonylamino)-3-methylbutanal:



10 At -78 °C DMSO (1.22 ml, 17.2 mmol) was added to a solution of oxalyl chloride (1.1 ml, 12.9 mmol) in dichloromethane (15 ml). The mixture was stirred for 15 min at -78 °C. A solution of 3-hydroxy-1,1-dimethylpropylcarbamic acid tert-butyl ester (1.75 g, 8.6 mmol) in dichloromethane (10 ml) was added dropwise over a 15 period of 15 min. The solution was stirred at -78 °C for another 15 min. Triethylamine (6.0 ml, 43 mmol) was added. The solution was stirred at -78 °C for 5 min and then warmed to room temp. The solution was diluted with dichloromethane (100 ml) and extracted with 1N hydrochloric acid (100 ml). The aqueous phase was 20 extracted with dichloromethane (50 ml). The combined organic layers were washed with a saturated solution of sodium hydrogencarbonate (100 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by column chromatography on silica (140 g) with ethyl acetate/heptane 25 (1:3) to give 1.10 g of 3-(tert-butoxycarbonylamino)-3-methylbutanal.

400 MHz-¹H-NMR (CDCl₃): d = 1.39 (s, 6 H); 1.45 (s, 9 H); 2.85 (d, 2 H); 4.73 (br. 1 H); 9.80 (t, 1 H).


Ethyl (2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoate:



Triethylphosphonoacetate (1.96 ml, 9.8 mmol) was dissolved in THF (30 ml). Potassium tert-butoxide (1.10 g, 9.8 mmol) was added. The solution was stirred for 40 min at room temp. A solution of 3-(tert-butoxycarbonylamino)-3-methylbutanal (1.10 g, 5.5 mmol) in THF (6 ml) was added slowly. The solution was stirred at room temp. for 75 min. It was diluted with ethyl acetate (100 ml) and 1N hydrochloric acid (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with a saturated solution of sodium hydrogencarbonate (60 ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by column chromatography on silica (90 g) with ethyl acetate/heptane (1:4) to give 1.27 g of ethyl (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoate.

200 MHz-¹H-NMR (CDCl₃): δ = 1.30 (s, 6 H); 1.30 (t, 3 H); 1.46 (s, 9 H); 2.62 (d, 2 H); 4.27 (q, 2 H); 4.42 (br, 1 H); 5.88 (d, 1 H); 6.94 (td, 1 H).

(2E)-5-(tert-Butoxycarbonylamino)-5-methylhex-2-enoic acid:




Ethyl (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoate (1.233 g, 4.54 mmol) was dissolved in dioxane (20 ml). Lithium hydroxide (0.120 g, 5.00 mmol) was added as a solid. Water (10 ml)

was added. The solution was stirred 16 h at room temp. The solution was diluted with water (70 ml) and was extracted with tert-butylmethylether (2 x 100 ml). The aqueous phase was acidified with 1N sodium hydrogensulfate solution (pH = 1) and 5 was extracted with tert-butylmethylether (3 x 70 ml). These organic layers were combined and dried over magnesium sulfate. The solvent was removed in vacuo to give 1.05 g of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid. The crude product was used for further synthesis.

10 400 MHz-¹H-NMR (DMSO d₆): δ = 1.15 (s, 6 H); 1.35 (s, 9 H); 2.53 (d, 2 H); 5.75 (d, 1 H); 6.57 (br, 1 H); 6.75 (td, 1 H); 12.15 (s, 1 H).

(R) N-Methyl-N-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamic acid tertbutyl ester:




15

Iso-butylchloroformate (1.22g, 9.0mmol) was dropwise added to a solution of (R) N-methyl-N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (3.0g, 9mmol) and N-methylmorpholine (0.91g, 9.0mmol) in dichloromethane (40ml) at -20°C. After 15 min at -20°C 20 acetamidoxim (1.33g, 18mmol) was added followed by addition of N-methyl-morpholine (0.91g, 9mmol). After 30min at -20°C the reaction mixture was heated to 20°C and diluted with N,N-

dimethylformamide (40ml). The dichloromethane was evaporated in vacuo and the reaction mixture was heated at 120°C for 16 h. The reaction mixture was poured into water (120ml) and extracted with ethyl acetate (total 180ml). The organic phases were collected, washed with water (40ml) and dried (magnesium sulfate). The solution was concentrated in vacuo to give 3.5g of crude (R) N-methyl-N-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamic acid tertbutyl ester that was used without further purification.

10

(R) N-Methyl-N-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]amine hydrochloride:



(R) N-methyl-N-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamic acid tertbutyl ester (3.3g, 9.0mmol) was dissolved in a saturated solution of hydrogen chloride in ethyl acetate (75ml). After 3h at 20°C the reaction mixture was filtered to give 1.52g of (R) N-methyl-N-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]amine hydrochloride.

20 m.p. 198-202°C.

¹H-NMR (DMSO-d₆) δ 2.35(s, 3H); 2.68(s, 3H); 3.43(dd, 1H); 3.80(dd, 1H); 5.29(dd, 1H); 7.30(d, 1H); 7.45-7.90(m, 7H).


HPLC: $R_t = 16.3$ min (Method a)

Calculated for $C_{16}H_{17}N_3O_1, HCl$:

C, 63.26; H, 5.97; N, 13.83%; found:

C, 63.37; H, 6.11; N, 13.53%.


5 ((1R)-1-(N-Methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
 10 (1.12g, 5.85mmol) and 1-hydroxy-7-azabenzotriazole (0.8g, 5.85mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)-alanine (1.84g, 5.85mmol) in N,N-dimethylformamide (45ml). After 30min at 20°C a mixture of (R) N-methyl-N-(1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-
 15 (2-naphthyl)ethyl)amine hydrochloride (1.27g, 4.18mmol) and triethylamine (0.42g, 4.18mmol) in N,N-dimethylformamide (15ml) were added. After 18h at 20°C the reaction mixture was poured on water (200ml) and extracted several times with ethyl acetate (total 110ml). The combined organic phases were washed with
 20 aqueous citric acid (10%, 40ml), a saturated solution of sodium hydrogencarbonate (3x40ml) and water (3x40ml). After drying (magnesium sulfate) the solution was concentrated in vacuo to give 2.4g of crude ((1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]-

oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester which was used for the next step without further purification.

5 (2R)-2-Amino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid:



((1R)-1-(N-Methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-
 10 (2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid
 tertbutyl ester (2.4g, 4.2mmol) was dissolved in a mixture of
 trifluoroacetic acid (40ml) and dichloromethane (40ml) at 20°C.
 After 10min the reaction mixture was concentrated in vacuo and
 coevaporated from dichloromethane (80ml). The residue was
 15 crystallised from ethyl acetate to give 1.19g of (2R)-2-amino-N-
 methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-
 ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid.
 mp 190-191°C.

$^1\text{H-NMR}$ (DMSO-d_6) δ 2.33(s, 3H); 2.88(s, 3H); 3.00-3.15(m, 2H); 3.45(dd, 1H); 3.65(dd, 1H); 4.71(t, 1H); 7.25-7.95(m, 14H).


HPLC: $R_t = 24.3$ min (Method a)

Calculated for $\text{C}_{29}\text{H}_{28}\text{N}_4\text{O}_2, \text{CF}_3\text{COOH}$:

5 C, 64.35; H, 5.05; N, 9.68%; found:

C, 64.30; H, 5.13; N, 9.44%.

[1,1-Dimethyl-4-((1R)-1-(N-methyl-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethylcarbamoyl)but-3-enyl]carbamic acid tertbutyl ester:



10

N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.28g, 1.48mmol) and 1-hydroxybenzotriazole monohydrate (0.23g, 1.48mmol) were added to a solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (0.36g, 1.48mmol) in N,N-dimethylformamide (5ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl]-3-(2-naphthyl)]propionamide, trifluoroacetic

acid (0.61g, 1.06mmol) and triethylamine (0.11g, 1.06mmol) in N,N-dimethylformamide (7ml) were added. After 18h at 20°C the reaction mixture was poured on water (80ml) and extracted several times with ethyl acetate (total 40ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo to give 0.71g of crude [1,1-dimethyl-4-((1R)-1-(N-methyl-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl)but-3-enyl]carbamic acid tertbutyl ester which was used for the next step without further purification.

HPLC: R_t = 34.9 min (Method a)

[1,1-Dimethyl-4-((1R)-1-(N-methyl-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl)but-3-enyl]carbamic acid tertbutyl ester (0.71g, 1.03mmol) was dissolved in a mixture trifluoroacetic acid (10ml) and dichloromethane (10ml). After 10min at 20°C the reaction mixture was concentrated in vacuo. The compound was chromatographed on silica (80g) using a 10% mixture of ammonia in ethanol and dichloromethane (9:91) as eluent to give 0.44g of the title compound.

HPLC: R_t = 23.6 min (Method a)


Calculated for $C_{36}H_{39}N_5O_3$, $0.75H_2O$:

C, 71.68; H, 6.77; N, 11.61%; found:

C, 71.76; H, 6.73; N, 11.12%.

Example 12:


4-Amino-4-methylpent-2-enoic acid [(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]amide:



5

Prepared according to method E.

(1,1-Dimethyl-3-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoyl]allyl)carbamic acid tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.26g, 1.38mmol) and 1-hydroxybenzotriazole monohydrate (0.21g, 1.38mmol) were added to a solution of N-tertbutoxycarbonyl-4-amino-4-methylpent-2-enoic acid (0.32g, 1.38mmol) in N,N-dimethylformamide (5ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid (0.57g, 0.99mmol) and triethylamine (0.10g, 0.99mmol) in N,N-dimethylformamide (6ml) were added. After 18h at 20°C the reaction mixture was poured on water (75ml) and extracted several times with ethyl acetate (total 30ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo to give 0.68g of crude (1,1-dimethyl-3-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl]-2-(2-naphthyl)ethylcarbamoyl]allyl)carbamic acid tertbutyl ester which was used for the next step without further purification.

20 HPLC: R_t = 33.4 min (Method a)

(1,1-Dimethyl-3-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl]-2-(2-naphthyl)ethylcarbamoyl]allyl)carbamic acid tertbutyl ester (0.68g, 1.01mmol) was dissolved in a mixture of trifluoroacetic acid (10ml) and dichloromethane (10ml). After 10min at 20°C the reaction mixture was concentrated in vacuo and chromatographed on silica gel (80g) using a 10% mixture of ammonia in ethanol and dichloromethane (1:9) as eluent to give 0.48g of the title compound.

30 HPLC: R_t = 23.3 min (Method a)


Calculated for $C_{35}H_{37}N_5O_3 \cdot 0.5H_2O$:

C, 71.90; H, 6.55; N, 11.98%; found:

C, 71.82; H, 6.55; N, 11.71%.


Example 13:

5 (2E)-4-Amino-4-methylpent-2-enoic acid N-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]-N-methylamide:



10 Prepared according to method E.

N-Methyl-N-((1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamate tertbutyl ester:




5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.34g, 7.0mmol) and 1-hydroxy-7-azabenzotriazole (0.95g, 7.0mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (2.31g, 7.0mmol) in N,N-dimethylformamide (50ml). After 30min at 20°C a mixture of (R) N-methyl-N-[(1-(3-methyl-
10 [1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)amine hydrochloride (1.52g, 5.0mmol) and triethylamine (0.51g, 5.0mmol) in N,N-dimethylformamide (10ml) was added. After 18h at 20°C the reaction mixture was poured on water (250ml) and extracted several times with ethyl acetate (total
15 130ml). The collected organic phases were washed with aqueous citric acid (10%, 50ml), a saturated solution of sodium hydrogencarbonate (3x50ml) and water (3x50ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and chromatographed on silica (110g) using heptane and ethyl acetate
20 (1:1) to give 2.4g of N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-

naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester.

HPLC: R_t = 36.5 min (Method a)

5 (2R)-2-Methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid:



N-methyl-N-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-
10 [1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester (2.4g, 4.2mmol) was dissolved in a mixture of trifluoroacetic acid (40ml) and dichloromethane (40ml) at 20°C. After 10min the reaction mixture was concentrated in vacuo and coevaporated from dichloromethane
15 (80ml). The residue was crystallised from ethyl acetate to give 1.9g of (2R)-2-methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid.

mp 184-188°C.

¹H-NMR (DMSO-d₆) δ 1.53(s, 3H); 2.34(s, 3H); 2.63(s, 3H); 3.05(dd, 1H); 3.21(dd, 1H); 3.40(dd, 1H); 3.55(dd, 1H); 4.60(t, 1H); 6.35(dd, 1H); 7.25(d, 1H); 7.40-7.90(m, 14H).


5 HPLC: R_t = 24.9 min (Method a)

Calculated for C₃₀H₃₀N₄O₂, CF₃COOH:

C, 64.86; H, 5.27; N, 9.45%; found:

C, 65.01; H, 5.35; N, 9.32%.

(2E)-(1,1-Dimethyl-3-[N-((1R)-1-(N-methyl-N-((1R)-1-(3-methyl-
10 [1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]allyl)carbamic acid
tertbutyl ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
15 (0.31g, 1.6mmol) and 1-hydroxy-7-azabenzotriazole (0.22g, 1.6mmol)
were added to a solution of (2E)-4-tertbutoxycarbonylamino-4-methylpent-2-enoic acid (0.37g, 1.6mmol) in N,N-dimethylformamide (5ml). After 30 min at 20°C a mixture of (2R)-2-methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-

ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid (0.68g, 1.2mmol) and triethylamine (0.12g, 1.2mmol) in N,N-dimethylformamide (5ml) were added. After 18h at 20°C the reaction mixture was poured on water (80ml) and extracted several times
 5 with ethyl acetate (total 55ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (3x15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and chromatographed on silica gel (80g) using heptane and
 10 ethyl acetate (3:7) as eluent to give 0.75g of ((2E)-1,1-dimethyl-3-[N-((1R)-1-(N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]allyl)carbamic acid tertbutyl ester.

HPLC: R_t = 33.8 min (Method a)

15 ((2E)-1,1-Dimethyl-3-[N-((1R)-1-(N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]allyl)carbamic acid tertbutyl ester (0.62g, 1.9mmol) was dissolved in a mixture of trifluoroacetic acid (9ml) and dichloromethane (9ml). After 10min
 20 at 20°C the reaction mixture was concentrated in vacuo and chromatographed on silica gel (80g) using a 10% mixture of ammonia in ethanol and dichloromethane (5:95) as eluent to give 0.44g of the title compound.

HPLC: R_t = 26.4 min (Method a)


25 Calculated for $C_{36}H_{39}N_5O_3 \cdot 0.75H_2O$:

C, 71.68; H, 6.77; N, 11.61%; found:

C, 71.81; H, 6.72; N, 11.17%.

Example 14:

3-Aminomethyl-N-((1R)-1-(N-((1R)-1-
 ((dimethylcarbamoyl)methoxy)methyl)-2-phenylethyl)-N-
 methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylbenzamide



5


Prepared according to method G

(2R)-2-(Methylamino)-3-phenylpropan-1-ol:

(2R)-2-(Methylamino)-3-phenylpropan-1-ol was prepared analogously to M. J. McKennon and A. I. Meyers, K. Drauz and M. Schwarm, J. Org. Chem. 1993 (58), 3568 - 3571.

m.p. 69 - 69°C (lit: M. J. McKennon, A. I. Meyers, K. Drauz and M. Schwarm, J. Org. Chem. 1993 (58), 3568 - 3571: 71 - 74 °C; A. Karim, A. Mortreux, F. Petit, G. Buono, G. Peiffer, C. Siv, J. Organomet. Chem. 1986, 317, 93: 68 °C, for (2S)-2-(methylamino)-3-phenylpropan-1-ol).


N-((1R)-1-Hydroxymethyl-2-phenylethyl)-N-methylcarbamaic acid tert-butylester:



(2R)-2-(Methylamino)-3-phenylpropan-1-ol (6.00g, 36.3mmol) was dissolved in THF (80ml). 1N sodium hydroxide solution (36.3ml, 36.3mmol) was added. A solution of di-tert-butyl dicarbonate (9.50g, 43.6mmol) in THF (60 ml) was slowly added at room temp. The solution was stirred 16 h at room temp. Water (200ml) and ethyl acetate (200ml) were added. The phases were separated. The aqueous phase was washed with ethyl acetate (2 x 100ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The product was purified on silica (170g) with ethyl acetate/heptane (1:1) to give 7.85g of N-((1R)-1-hydroxymethyl-2-phenylethyl)-N-methylcarbamic acid tert-butylester.

$^1\text{H-NMR}$ (CDCl_3): δ 1.32 - 1.40 (br, 9H); 2.55 - 2.95 (m, 5 H); 3.65 - 3.67 (br, 2 H); 4.10 - 4.35 (br, 1H); 7.05 - 7.35 (m, 5 H).

((2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid ethylester:




20

N-((1R)-1-Hydroxymethyl-2-phenylethyl)-N-methylcarbamaic acid (3.98g, 15.0mmol) was dissolved in 1,2-dichloroethane (150ml). The

solution was warmed to 75 - 80°C. Rhodium(II) acetate (0.1g, 0.4mmol) was added. During a time of 6h a solution of ethyl diazoacetate (2.4ml, 22.5mmol) in dichloromethane (100ml) was added. After 3h another portion of rhodium(II) acetate (0.1g, 0.4mmol) was added. After all ethyl diazoacetate was added, the solution was cooled to room temp. It was filtrated through a plug of celite. The solvent was removed in vacuo. The crude product was chromatographed on silica (100g) to give 1.53g of ((2R)-2-((tert-butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid ethyl ester.

¹H-NMR (CDCl₃): δ 1.28 (m, 3 H); 1.39 and 1.48 (both s, together 9H); 2.65 - 2.95 (m, 9 H); 3.58 (m, 1 H); 3.67 (br, 1H); 3.98 - 4.27 (m, 4 H); 4.35 - 4.55 (br, 1H); 7.10 - 7.30 (m, 5 H).

((2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid:




((2R)-2-((tert.-butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid ethyl ester (0.60g, 1.71mmol) was dissolved in dioxane (5ml). A solution of lithium hydroxide (0.05g, 2.20mmol) in water (2ml) was added. The solution was stirred at room temp. for 56h. Ethyl acetate (10ml) and water (2ml) were added. The phases were separated. The aqueous phase was extracted with ethyl acetate (10ml). The combined organic layers were extracted with 1N sodium hydroxide solution (20ml). The combined aqueous phases were acidified with a 1M sodium hydrogensulfate solution (pH = 2) and extracted with ethyl acetate (2 x 20ml). These ethyl acetate layers were combined and dried over magnesium sulfate. The solvent

was removed in vacuo to give 0.38g of crude ((2R)-2-((tert-butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid, that was used for the following steps.

¹H-NMR (DMSO d₆): δ 1.15 and 1.27 (both s, together 9H); 2.55 - 2.70 (m, 5 H); 3.45 - 3.65 (m, 2 H); 4.00 - 4.10 (m, 2 H); 4.30 - 4.50 (m, 1H); 7.15 - 7.35 (m, 5 H); 13.60 (br, 1H).

N,N-Dimethyl-2-((2R)-2-methylamino-3-phenylpropoxy)acetamide:




((2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropoxy)acetic acid (0.37g, 1.14mmol) and 1-hydroxy-7-azabenzotriazole (0.26g, 1.14mmol) were dissolved in N,N-dimethylformamide (7ml). N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.26g, 1.37mmol) was added. The solution was stirred for 30 min. A 33% solution of dimethylamine in ethanol (0.33ml, 1.26mmol) was added. The solution was stirred over night. Water (20ml) and ethyl acetate (15ml) were added. The organic phase was washed with a 1M solution of sodium hydrogensulfate (30ml) and a saturated solution of sodium hydrogencarbonate (30ml). It was dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by column chromatography on silica (15g) using ethyl acetate and dichloromethane (1:1) as eluent. This product was dissolved in dichloromethane (3ml) and was cooled to 0°C. Trifluoroacetic acid (1ml) was added. The solution was stirred at 0°C for 20min. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (10ml) and 1N sodium hydroxide solution (10ml). The phases were separated. The aqueous phase was extracted with dichloromethane (4 x 10ml). The combined organic layers were dried over magnesium sulfate. The solvent was removed

in vacuo to give 140mg of crude N,N-dimethyl-2-((2R)-2-methylamino-3-phenylpropoxy)acetamide, which was used for further syntheses.

¹H-NMR (CDCl₃): δ 2.25 (s, 1H); 2.45 (s, 3 H); 2.60 - 3.10 (m, 3 H); 3.94 (s, 1 H); 3.99 (s, 3H); 3.35 - 3.55 (m, 2 H); 4.15 (s, 2 H); 7.10 - 7.40 (m, 5 H).

HPLC : R_t=12.18 min (Method b).

N-((1R)-1-(N-[(1R)-1-((Dimethylcarbamoyl)methoxy)methyl)-2-phenylethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-10 methylcarbamic acid tert-butylester:




N,N-Dimethyl-2-((2R)-2-methylamino-3-phenylpropoxy)acetamide (126mg, 0.50 mmol), (2R)-2-((tert-butoxycarbonyl)methylamino)-3-(2-naphthyl)propionic acid (250mg, 0.75 mmol) and 1-hydroxy-7-15 azabenzotriazole (103mg, 0.76 mmol) were dissolved in dichloromethane (6ml) and N,N-dimethylformamide (5ml) and then stirred 30 min at 0°C with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide

hydrochloride (146mg). Diisopropylethylamine (87μl) was added and 20 stirring was continued for 1h at 0°C. After this the dichloromethane was evaporated from the mixture by a stream of nitrogen and ethyl acetate (25ml) was added. The mixture was extracted sequentially with 5% aqueous sodium hydrogencarbonate (2 x 25ml), 5% aqueous potassium hydrogensulfate (2 x 25ml) and 25 water (25ml) and the organic phase was dried (sodium sulfate) and

concentrated in vacuo yielding 265 mg of crude N-((1R)-1-(N-((1R)-1-(((dimethylcarbamoyl) methoxy)methyl)-2-phenylethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butylester.

3-Aminomethyl-N-((1R)-1-(N-[(1R)-1-
(((dimethylcarbamoyl)methoxy)methyl)-2-phenylethyl]-N-
methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylbenzamide:



5 Half of the crude N-((1R)-1-(N-[(1R)-1-
(((dimethylcarbamoyl)methoxy)methyl)-2-phenylethyl]-N-
methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamamic acid tert-
butylester (132 mg, 0.23 mmol) was dissolved in a mixture of
dichloromethane and trifluoroacetic acid 1:1 (2 ml) and stirred
10 for 10min. The mixture was concentrated by a stream of nitrogen
and the resulting oil was redissolved in 1 ml 1N hydrochloric
acid, diluted with water to a volume of 50 ml and lyophilized.
This lyophilized product was dissolved in dichloromethane (5ml)
and diisopropylethyl amine (171 μ l) was added. To this mixture was
15 added a solution in dichloromethane (5ml) of 3-tert-
butyloxycarbonylaminomethylbenzoic acid (503mg, 2.0 mmol) which
immediately before had been converted to the symmetrical anhydride
by stirring with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide
hydrochloride (191.6mg, 1.0 mmol) for 15 min. The reaction
20 mixture was then concentrated to an oil and redissolved in ethyl
acetate (25ml). This mixture was extracted sequentially with 5%
aqueous sodium hydrogencarbonate (50ml), 5% aqueous potassium
hydrogen- sulfate (50ml) and water (50ml) and the organic phase
was dried (sodium sulfate) and concentrated by a stream of
25 nitrogen to dryness. This product was dissolved in a mixture of
dichloromethane and trifluoroacetic acid 1:1 (4ml). After 10 min
the mixture was concentrated by a stream of nitrogen and the

resulting oil was redissolved in 5ml 70% acetonitrile / 0.1% trifluoroacetic acid and diluted with water to a volume of 50 ml. The crude product of the title compound was then purified by semipreparative HPLC in four runs on a 25 mm x 250 mm column 5 packed with 7 μ C-18 silica which was preequilibrated with 29% acetonitrile in 0.05M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid.

The column was eluted with a gradient of 29% - 39% acetonitrile in 0.05M ammonium sulfate, pH 2.5 at 10 ml/min during 47 min at 10 40 °C and the peptide containing fractions were collected, diluted with 3 volumes of water and applied to a Sep-Pak® C18 cartridge (Waters part. #:51910) which was equilibrated with 0.1% trifluoroacetic acid . The peptide was eluted from the Sep-Pak® cartridge with 70% acetonitrile/0.1% trifluoroacetic acid and 15 isolated from the eluate by lyophilisation after dilution with water.

The final product obtained was characterised by analytical RP-HPLC (retention time) and by Plasma desorption mass spectrometry (molecular mass). The molecular mass found (MH⁺: 592.9amu) agreed 20 with the expected structure (teor. MH⁺: 593.4amu) within the experimental error of the method.

The RP-HPLC analysis was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5 μ C-18 silica column (The Separations Group, Hesperia) which was eluted at 1 ml/min at 25 25 °C. Two different elution conditions were used:


- A1: The column was equilibrated with 5% acetonitrile in a buffer consisting of 0.1M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid and eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min.
- 30 B1: The column was equilibrated with 5% acetonitrile / 0.1% trifluoroacetic acid / water and eluted by a gradient of 5% acetonitrile / 0.1% trifluoroacetic acid / water

to 60% acetonitrile / 0.1% trifluoroacetic acid / water during 50 min.

The retention time using elution conditions A1 and B1 was found to be 30.92 min and 35.15 min, respectively.


5 Example 15

5-((1R)-1-(((2R)-2-(((2E)-4-Amino-4-methylpent-2-enoyl)methylamino)-3-(2-naphthyl)propionyl)methylamino)-2-phenylethyl)-[1,3,4]-oxadiazole-2-carboxylic acid amide:



10

(2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropionic acid ethyl ester:




(2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropionic acid 15 (4.0g, 14.27mmol) was dissolved in dichloromethane (5ml) and ethanol (0.95ml, 16.27mmol). 4-Dimethylaminopyridine (0.19g, 1.57mmol) was added. The solution was cooled to 0 °C and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (2.98g, 15.55mmol) was added. The reaction mixture was stirred for 2h at 20 °C for 16h at room temp. The solvent was removed in vacuo and the

residue was dissolved in ethyl acetate/water (30ml/30ml). The phases were separated. The organic phase was washed with a saturated solution of sodium hydrogencarbonate and water and dried over magnesium sulfate. The crude product was purified by flash chromatography on silica (180g) with ethyl acetate/heptane 1:2 to give 1.95g of (2R)-2-((tert-butoxycarbonyl)methylamino)-3-phenylpropionic acid ethylester.

¹H-NMR (CDCl₃): δ 1.15 - 1.50 (m, 12 H); 2.71 (m, 3 H); 3.00 (m, 1 H); 3.80 (m, 1 H); 4.20 (br q, 2 H); 4.55 and 4.90 (both br dd, 10 together 1 H); 7.10 - 7.40 (m, 5 H).


((1R)-1-Hydrazinocarbonyl-2-phenylethyl)methylcarbamic acid tert-butyl ester:



(2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropionic acid ethylester (1.9g, 6.16mmol) was dissolved in anhydrous ethanol (15mL). Hydrazine hydrate (3.0ml, 61.6mmol) was added dropwise. The solution was stirred at room temp. over night. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (40ml) and washed with water (40ml). The organic phase was dried over magnesium sulfate. After removal of the solvent in vacuo 1.40g of crude ((1R)-1-hydrazinocarbonyl-2-phenylethyl)methylcarbamic acid tert-butylester was obtained, which was used for the further synthesis.

¹H-NMR (CDCl₃): δ 1.20 - 1.50 (m, 9 H); 2.76 (s, 3 H); 3.00 (m, 1 H); 3.35 (m, 1 H); 3.85 (br, 2 H); 4.75 and 4.85 (both m, together 1 H); 7.10 - 7.40 (m, 5 H); 7.45 (br, 1 H).


1-((2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropionyl)-2-ethoxycarbonylformylhydrazine:



((1R)-1-Hydrazinocarbonyl-2-phenylethyl)methylcarbamic acid tert-butylester (1.4g, 4.76mmol) was dissolved in dichloromethane (40ml). Triethylamine (0.8ml, 5.71mmol) was added and the solution was cooled to -15°C. Ethyl oxalyl chloride (0.59ml, 5.24mmol) was added dropwise. The solution was stirred for 15min at -15°C. It was warmed to room temp. and extracted with water (2x 20ml) and 5% citric acid (30ml) and washed with a saturated solution of sodium hydrogencarbonate. The organic layer was dried over magnesium sulfate. The solvent was removed in vacuo and the crude product was purified by flash chromatography on silica (140g) with ethyl acetate/dichloromethane 1:3 to give 1.40g of 1-((2R)-2-((tert-butoxycarbonyl)methylamino)-3-phenylpropionyl)-2-ethoxycarbonylformylhydrazine.

¹H-NMR (CDCl₃): δ 1.30 - 1.50 (m, 12 H); 2.80 (br, 3 H); 3.05 (m, 1 H); 3.35 (m, 1 H); 4.37 (br m, 2 H); 4.82 and 4.95 (br and br t, together 1H); 7.05 - 7.35 (m, 5 H); 8.60, 8.95, 9.15, 9.45 (all 20 br, together 2 H).


5-((1R)-1-((tert-Butoxycarbonyl)methylamino)-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid ethylester:



1-((2R)-2-((tert-Butoxycarbonyl)methylamino)-3-phenylpropionyl)-2-ethoxycarbonylformylhydrazine (1.4g, 3.55mmol) was dissolved in ether (25ml) and THF (10ml). Pyridine (1.44ml 17.75mmol) was added, and the solution was cooled to 0°C. Thionyl chloride (0.3ml, 3.90mmol) was added dropwise. The reaction mixture was stirred at 0°C for 2h. The precipitation was filtered off. The solvent was removed in vacuo without warming. The residue was dissolved in toluene (25ml) and the solution was warmed to reflux for 2h. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (70g) with ethyl acetate/dichloromethane 1:2 to give 721mg of 5-((1R)-1-((tert-butoxycarbonyl)methylamino)-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid ethylester.

¹H-NMR (CDCl₃): δ 1.35 (br d, 9 H); 1.47 (t, 3 H); 2.70 (br, 3 H); 3.30 (br, 1 H); 3.50 (br, 1 H); 4.52 (br, 2 H); 5.55 and 5.88 (both br, together 1H); 7.15 - 7.40 (m, 5 H).


((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methyl carbamic acid tert-butylester:



5-((1R)-1-((tert-Butoxycarbonyl)methylamino)-2-phenylethyl)-
 5 [1,3,4]oxadiazole-2-carboxylic acid ethylester (600mg, 1.6mmol)
 was dissolved in THF (4ml) and added to refluxing ammonia. The
 solution was stirred for 3h. The ammonia was removed in a
 stream of nitrogen. The residue was dissolved in ethyl acetate/10%
 sodium hydrogensulfate solution (20ml/20ml). The phases were
 10 separated and the organic phase was washed with a saturated
 solution of sodium hydrogencarbonate and dried over magnesium
 sulfate. The solvent was removed in vacuo. The crude product was
 purified by flash chromatography on silica (40g) with ethyl
 acetate/heptane 2:1 to give 383mg of ((1R)-1-(5-carbamoyl-
 15 [1,3,4]oxadiazol-2-yl)-2-phenylethyl)methyl carbamic acid tert-
 butylester.

¹H-NMR (CDCl₃): δ 1.30 (br, 9 H); 2.75 (br d, 3 H); 3.30 (dd, 1 H);
 3.50 (br, 1 H); 5.55 and 5.85 (both br, together 1 H); 6.27 (br,
 1 H); 7.10 (br, 1 H); 7.20 - 7.40 (m, 5 H).


20 5-((1R)-1-Methylamino-2-phenylethyl)-[1,3,4]oxadiazole-2-
 carboxylic acid amide:



((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamic acid tert-butylester (350mg, 1.01mmol) was dissolved in dichloromethane (6ml). The solution was cooled 5 to 0°C. Trifluoroacetic acid (2ml) was added dropwise. The solution was stirred for 30min. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (6ml) and the solvent was removed in vacuo. The residue was again dissolved in dichloromethane (6ml) and the solvent was removed in vacuo. The 10 residue was dissolved in dichloromethane (10 ml). This phase was washed with water. The aqueous phase was lyophilized to give 247mg of crude 5-((1R)-1-methylamino-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid amide, which was used for the further synthesis.

¹H-NMR (DMSO d₆): δ 2.65 (s, 3H); 3.35 (dd, 1 H); 3.62 (dd, 1 H); 15 5.20 (dd, 1 H); 7.10 - 7.40 (m, 5 H); 8.35 (s, 1 H); 8.68 (s, 1 H).


((1R)-1-(((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbonyl)-2-(2-naphthyl)ethyl)methylcarbamic 20 acid tert-butylester:



5-((1R)-1-Methylamino-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid amide (240mg, 0.98mmol), (R)-2-((tert-butoxycarbonyl)methylamino)-3-(2-naphthyl)propionic acid (320mg, 0.98mmol) and 1-hydroxy-7-azabenzotriazole (133mg, 0.98mmol) were dissolved in dichloromethane (8ml) and DMF (4ml). The solution was cooled to 0°C and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (230mg, 1.18mmol) was added. After 10 min triethylamine (0.35ml, 2.46mmol) was added. The solution was stirred for 1h at 0°C and subsequently for 16h at room temp. The solution was diluted with ethyl acetate (30ml) and water (20ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (20ml). The combined organic layers were washed with a saturated solution of sodium hydrogencarbonate (30ml) and dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (50g) with ethyl acetate to give 301mg of ((1R)-1-((1R)-1-(5-carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamoyl)-2-(2-naphthyl)ethyl)methylcarbamic acid tert-butylester.

¹H-NMR (CDCl₃): δ 0.84, 0.95, 1.07, 1.25 (all s, together 9 H); 2.05, 2.15, 2.42, 2.75, 2.76, 2.77, 2.87, 3.98 (all s, together 6 H); 6.90 - 7.90 (m, 12 H).

5-((1R)-1-(Methyl((2R)-2-methylamino-3-(2-naphthyl)propionyl)amino)-2-phenylethyl)-[1,3,4]oxadiazol-2-carboxylic acid amide:




5 ((1R)-1-(((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamoyl)-2-(2-naphthyl)ethyl)methylcarbamic acid tert-butylester (300mg, 0.55mmol) was dissolved in dichloromethane (3ml) and cooled to 0°C. Trifluoroacetic acid (3ml) was added dropwise. The solution was stirred for 5min at 10 0°C. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (5ml), and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (5ml), and the solvent was removed in vacuo. The residue was dissolved in 3M hydrogen chloride in ethyl acetate (5ml), and the solvent was removed in 15 vacuo. The residue was dissolved in 3M hydrogen chloride in ethyl acetate (5ml), and the solvent was removed in vacuo to give 238mg of crude 5-((1R)-1-(methyl((2R)-2-methylamino-3-(2-naphthyl)propionyl)amino)-2-phenylethyl)-[1,3,4]oxadiazol-2-carboxylic acid amide, which was used for the further synthesis.

20 ¹H-NMR (CDCl₃): δ 2.40 (s, 3H); 2.55 - 4.40 (m, 9 H); 7.10 - 7.90 (m, 9H).

((E)-3-(((1R)-1-(((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamoyl)-2-(2-

naphthyl)ethyl)methylcarbamoyl)-1,1-dimethylallyl)carbamic acid tert-butylester:



(2E)-4-tert-Butoxycarbonylamino-4-methylpent-2-enoic acid (143mg, 5 0.62mmol) was dissolved in dichloromethane (4ml). 1-Hydroxy-7-azabenzotriazole (85mg, 0.62mmol) and subsequently N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (119mg, 0.62mmol) were added. The solution was stirred for 15min at room temp. 5-((1R)-1-(Methyl(2R)-2-methylamino-3-(2- 10 naphthyl)propionyl)amino)-2-phenylethyl)-[1,3,4]oxadiazol-2-carboxylic acid amide (230mg, 0.52mmol) was added. The solution was stirred for 5min and ethyldiisopropylamine (0.11ml, 0.62mmol) was given to the reaction mixture. It was stirred for 16h at room temp., diluted with ethyl acetate (20ml) and extracted with water 15 (20ml). The phases were separated. The aqueous phase was extracted with ethyl acetate (2 x 10ml). The combined organic layers were washed with a saturated solution of sodium hydrogencarbonate and dried over magnesium sulfate. The crude product was purified by flash-chromatography on silica (40g) with dichloromethane/ethyl 20 acetate 1:1 to give 126mg of ((E)-3-(((1R)-1-(((1R)-1-(5-carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamoyl)-2-(2-naphthyl)ethyl)methylcarbamoyl)-1,1-dimethylallyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃): δ 1.1 - 1.5 (m, 15 H); 2.6 - 3.7 (m, 12H).

HPLC (Method b): $R_t = 44.95$ min.

PDMS: 668.8 ([M]⁺)


((E)-3-(((1R)-1-(((1R)-1-(5-Carbamoyl-[1,3,4]oxadiazol-2-yl)-2-phenylethyl)methylcarbamoyl)-2-(2-naphthyl)ethyl)methylcarbamoyl)-5 1,1-dimethylallyl)carbamic acid tert-butylester (120mg, 0.18mmol) was dissolved in dichloromethane (3ml). The solution was cooled to 0°C. Trifluoroacetic acid (3ml) was added dropwise. The reaction mixture was stirred for 5min at 0°C. The solvent was removed in vacuo without warming. The residue was dissolved in 10 dichloromethane (5ml) and the solvent was removed in vacuo. This last procedure was repeated two times. The residue was dissolved in water (5ml) and 1N hydrochloric acid (1ml, 1mmol) was added. The solvent was removed in vacuo. The residue was dissolved in 3M hydrogen chloride in ethyl acetate (3ml), and the solvent was 15 removed in vacuo. This last procedure was repeated. The crude product was purified by HPLC-chromatography on a 25mm x 250mm 5 μ C18 silica column with a gradient of 28% to 38% acetonitrile in a 0.1M ammonium sulfate buffer, which was adjusted to pH 2.5 with 4M sulfuric acid to give 64mg of the title compound.

20 HPLC (Method b): $R_t = 30.133$ min

PDMS: 569.6 ([M+H]⁺)


Example 16

Piperidine-4-carboxylic acid N-methyl-N-{-1(methyl-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2- 25 (2-naphthyl)ethyl}amide:



Prepared according to method E.


N-Methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutylester:



5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.34g, 7.0mmol) and 1-hydroxy-7-azabenzotriazole (0.95g, 7.0mmol) were added to a solution of (R) N-methyl-N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (2.31g, 7.0mmol) in N,N-dimethylformamide (50ml). After 30min at 20°C a mixture of (R) N-methyl-N-(1-(3-
10 methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)amine hydrochloride (1.52g, 5.0mmol) and triethylamine (0.51g, 5.0mmol) in N,N-dimethylformamide (10ml) were added. After 18h at 20°C the reaction mixture was poured on water (250ml) and extracted several times with ethyl acetate (total 130ml). The collected organic
15 phases were washed with aqueous citric acid (10%, 50ml), a saturated solution of sodium hydrogencarbonate (50ml) and water (3x50ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and the residue was chromatographed on silica (110g) using ethyl acetate and heptane (1:1) as eluent to
20 give 2.4g of N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(3-methyl-[1,2,4]-oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butylester as a foam.

HPLC: R_t = 36.5 min (method a)

(2R)-2-Methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid:



5 N-Methyl-N-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbonyl)-2-(2-naphthyl)ethyl]carbamic acid tert-butylester (2.4g, 4.2mmol) was dissolved in a mixture of trifluoroacetic acid (40ml) and dichloromethane (40ml) at 20°C. After 10min the reaction mixture
10 was concentrated in vacuo and coevaporated from heptane (80ml) and dichloromethane (80ml). The residue was crystallised from ethyl acetate to give 1.12g of (2R)-2-methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid.

15 mp 184-188°C.

¹H-NMR (DMSO-d₆) δ 1.52(s, 3H); 2.32(s, 3H); 2.68(s, 3H); 3.03(dd, 1H); 3.22(dd, 1H); 3.55(dd, 1H); 4.62(t, 1H); 6.35(dd, 1H); 7.25-7.95(m, 14H).

HPLC: R_t = 24.9min (Method a)


20 Calculated for C₃₀H₃₀N₄O₂, CF₃COOH, 0.25EtOAc:

C, 64.49; H, 5.41; N, 9.12%; found:

C, 65.01; H, 5.35; N, 9.32%.

4-(N-Methyl-N-((1R)-1-[N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl]-2-(2-naphthyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butyl ester:

5



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.37g, 1.91mmol) and 1-hydroxybenzotriazole monohydrate (0.26g, 1.91mmol) were added to a solution of N-tert-butoxycarbonyl-4-piperidine carboxylic acid (0.44g, 1.91mmol) in N,N-dimethylformamide (5ml). After 45 min at 20°C a mixture of (2R)-2-methylamino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)-3-(2-naphthyl)]propionamide, trifluoroacetic acid (0.81g, 1.37mmol) and triethylamine (0.19g, 1.37mmol) in N,N-dimethylformamide (10ml) were added. After 18h at 20°C the reaction mixture was poured on water (100ml) and extracted several times with ethyl acetate (total 70ml). The organic phases were collected and washed with aqueous citric acid (10%, 20ml), a saturated solution of sodium hydrogencarbonate (20ml) and water (3x20ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and the residue was

chromatographed on silica (80g) using ethyl acetate and heptane (3:2) as eluent to give 0.88g of 4-(N-methyl-N-((1R)-1-[N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl]-2-(2-naphthyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butyl ester.

HPLC: $R_t = 36.1$ min (Method a)

4-(N-Methyl-N-((1R)-1-[N-methyl-N-((1R)-1-(3-methyl-
10 [1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl]-2-(2-naphthyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.88g, 1.28mmol) was dissolved in a mixture of trifluoroacetic acid (12ml) and dichloromethane (12ml). After 10min at 20°C the reaction mixture was concentrated in vacuo. The
15 compound was chromatographed on silica (75g) using a 10% mixture of ammonia in ethanol and dichloromethane (1:9) as eluent to give 0.56g of two isomers of the title compound.

HPLC: diastereoisomer I: $R_t = 25.24$ min (Method a)
diastereoisomer II: $R_t = 25.26$ min (Method a)


20 Calculated for $C_{30}H_{39}N_5O_3 \cdot H_2O$:

C, 71.15; H, 6.80; N, 11.52%; found:
C, 71.27; H, 6.68; N, 11.28%.

Example 17


Piperidine-4-carboxylic acid N-(1-(N-[methyl-N-[1-(3-methyl-[1,2,4]-oxadiazole-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)amide:

5



Prepared according to method E.

4-((1R)-1-(N-Methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl)carbamoyl)-2-(2-naphthyl)ethyl)carbamoylpiperidine-1-carboxylic acid tert-butyl-ester:



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.42g, 2.2mmol) and 1-hydroxybenzotriazole monohydrate (0.34g, 2.2mmol) were added to a solution of N-tert-butoxycarbonyl-4-piperidine carboxylic acid (0.50g, 2.2mmol) in N,N-dimethylformamide (5ml). After 30 min at 20°C a mixture of (2R)-2-amino-N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid (0.9g, 1.54mmol) and triethylamine (0.16g, 1.54mmol) in N,N-dimethylformamide (10ml) were added. After 18h at 20°C the reaction mixture was poured on water (85ml) and extracted several times with ethyl acetate (total 90ml). The organic phases were collected and washed with aqueous citric acid (10%, 15ml), a saturated solution of sodium hydrogencarbonate (15ml) and water (3x15ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and the residue was chromatographed on silica (110g) using ethyl acetate and heptane (1:1) as eluent to give 0.50g of 4-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoylpiperidine-1-carboxylic acid tert-butyl ester.

¹H-NMR (DMSO-d₆) δ 2.40(s, 3H); 2.95(s, 3H); 3.45(dd, 1H); 3.60(dd, 1H); 4.85(m, 1H); 6.08(m, 1H); 7.10(d, 1H); 7.40-7.90(m, 13H).

HPLC: R_t = 34.0 min (Method a)

4-[(1R)-1-(N-Methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]carbamoylpiperidine-1-carboxylic acid tert-butyl ester (0.50g, 0.74mmol) was dissolved in a mixture of trifluoroacetic acid (10ml) and dichloromethane (10ml). After 10min at 20°C the reaction mixture was concentrated in vacuo. The compound was chromatographed on silica (38g) using a 10% mixture

of ammonia in ethanol and dichloromethane (3:7) as eluent to give 0.26g of the title compound.

$^1\text{H-NMR}$ (DMSO-d_6) δ 3.45(dd, 1H); 3.61(dd, 1H); 4.72(m, 1H); 6.10(dd, 1H); 7.20(d, 1H); 7.40-8.00(m, 14H).

5

HPLC: $R_t = 24.8$ min (Method a)


Calculated for $\text{C}_{35}\text{H}_{37}\text{N}_5\text{O}_3, 0.5 \text{ H}_2\text{O}$:

C, 71.90; H, 6.55; N, 11.98%; found:


C, 71.77; H, 6.52; N, 12.09%.

10 Example 18:

5-{1-[N-(2-(piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl)-N-methylamino]-2-(2-naphthyl)ethyl}-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester:



(R) 5-(1-Methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester:




(R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester hydrochloride (1.64g, 4.5mmol) was suspended in 2-propanol (35ml). After addition of tetraisopropyl titanate (1.3g, 4.5mmol) the reaction mixture was refluxed for 18h. Hydrochloric acid (1N, 30ml) was added and the reaction mixture was extracted with ethyl acetate (150ml). The organic phase was washed with a saturated aqueous solution of sodium hydrogencarbonate (50ml) and water (3x50ml). After drying (magnesium sulfate) the solution was concentrated in vacuo to give 1.3g of (R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester that was used for the next step without further purification.

¹H-NMR (DMSO-d₆) δ 1.31(d,6H); 2.21(d,3H); 3.3(m,2H); 4.40(t,1H); 5.72(m,1H); 7.35-7.95(m, 7H).

HPLC: R_t = 20.5 min (Method a)

5-((1R)-1-[N-((2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)-propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester:




5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (2.15g, 6.8mmol) and 1-hydroxy-7-azabenzotriazole (0.93g, 6.8mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (2.15g, 6.8mmol) in N,N-dimethylformamide (50ml). After 30min at 20°C a solution of 10 (R) 5-(1-methylamino-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester (1.65g, 4.9mmol) in N,N-dimethylformamide (15ml) was added. After 18h the reaction mixture was poured on water (500ml) and extracted several times with ethyl acetate (total 450ml). The collected organic phases were washed 15 with aqueous citric acid (10%, 75ml), a saturated solution of sodium hydrogencarbonate (75ml), water (3x75ml) and dried (magnesium sulfate). The solution was concentrated in vacuo and the residue was chromatographed on silica (160g) using ethyl acetate and heptane (1:2) as eluent to give 2.4g of 5-((1R)-1-[N-20 ((2R)-2-tert-butoxycarbonylamino-3-(2-naphthyl)propionyl)-N-

methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester.


HPLC: $R_t = 36.5$ min (Method a)

5-((1R)-1-[N-((2R)-2-Amino-3-(2-naphthyl)propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester, trifluoroacetic acid:



5-((1R)-1-[N-((2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)-
10 propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-
[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester (2.1g, 3.3mmol) was suspended in a saturated mixture of trifluoroacetic acid and dichloromethane (1:1, 60ml). After 10min at 20°C, the reaction mixture was concentrated in vacuo to give 2.2g of 5-
15 ((1R)-1-[N-((2R)-2-amino-3-(2-naphthyl)propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester, trifluoroacetate, that was used for the next step without further purification.

4-((1R)-1-(N-[(1R)-1-(3-(2-propoxy)carbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester:



5 N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.22g, 6.35mmol) and 1-hydroxybenzotriazole monohydrate (0.97g, 6.35mmol) were added to a solution of N-tert-butoxycarbonyl-4-piperidinecarboxylic acid (1.46g, 6.35mmol) in N,N-dimethylformamide (20ml). After 30min at 20°C a solution of 5-
 10 ((1R)-1-[N-(2R)-2-amino-3-(2-naphthyl)propionyl]-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester (2.95g, 4.53mmol) and triethylamine (0.47g, 4.53mmol) in N,N-dimethylformamide (20ml) was added. After 18h at 20°C the reaction mixture was poured on water (240ml) and
 15 extracted several times with ethyl acetate (total 240ml). The organic phases were collected and washed with aqueous citric acid (10%, 35ml), a saturated solution of sodium hydrogencarbonate (35ml) and water (3x35ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and purified by flash
 20 chromatography on silica gel (110g) using ethyl acetate and heptane (1:1) to give 2.6g of 4-((1R)-1-(N-[(1R)-1-(3-(2-

propoxy) carbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-carbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester.

¹H-NMR (DMSO-d₆) δ


5 HPLC: R_t = 35.9 min (Method a)

4-((1R)-1-(N-([(1R)-1-(3-(2-Propoxy) carbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (1.0g, 1.34mmol) was dissolved in a mixture trifluoroacetic acid and dichloromethane (1:1, 25ml). After 10 min at 20°C the reaction mixture was concentrated in vacuo. The compound was purified by flash chromatography with silica gel (75g) using a mixture of dichloromethane and 10% ammonia in ethanol (9:1) as eluent to give 0.77g of the title compound.

15 ¹H-NMR (DMSO-d₆) δ .


Example 19:

5-(1-[N-(2-(piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid, trifluoro acetate:



Prepared according to method E.

4-(1-([1-(3-Carboxy-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester :



4-((1R)-1-([1-(3-Ethoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.79g, 1.06mmol) was dissolved in dioxane (5.5ml). Water (3ml) and solid lithium hydroxide (0.03g) was added. After 18h at 20°C the reaction mixture was diluted with water (15ml) and extracted with tert-butyl-methylether (2x10ml). The aqueous phase was acidified with 1N aqueous sodium hydrogenphosphate (2.5ml) and extracted with tert-butyl-methylether (3x40ml). The collected organic phases were dried (magnesium sulfate) and concentrated in vacuo. The residue was chromatographed on silica (60g) using a mixture of dichloromethane and 10% ammonia in ethanol (4:1) as eluent to give 0.41g of 4-(1-([1-(3-carboxy-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-

(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester.

¹H-NMR (DMSO-d₆) δ .


4-(1-([1-(3-Carboxy-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)-ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester
5 (0.41g, 0.58mmol) was dissolved in a mixture trifluoroacetic acid and dichloromethane (1:1, 12ml). After 10 min at 20°C the reaction mixture was concentrated in vacuo to give 0.4g of the title compound as a crude product.

PDMS: (teor. MH⁺ = 606.7; found MH⁺ = 605.9)

Example 20:

Piperidine-4-carboxylic acid (1-{N-[1-(3-methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)amide:


5



Prepared according to method E.

4-(1-(N-[1-(3-Methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tertbutyl-ester:

5



4-((1R)-1-(N-[(1R)-1-(3-Propoxycarbonyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.80g, 1.07mmol) was dissolved in 33% methylamine in ethanol and stirred at 90°C for 18h in a closed reaction vessel. The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica (60g) using ethyl acetate and heptane (7:3) as eluent to give 0.15g of 4-(1-(N-[1-(3-methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert butyl ester.

HPLC: R_t = 31.5 min (Method a)


4-(1-(N-[1-(3-Methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl]-N-methylcarbamoyl)-2-(2-

naphthyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert butyl ester (0.15g, 0.21mmol) was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1,4ml). After 5min at 20°C the reaction mixture was concentrated in vacuo. The compound 5 was purified by flash chromatography with silica gel (40g) using a mixture of dichloromethane and 10% ammonia in ethanol (9:1) as eluent to give 0.08g of the title compound.

HPLC: R_t = 20.9 min (Method a)


Example 21:

(2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl)amide:



5

(R) 5-(1-Methylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid benzylamide:



10 (R) 5-(1-Methylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester (3.3g, 9.0mmol) was dissolved in ethanol (30ml). Benzylamine (3ml) was added and the reaction mixture was stirred for 18h at 20°C. The reaction mixture was concentrated in vacuo and the residue was crystallised from ethanol to give 2.07g of (R)
 15 5-(1-methylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid benzylamide.

m.p. 128-128.5°C

$^1\text{H-NMR}$ (DMSO-d_6) δ 2.22 (s, 3H); 3.08 (dd, 1H); 3.18 (dd, 1H); 4.26 (t, 1H); 4.45 (d, 2H); 7.10-7.45 (m, 1H); 9.50 (t, 1H).

HPLC: $R_t = 17.3$ min (Method a)


Calculated for $\text{C}_{19}\text{H}_{20}\text{N}_4\text{O}_2 \cdot 0.25 \text{ EtOH}$:

5 C, 67.32; H, 6.23; N, 16.10%; found:

C, 67.35; H, 6.03; N, 16.25%.

((1R)-1-(N-Methyl-N-[(1R)-1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester:


10



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.64g, 8.57mmol) and 1-hydroxy-7-azabenzotriazole (1.17g, 8.57mmol) were added to a solution of (R) N-tert-butoxycarbonyl-3-(2-naphthyl)alanine (2.70g, 8.57mmol) in N,N-dimethylformamide 15 (40ml). After 20min at 20°C a solution of (R) 5-(1-methylamino-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid benzylamide (2.06g, 6.12mmol) in dimethylformamide (40ml) was added. After 18h at 20°C the reaction mixture was poured on water (250ml) and extracted several times with ethyl acetate (total 200ml). The

collected organic phases were washed with aqueous citric acid (10%, 50ml), a saturated solution of sodium hydrogencarbonate (3x50ml) and water (3x50ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and the residue was chromatographed on silica (150g) using ethyl acetate and heptane (1:1) as eluent to give 3.9 of ((1R)-1-(N-methyl-N-[(1R)-1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tertbutyl ester.

10 2-Amino-N-methyl-N-[1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide, trifluoro acetic acid:



((1R)-1-(N-methyl-N-[(1R)-1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butylester (3.9g, 6.15mmol) was dissolved in a mixture of trifluoroacetic acid (40ml) and dichloromethane (40ml) at 20°C. After 10min the reaction mixture was concentrated in vacuo and coevaporated from heptane and then from dichloromethane to give 20 4g of two isomers of crude 2-amino-N-methyl-N-[1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-


naphthyl)propionamide, trifluoro acetic acid that was used for the next step without further purification.

$^1\text{H-NMR}$ (DMSO-d_6) δ 2.88 (s); 3.21 (s); 3.32 (m); 3.55 (m); 4.52 (m); 5.95 (m); 6.21 (m).

5 HPLC: isomer I: R_t = 24.2 min (Method a)
isomer II: R_t = 25.4 min (Method a)

[(2E)-1,1-Dimethyl-4-(1-(N-methyl-N-[1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethylcarbamoyl)but-3-enyl]carbamic acid tert-butylester:

10



N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.40g, 2.1mmol) and 1-hydroxybenzotriazole monohydrate (0.32g, 2.1mmol) were added to a solution of (2E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid (0.51g, 2.1mmol) in 15 N,N-dimethylformamide (5ml). After 30 min at 20°C a mixture of 2-amino-N-methyl-N-[1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]-3-(2-naphthyl)propionamide, trifluoroacetic acid (1.0g, 1.5mmol) and triethylamine (0.15g, 1.5mmol) in N,N-dimethylformamide (12ml) were added. After 18h at 20°C the

reaction mixture was poured on water (100ml) and extracted several times with ethyl acetate (total 65ml). The organic phases were collected and washed with aqueous citric acid (10%, 20ml), a saturated solution of sodium hydrogencarbonate (20ml) and water 5 (3x20ml). After drying (magnesium sulfate) the solution was concentrated in vacuo and the residue was chromatographed on silica (85g) using ethyl acetate and heptane (1:1) as eluent to give 0.77g of two isomers of [(2E)-1,1-dimethyl-4-(1-(N-methyl-[1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethylcarbamoyl)but-3-enyl]carbamic acid tert-butylester. 10


HPLC: Isomer I: R_t = 34.1 min (Method a)
Isomer II: R_t = 34.4 min (Method a)

[(2E)-1,1-Dimethyl-4-(1-(N-methyl-N-[1-(3-benzylcarbamoyl- 15 [1,2,4]oxadiazol-5-yl)-2-phenylethyl]carbamoyl)-2-(2-naphthyl)ethylcarbamoyl)but-3-enyl]carbamic acid tert-butylester (0.77g, 1.0mmol) was dissolved in a mixture trifluoroacetic acid (2ml) and dichloromethane (2ml). After 10min at 20°C the reaction mixture was diluted with dichloromethane (25ml) and neutralised 20 with a saturated aqueous solution of sodium hydrogencarbonate. The organic phase was dried (magnesium sulfate) and concentrated in vacuo to give 0.7g of two isomers of the title compound.

HPLC: Isomer I: R_t = 24.5 min (Method a)
Isomer II: R_t = 25.3 min (Method a)

Example 22:


(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-[N-((1R)-1-benzyl-2,5-dihydroxypentyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl)-N-methylamide:



5

Prepared according to method J.

N-((1R)-1-Formyl-2-phenylethyl)-N-methylcarbamic acid tert-butylester:




10

Oxalyl chloride (4.24 mL, 48.61 mmol) was dissolved in dichloromethane (30 mL). The solution was cooled to -63 °C. A solution of DMSO (4.6 mL, 64.81 mmol) in dichloromethane (20 mL) was added dropwise. The solution was stirred for 5 min and a

solution of N-((1R)-1-(hydroxymethyl)-2-phenylethyl)-N-methylcarbamic acid tert-butylester (8.6 g, 32.41 mmol) in dichloromethane (200 mL) was added dropwise over a period of 30 min. The reaction mixture was stirred for 20 min at -63 °C. A solution of triethylamine (18.07 mL, 129.62 mmol) in dichloromethane (40 mL) was added over a period of 25 min. The solution was warmed to -35 °C and immediately cooled to -63 °C. It was stirred at this temp. for 1 h. Acetic acid (8.15 mL, 142.58 mmol) was added. The reaction mixture was warmed to 10 °C and washed with water (2 x 200 mL) and satd. sodium hydrogencarbonate solution (150 mL). The org. phase was dried over magnesium sulfate. The solvent was removed in vacuo to give 7.536 of N-((1R)-1-formyl-2-phenylethyl)-N-methylcarbamic acid tert-butylester

¹H-NMR (CDCl₃): δ = 1.40 and 1.44 (both s, together 9H); 2.52 and 2.58 (both s, together 3H); 2.90 and 3.00 (both dd, together 1H); 3.81 (dd, 1H); 4.00 and 4.20 (both dd, together 1H); 7.10 - 7.35 (m, 5H).


N-((1R)-1-Benzyl-2-hydroxypent-4-enyl)-N-methylcarbamic acid tert-butylester



N-((1R)-1-Formyl-2-phenylethyl)-N-methylcarbamic acid tert-butylester (6.0 g, 20.0 mmol) was dissolved in ether (150 mL). The solution was cooled to -78 °C and allylmagnesium bromide (22 mL of a 1.0 M solution in ether, 22 mmol) was added dropwise. After 5 addition, the solution was warmed to room temp. It was given onto 10% ammonium chloride solution in water (200 mL). The phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with satd. sodium hydrogencarbonate solution (100 mL) and dried over 10 magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (260 g) with ethyl acetate/heptane 1:1 to give 4.00 g of N-((1R)-1-benzyl-2-hydroxypent-4-enyl)-N-methylcarbamic acid tert-butylester.

¹H-NMR (CDCl₃): δ = 1.10 - 1.50 (m, 9H); 1.90 - 3.40 (m, 8H); 3.50 - 4.10 (m, 2H); 5.00 - 5.30 (m, 2H); 5.90 (m, 1H); 7.10 - 7.40 (m, 5H).

((1R)-1-Benzyl-2,5-dihydroxypentyl)methyl carbamic acid tert-butylester




N-((1R)-1-Benzyl-2-hydroxypent-4-enyl)-N-methylcarbamic acid tert-butylester (3.95 g, 11.60 mmol) was dissolved in THF (90 mL) and added to a solution of 9-borabicyclo[3.3.1]nonane (46.64 mL of a 0.5M solution in THF, 23.32 mmol) in THF (90 mL). The solution was heated to reflux for 16 h. The mixture was cooled to room temp. Ethanol (22 mL) was added dropwise. 6N Sodium hydroxide solution in water (6.6 mL, 39.44 mmol) and subsequently hydrogen peroxide (35% solution in water) were added slowly. The reaction mixture was heated to reflux for 1 h and cooled to room temp. It was given onto 1N sodium hydroxide solution (200 mL). The phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with a 37% solution of sodium hydrogensulfite (150 mL). The solution was dried over magnesium sulfate. It was washed with a 37% solution of sodium hydrogensulfite (200 mL) and dried over magnesium sulfate. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (200 mL), washed with 37% solution of sodium hydrogensulfite (200 mL) and dried over magnesium sulfate. The crude product was chromatographed on silica (180 g) with ethyl acetate and subsequently on silica (100 g) with dichloromethane/methanol/25% aqueous ammonia 100:10:1 to give 586 mg of ((1R)-1-benzyl-2,5-dihydroxypentyl)methylcarbamic acid tert-butylester

MS (EI): 365 (20%; [M+1]⁺)

¹H-NMR (CDCl₃): δ = 1.22 and 1.40 (both s, together 9H); 1.60 - 1.90 (m, 5H); 2.50, 2.60, and 2.73 (all s, together 3H); 2.80 - 4.00 (m, 7H); 7.10 - 7.35 (m, 5H).

(5R)-4-Hydroxy-5-(methylamino)-6-phenylhexyl acetate




((1R)-1-Benzyl-2,5-dihydroxypentyl)methylcarbamic acid tert-butylester (560 mg, 1.52 mmol) was dissolved in ethyl acetate (10 mL). 3M Hydrogen chloride in ethyl acetate (2.0 mL, 6.08 mmol) was added. The solution was stirred at room temp. for 1 h. It was diluted with ethyl acetate (10 mL) and extracted with 1N sodium hydroxide solution (30 mL). The aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were dried over magnesium sulfate. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (5 mL). The solution was cooled to 0 °C. Trifluoroacetic acid (5 mL) was added. The solution was stirred at this temp. for 5 min. The solvents were removed in vacuo. The residue was dissolved in ethyl acetate (10 mL). The solution was extracted with 1N sodium hydroxide solution (10 mL). The aqueous phase was extracted with ethyl acetate (2 x 5 mL). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (40 g) with dichloromethane/methanol/25% aqueous ammonia 100:10:1 to give 136 mg of (5R)-4-hydroxy-5-(methylamino)-6-phenylhexyl acetate.

$^1\text{H-NMR}$ (CDCl_3): δ = 1.50 - 2.05 (m, 4H); 2.07 (s, 3H); 2.30 (s, 3H); 2.55 (dd, 1H); 2.65 (td, 1H); 2.82 (dd, 1H); 3.75 (td, 1H); 4.15 (m, 2H); 7.15 - 7.35 (m, 5H).

HPLC (method B): 17.87 min (85%)

(5R)-5-(((2R)-2-(((2E)-5-Amino-5-methylhex-2-enoyl)methylamino)-3-(2-naphthyl)propionyl)methylamino)-4-hydroxy-6-phenylhexyl acetate



5 (5R)-4-Hydroxy-5-(methylamino)-6-phenylhexyl acetate (126 mg, 0.475 mmol), (2R)-2-(tert-butoxycarbonylmethylamino)-3-(2-naphthyl)propionic acid (313 mg, 0.95 mmol and 1-hydroxy-7-azabenzotriazole (65 mg, 0.475 mmol) was dissolved in dichloromethane/dimethylformamide 2:1 (9 ml) at 0 °C. N-ethyl-N'-10 (3-dimethylaminopropyl)carbodiimide hydrochloride (91 mg, 0.475 mmol) was added and the mixture stirred at 0 °C for h and then at room temp. for 48h. The dichloromethane was evaporated from the mixture using a stream of nitrogen and ethyl acetate (50 ml) was added. The resulting solution was extracted sequentially with 5% 15 aqueous sodium hydrogencarbonate (50 ml), water (50 ml), 5% aqueous potassium hydrogen sulphate (50 ml) and water (50 ml). The resulting organic phase was dried with sodium sulfate and concentrated in vacuum on a rotary evaporator to dryness.

This dry material was dissolved in dichloromethane (2 ml) and 20. trifluoroacetic acid (2 ml) and allowed to react for 10 min and

then concentrated to an oil using a stream of nitrogen and the resulting oil was dissolved in 70% acetonitrile (1 ml). 1 N hydrochloric acid (3 ml) and water (47 ml) were added and the resulting mixture was immediately frozen and lyophilized.

5 This lyophilized product was dissolved in dichloromethane/
dimethylformamide 2:1 (9 ml) and (2E)-5-tert-
butyloxycarbonylamino-5-methylhex-2-enoic acid (231 mg, 0.95 mmol)
and 1-hydroxy-7-azabenzotriazole (129 mg, 0.95 mmol) was added.
The mixture was cooled to 0°C, N-ethyl-N'-(3-dimethylaminopropyl)-
10 carbodiimide hydrochloride (91 mg) and diisopropylethylamine (81
μl, 0.475 mmol) was added and the mixture was stirred for 1h at
0°C and for 18 h at room temp. The dichloromethane was evaporated
from the mixture using a stream of nitrogen and ethyl acetate (50
ml) was added. The resulting solution was extracted sequentially
15 with 5% aqueous sodium hydrogencarbonate (50 ml), water (50 ml),
5% aqueous potassium hydrogen sulfate (50 ml) and water (50 ml).
The resulting organic phase was dried with sodium sulfate and
concentrated in vacuum on a rotary evaporator to dryness.
The dry material was dissolved in dichloromethane (2 ml) and
20 trifluoroacetic acid (2 ml) and allowed to react for 10 min and
then concentrated to an oil using a stream of nitrogen. The
resulting oil was dissolved in 70% acetonitrile (5 ml) and water
(45 ml).

15 ml Of the solution of crude (5R)-5-(((2R)-2-(((2E)-5-amino-5-
25 methylhex-2-enoyl)methylamino)-3-(2-
naphthyl)propionyl)methylamino)-4-hydroxy-6-phenylhexyl acetate
was cooled to 0°C and 1M sodium hydroxide (15ml) was added
dropwise under stirring. After stirring 10 min at 0°C acetic acid
(2 ml) and water (50 ml) were added. The product was isolated from
30 this solution by semipreparative HPLC in three runs on a 25 mm x
250 mm column packed with 7μ C-18 silica which was preequilibrated
with 28% acetonitrile in 0.05M ammonium sulfate, which was
adjusted to pH 2.5 with 4M sulfuric acid.

The column was eluted with a gradient of 28% - 38% acetonitrile in 0.05M ammonium sulfate, pH 2.5 at 10 ml/min during 47 min at 40 °C and the peptide containing fractions were collected, diluted with 3 volumes of water and applied to a Sep-Pak® C18 cartridge 5 (Waters part. #:51910) which was equilibrated with 0.1% trifluoroacetic acid . The peptide was eluted from the Sep-Pak® cartridge with 70% acetonitrile 0.1% trifluoroacetic acid and isolated from the eluate by lyophilisation after dilution with water.


- 10 The final product obtained was characterised by analytical RP-HPLC (retention time) and by Plasma desorption mass spectrometry (molecular mass). Mass spectrometry which was performed using a Bio-lon 20 time-of-flight instrument (Bio-lon Nordic AB, Uppsala Sweden). The result agreed with the expected structure (M+H found 15 = 560.2, M+H theory = 560.8).

The RP-HPLC analysis was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5µ C-18 silica column (The Separations Group, Hesperia) which was eluted at 1 ml/min at 42 °C. Two different elution conditions were used:

- 20 A1: The column was equilibrated with 5% acetonitrile in a buffer consisting of 0.1M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid and eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min.
- 25 B1: The column was equilibrated with 5% acetonitrile / 0.1% trifluoroacetic acid / water and eluted by a gradient of 5% acetonitrile / 0.1% trifluoroacetic acid / water to 60% acetonitrile / 0.1% trifluoroacetic acid / water during 50 min.
- 30 The retention time using elution conditions A1 and B1 was found to be 30.08 min and 31.78 min, respectively.

Example 23:


3-Aminomethyl-N-((1R)-1-(N-[(1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylbenzamide



5

Prepared according to method K

N-((1R)-1-(2-Hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamamic acid tert-butylester:




10

((2R)-2-(tert-Butoxycarbonylmethylamino)-3-phenylpropoxy)acetic acid ethyl ester (0.50 g, 1.42 mmol) was dissolved in THF (4 mL). Lithium boronhydride (1.56 mL of a 2.0 M solution in THF, 3.13 mmol) was added dropwise. Ethanol (8 mL) was added. The reaction mixture was stirred 16 h at room temp. The solution was acidified

with 10% citric acid to pH = 4. The solvent was removed in vacuo. The residue was dissolved in water (50 mL). This solution was extracted with dichloromethane (3 x 40 mL). The combined organic layers were dried over magnesium sulfate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g) with dichloromethane/ethyl acetate 1:1 as eluent to give 0.29 g of N-((1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamic acid tert-butylester

$^1\text{H-NMR}$ (CDCl_3): δ = 1.32 and 1.41 (both s, together 9H); 2.50 - 2.85 (m, 5H); 3.40 - 3.80 (m, 6H); 4.40 and 4.60 (both br, together 1H); 7.10 - 7.35 (m, 5H).

2-((2R)-2-Methylamino-3-phenylpropoxy)ethanol:



N-((1R)-1-(2-Hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamic acid tert-butylester (0.29 g, 0.90 mmol) was dissolved in dichloromethane (3 mL). Trifluoroacetic acid (1 mL) was added. The solution was stirred at 0 °C for 15 min. The solvents were removed in vacuo. The residue was dissolved in dichloromethane (10 mL) and extracted with 1N sodium hydroxide (10 mL). The organic phase was dried over magnesium sulfate. The solvent was removed in vacuo to give 0.11 g of crude 2-((2R)-2-methylamino-3-phenylpropoxy)ethanol, which was used for further syntheses.

HPLC (method b): 9.10 min.

¹H-NMR (CDCl₃): δ = 2.48 (s, 3H); 2.75 (dd, 1H); 2.80 - 3.00 (m, 2H); 3.40 (dd, 1H); 3.45 - 3.65 (m, 3H); 3.65 - 3.80 (m, 2H); 7.15 - 7.35 (m, 5H).

2-((2R)-2-Methylamino-3-phenylpropoxy)ethanol (91 mg, 0.435 mmol),
5 (2R)-2-(tert-butoxycarbonylmethylamino)-3-(2-naphthyl)propionic acid (215 mg, 0.653 mmol) and 1-hydroxy-7-aza-benzotriazole (HOAT) (89 mg, 0.653 mmol) was dissolved in dichloromethane (10 ml) and N,N-Dimethylferamide (5 ml). After cooling to 0 °C N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
10 hydrochloride (125 mg, 0.653 mmol) was added and after stirring 30 min at 0 °C diisopropylethylamine (75 µl, 0.435 mmol) was added. After stirring at room temp. the dichloromethane was removed by a stream of nitrogen and ethyl acetate (25 ml) was added. The mixture was extracted with 5% sodium hydrogencarbonate (2 x 25
15 ml), 5% potassium hydrogensulfate and water (25 ml). The organic phase was dried over sodium sulfate and concentrated in vacuum to give N-((1R)-1-(N-((1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butylester as a dry residue (240 mg).
20 Half of this N-((1R)-1-(N-((1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butylester (120 mg, 0.230 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (1 ml) and allowed to react for 10 min and then concentrated to an
25 oil using a stream of nitrogen and the resulting oil was dissolved in 70% acetonitrile (1 ml). 1 N hydrochloric acid (1 ml) and water (50 ml) was added and the resulting mixture was immediately frozen and lyophilized.

This lyophilized product was dissolved in dichloromethane (5 ml)
30 and a solution of 3-(tert-butoxycarbonylaminomethyl)benzoic acid (503 mg, 2.0 mmol) and N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (192 mg, 1 mmol) in dichloromethane (5

ml) which had been allowed to react at 0 °C for 15 min was added. Finally diisopropylethylamine (171 μ l, 1.0 mmol) was added and the mixture was stirred for 72 h at room temp. The dichloromethane was evaporated from the mixture using a stream of nitrogen and ethyl acetate (25 ml) was added. The resulting solution was extracted sequentially with 5% aqueous sodium hydrogencarbonate (2 x 25 ml), water (25 ml), 5% aqueous potassium hydrogensulfate (25 ml) and water (25 ml). The resulting organic phase was dried with sodium sulfate and concentrated in vacuum on a rotary evaporator to dryness. The dry material was dissolved in dichloromethane (2 ml) and trifluoroacetic acid (2 ml) and allowed to react for 10 min and then concentrated to an oil using a stream of nitrogen. The resulting oil was dissolved in 70% acetonitrile (5 ml) and water (400 ml).

15 Analytical HPLC using conditions A1 (described below) showed the presence of two major peaks with the retention times 28.82 min and 35.67 min a minor peak at 29.98 min. Plasma desorption mass spectrometry of collected fractions. Mass spectrometry which was performed using a Bio-lon 20 time-of-flight instrument (Bio-lon 20 Nordic AB, Uppsala Sweden), indicated that the minor product was the desired product. The result agreed with the expected structure (M+H found = 553.0, M+H theory = 554.7). The other two product resulted from acylations during synthesis of the hydroxy group left unprotected.

25 All three compounds were isolated by semipreparative HPLC in four runs on a 25 mm x 250 mm column packed with 7 μ C-18 silica which was preequilibrated with 37% acetonitrile in 0.05M ammonium sulphate, which was adjusted to pH 2.5 with 4M sulphuric acid. The column was eluted with a gradient of 37% - 44% acetonitrile in 0.05M ammonium sulfate, pH 2.5 at 10 ml/min during 47 min at 40 °C and each of the product containing fractions were collected, diluted with 3 volumes of water and applied to Sep-Pak® C18 cartridges (Waters part. #:51910) which were equilibrated with 0.1% trifluoroacetic acid . The products were eluted from the Sep-

Pak® cartridges with 70% acetonitrile 0.1% trifluoroacetic acid and isolated from the eluate by lyophilisation after dilution with water.

The compounds corresponding to the two major peaks were saponified 5 to reverse the undesired acylations in order to increase the yield of the target compound. The compounds were dissolved in 1.5 ml 0.066 N sodium hydroxide for 15 min followed by neutralisation with 1 ml 1N hydrochloric acid. Then the target compound was isolated by semipreparative HPLC using a procedure similar to the 10 one described above.

The final product obtained was characterised by analytical RP-HPLC (retention time). The RP-HPLC analysis was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5µ C-18 silica column (The Separations Group, Hesperia) which was eluted 15 at 1 ml/min at 42 °C. Two different elution conditions were used:


A1: The column was equilibrated with 5% acetonitrile in a buffer consisting of 0.1M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid and eluted by a gradient of 5% to 60% acetonitrile in the same buffer during 50 min. 20

B1: The column was equilibrated with 5% acetonitrile / 0.1% trifluoroacetic acid / water and eluted by a gradient of 5% acetonitrile / 0.1% trifluoroacetic acid / water to 60% acetonitrile / 0.1% trifluoroacetic acid / water during 50 min. 25

The retention time using elution conditions A1 and B1 was found to be 29.87 min and 34.28 min, respectively.


Example 24:

Piperidine-4-carboxylic acid ((1R,2E)-4-hydroxymethyl-5-(2-naphthyl)-1-((2-naphthyl)methyl)pent-2-enyl)amide



5


((1R)-4-(tert-Butyldimethylsilanyloxymethyl)-1-((2-naphthyl)methyl)-5-(2-naphthyl)pent-2-enyl)carbamic acid tert-butylester



This compound was prepared as in example 9. ((1R)-1-benzenesulfonylmethyl-2-(2-naphthyl)ethyl)carbamic acid tert-butylester (3.71 g; 8.74 mmol) and 2-(tert-butyldimethylsilanyloxymethyl)-3-(2-naphthyl)propionaldehyde (4.3 g; 13.11 mmol) were used as starting materials. Chromatography was carried out using diethylether/heptane 1:3 as eluent on silica (5 x 25 cm) to afford 2.20 g of ((1R)-4-(tert-butyldimethylsilanyloxymethyl)-1-((2-naphthyl)methyl)-5-(2-naphthyl)pent-2-enyl) carbamic acid tert-butyl ester as a mixture of isomers.

¹H-NMR (CDCl₃) (selected peaks) δ 0.0-0.05 (four s, 6H), 0.85-0.95 (four s, 9H), 1.30-1.40 (three s, 9H), 5.2-5.5 (m, 2H)

(3E,5R) 5-Amino-6-(2-naphthyl)-2-((2-naphthyl)methyl)hex-3-en-1-ol




((1R)-4-(tert-Butyldimethylsilanyloxymethyl)-1-((2-naphthyl)methyl)-5-(2-naphthyl)pent-2-enyl)carbamic acid tert-butylester (2.20 g; 3.60 mmol) was dissolved in a mixture of acetonitrile (100 ml) and an aqueous solution of hydrogen fluoride

(48%, 4.5 ml). After stirring for 3 h a mixture of ethyl acetate (200 ml) and aqueous sodium carbonate (10%, 200 ml) was added. The phases were separated and the organic phase was dried (Magnesium sulfate) and evaporated in vacuo. The residue was chromatographed on silica (4 x 38 cm) using a mixture of ethyl acetate (85%), ethanol (14%) and conc. aqueous ammonia (1%) as eluent. Two close spots were separated this way. The one that eluted first was clean on HPLC whereas the following contained several isomers. The first fraction had E-geometry and 220 mg of (3E,5R)-5-amino-6-((2-naphthyl)-2-(2-naphthyl)methyl)hex-3-en-1-ol were taken to the next step.

¹H-NMR (CDCl₃) δ 1.45 (s(br), 3H); 2.55-2.92 (m, 5H); 3.35-3.68 (m, 3H); 5.37 (dd, part of ABX-syst., J₁=15Hz, J₂=7Hz, 1H), 5.52 (dd, part of ABX-syst., J₁=15Hz, J₂=5Hz, 1H), 7.15-7.84 (m, 14 H).

- 15 (N-tert-Butyloxycarbonyl-piperidine-4-carboxylic acid ((1R,2E)-(4-hydroxymethyl)-5-(2-naphthyl)-1-((2-naphthyl)methyl)pent-2-enyl)amide



N-tert-Butyloxycarbonylpiperidine-4-carboxylic acid (378 mg; 0.991 mmol) and EDAC (198 mg; 1.038 mmol) were dissolved in methylene chloride (15 ml) and stirred for 15 min. (3E,5R)-5-Amino-6-(2-naphthyl)-2-((2-naphthyl)methyl)hex-3-en-1-ol (180 mg; 0.472 mmol) 5 was added and the mixture was stirred for 6 h. The organic phase was washed with sodium hydrogensulfate (10%, 10 ml) and sodium hydrogencarbonate (satd., 15 ml), dried (Magnesium sulfate). The solvent was removed in vacuo and the residue was chromatographed on silica (30 x 2.5 cm) using ethyl acetate/heptane 1:1 as eluent 10 to afford 220 mg of N-tert-butyloxycarbonylpiperidine-4-carboxylic acid ((1R,2E)-4-(hydroxymethyl)-5-(2(-naphthyl)-1-(2-naphthyl)methyl)-pent-2-enyl)amide

¹H-NMR (CDCl₃): δ: 1.35-1.55 (m, (s at 1.45); 15 H); 1.93-2.01 (m, 1H); 2.55-2.68 (m, 4H); 2.70-2.90 (m, 2H); 3.01 (dd, 1H); 3.38 15 (dd, 1H); 3.55 (d(br), 1H); 4.67 (p, 1H); 5.18 (d, 1H); 5.31 (dd, 1H), 5.37 (dd, 1H), 7.15-7.79 (m, 14H).

N-tert-Butyloxycarbonylpiperidine-4-carboxylic acid ((1R,2E)-4-(hydroxymethyl)-5-(2-naphthyl)-1-(2-naphthyl)methyl)pent-2-enyl)-amide (220 mg; 0.371 mmol) was 20 dissolved in methylene chloride (5 ml) and trifluoroacetic acid (5 ml) and stirred for 90 min. The volatiles were removed in vacuo and methylene chloride (20 ml) was added and removed in vacuo 3 times successively to afford 170 mg of the title compound.


¹H-NMR (CDCl₃) (selected peaks) δ 4.60 (1H); 5.43 (m, 2H); 7.00-7.77 25 (14 H), 8.7 and 9.05 (s(br), 2H).

ESMS: (M+H)⁺: 493.2


HPLC (A1): R_t = 36.15 min.

Example 25:

Piperidine-4-carboxylic acid ((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl-carbamoyl)ethyl)amide:




((1R)-2-(2-Naphthyl)-1-(phenethylcarbamoyl)ethyl)carbamic acid
tert-butylester



D-tert-Butyloxycarbonyl-(2-naphthyl)alanine (5.0 g, 15.85 mmol) was dissolved in dry methylene chloride (80 ml). HOBT (2.14 g; 15.85 mmol) and EDAC (3.34; 17.43 mmol) were added and the mixture was stirred for 15 min. Phenethylamine (2.0 ml; 15.85 mmol) was added and the mixture was stirred 24 h at room temperature. Methylene chloride (200 ml) was added and the organic phase was washed with water (100 ml), sodium hydrogencarbonate (satd. 100 ml) and dried (Magnesium sulfate). The solvent was removed in vacuo and the residue was chromatographed on silica (3.5 x 40 cm) using methylene chloride/ethyl acetate (6:1) as eluent to afford 4.95 g of (1R)-2-(2-naphthyl)-1-(phenethylcarbamoyl)ethyl carbamic acid tert-butyl ester

H-NMR (CDCl₃): δ: 1.39 (s, 9H); 2.52 (m, 1H); 2.64 (m, 1H); 3.15 (dd, 1H); 3.23 (dd, 1H); 3.36 (m; 1H); 3.45 (m, 1H); 4.31 (dd, 1H); 5.08 (s(br); 1H); 5.62 (s(br); 1H); 6.85-7.82 (12 arom.)


(1R)-2-(2-Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl carbamic acid tert-butylester



((1R)-2-(2-Naphthyl)-1-(phenethylcarbamoyl)ethyl)carbamic acid tert-butyl ester (2.20 g, 5.26 mmol) was dissolved in dry THF (50 ml). Triphenylphosphine (2.76 g ; 10.52 mmol) diethylazodicarboxylate (1.66 g, 10.52 mmol) and trimethylsilyl azide 5 (1.22 g; 10.52 mmol) were added. The mixture was stirred overnight at room temperature. Ammonium ceric nitrate (23.06 g; 21.04 mmol) was dissolved in water (400 ml) and added dropwise to the reaction mixture. THF (120 ml) was added and the reaction mixture was extracted with methylene chloride (3 x 300 ml). The organic phase 10 was dried (magnesium sulfate) and the solvent was removed in vacuo. The residue was chromatographed on silica (5 x 40 cm) using ethyl acetate/heptane as eluent (1:1) to afford 0.30 g of ((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl)carbamic acid tert-butylester

15 H-NMR (CDCl₃) δ 1.32 (s, 9H); 2.72 (m, 1H); 2.98 (m, 1H); 3.13 (dd; 1H); 3.41 (dd, 1H); 4.42 (t, 2H); 4.99 (dd; 1H); 5.12 (d, 1H); 6.82-7.80 (12 arom.H)


((1R)-2-(2-Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylamine



((1 R) - 2 - (2 - Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl)carbamic acid tert-butylester (0.30 g; 0.68 mmol) was dissolved in methylene chloride (20 ml) and trifluoroacetic acid (2 ml) was added. The mixture was stirred for 3 h at RT. The solvent was removed in vacuo and the residue was dissolved in methylene chloride (50 ml) and washed with sodium hydrogencarbonate (10 %; 30 ml). The organic phase was dried (Magnesium sulfate) and the solvent removed in vacuo. The residue was chromatographed on silica (2.5 X 15 cm) using ethyl acetate as eluent to afford 170 mg of (1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylamine.

H-NMR (CDCl₃) δ 1.75 (s(br); 2H); 3.00 (m 2H); 3.09 (d, 2H); 3.92 (t, 1H); 4.25 (m, 2H); 6.85-7.85 (12 arom.H).

((1R)-2-(2-Naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethyl)carbamic acid tert-butyl ester




D-tert-Butyloxycarbonyl-(2-Naphthyl)alanine (0.129 g; 0.408 mmol) was dissolved in methylene chloride (10 ml). HOBT (55 mg; 0.408 mmol) and EDAC (86 mg; 0.449 mmol) were added and the mixture was stirred for 15 min. at RT. (1R)-2-(2-Naphthyl)

5. -1-(1-phenethyl-1H-tetrazol-5-yl)ethylamine (141 mg; 0.408 mmol) was added and the mixture was stirred overnight. Methylene chloride (25 ml) was added and the organic phase was washed with sodium hydrogen carbonate (10 %; 25 ml), sodium hydrogen sulfate (10 %; 25 ml) and water (25 ml). The organic phase was dried (Magnesium sulfate) and the solvent was removed in vacuo to afford 237 mg of ((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethyl)carbamic acid tert-butylester.

H-NMR (CDCl₃) δ 1.30 (s, 9H); 2.75 (m, 1H); 2.95 (m, 4H); 3.33 (dd, 1H); 4.15 (m, 2H); 4.30 (m, 1H); 4.65 (d(br), 1H); 5.18 (dd, 1H); 6.60-7.85 (19 arom. H).


(2R)-2-Amino-3-(2-naphthyl)-N-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl)propionamide



((1R)-2-(2-Naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethyl)carbamic acid tert-butyl ester (215 mg; 0.34 mmol) was dissolved in a mixture of methylene chloride (4 ml) and trifluoroacetic acid (2 ml) and stirred at 5 room temperature for 30 min. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate and aqueous sodium hydrogencarbonate (10%; 10 ml). The phases were separated, the organic phase was dried (Magnesium sulfate) and the solvent removed in vacuo. The residue was chromatographed on silica (3 x 10 20 cm) using ethyl acetate as eluent to afford 152 mg of (2R)-2-amino-3-(2-naphthyl)-N-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl)propionamide.

H-NMR (CDCl₃) δ 2.16 (dd, 1H); 2.80-3.15 (m, 4H); 3.35-3.55 (m, 2H); 4.48 (dd, 2H); 5.19 (dd, 1H); 6.90-8.02 (21 H)

15 4-((1R)-2-(2-Naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetra-zol-5-yl)ethylcarbamoyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester



N-tert-butyloxycarbonylpiperidine-4-carboxylic acid (68 mg; 0.296 mmol) was dissolved in methylene chloride (7 ml). HOBT (40 mg; 0.296 mmol) and EDAC (62 mg; 0.326 mmol) were added and the mixture was stirred 15 min at RT. (2R)-2-Amino-3-(2-Naphthyl)-N-((1R)-2-(2-Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethyl)propionamide (152 mg; 0.296 mmol) was added and stirring was continued overnight. Methylene chloride (25 ml) was added. The organic phase was washed with aqueous sodium hydrogencarbonate (25 ml), aqueous sodium hydrogensulfate (10%; 25 ml) and water (25 ml). The organic phase was dried (Magnesium sulfate) and the solvent removed in vacuo to afford 170 mg of 4-((1R)-2-(2-Naphthyl)-1-((1R)-2-(2-Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester.

15 ¹H-NMR (CDCl₃) δ 1.25-1.52 (m and s, 13H); 1.79 (m, 1H); 2.58 (m, 2H); 2.75 (m, 1H); 2.86 (dd, 1H); 2.96 (dd, 1H); 3.05 (d, 2H); 3.27 (dd, 1H); 3.98 (m, 2H); 4.15 (m, 2H); 4.57 (dd, 1H); 5.04 (dd, 1H); 5.72 (d(br); 1H); 6.53 (d(br); 1H); 6.71-7.80 (19 arom. H)

20 4-((1R)-2-(2-Naphthyl)-1-((1R)-2-(2-Naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethylcarbamoyl)piperidine-1-carboxylic acid tert-butylester (164 mg; 0.218 mmol) was dissolved in methylene chloride (6 ml) and trifluoroacetic acid (3 ml) and stirred for 20 min at RT. The solvent was removed in vacuo. Methylene chloride (10 ml) was added and the organic phase was washed with aqueous sodium hydrogencarbonate (10%; 10 ml). The organic phase was dried (Magnesium sulfate) and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (5 ml) and hydrogen chloride in ethyl acetate (3M; 2 ml) was added.

30 The solvent was removed in vacuo. The residue was dissolved in methanol (5 ml) and evaporated and this was repeated 3 times with


methylene chloride to afford 110 mg of the title compound as a hydrochloride.

H-NMR (CDCl₃) (selected peaks) δ 2.50 (m, 2H); 2.73 (m, 1H); 2.89-3.09 (m, 7H); 3.31 (dd, 1H); 4.21 (m, 2H); 4.68 (dd, 1H); 5.10 (dd, 5 1H); 6.70-7.75 (19 arom. H)


HPLC: R_t = 38.07 min (A1)

Example 26:

Piperidine-4-carboxylic acid N-methyl-N-((1R)-2-(2-naphthyl)-1-((1R)2-(2-naphthyl)-1-thiocarbamoylethylcarbamoyl)ethyl)amide:




(2R)-2-(N-tert-Butoxycarbonyl-N-methylamino)-3-(2-naphthyl)propionic acid methylester



(2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionic acid
 5 (10.0 g; 32.79 mmol) was dissolved in dry DMF (100 ml).
 Iodomethane (12.25 ml; 196.72 mmol) and silver oxide (26.6 g;
 114.75 mmol) were added. The reaction mixture was stirred 12
 hours at room temperature. The reaction mixture was filtered
 and methylene chloride (400 ml) was added to the filtrate. The
 10 organic phase was washed with aqueous potassium cyanide (5%; 2
 x 100ml), water (3 x 150 ml) and dried (MgSO₄). The solvent was
 removed in vacuo to afford 10.9 g of
 (2R)-(N-tert-butoxycarbonyl-N-methylamino)-3-(2-
 naphthyl)propionic acid methylester.

15 ¹H-NMR (CDCl₃) δ (mixture of rotameres) 1.30, 1.35 (two s, 9H);
 2.71, 2.74 (two s, 3H); 3.45, 3.19 (two m, 2H); 3.72, 3.74 (two
 s, 3H); 4.65, 5.06 (two dd, 1H); 7.30-7.80 (7 arom. H)


(2R)-2-(N-tert-Butoxycarbonyl-N-methylamino)-3-(2-naphthyl)pro-
 pionic acid.



(2R)-2-(N-tert-Butoxycarbonyl-N-methylamino)-3-(2-naphthyl)propionic acid methylester (15.0 g; 43.73 mmol) was dissolved in dioxane (150 ml) and cooled on an icebath. Water (115 ml) and lithium hydroxide (1.15 g; 48.10 mmol) were added. The reaction mixture was stirred 4 hours at room temperature. Ethyl acetate (300 ml) and water (200 ml) were added. Sodium hydrogensulfate (3%) was added until acidic reaction (pH = 10 2.5). The organic phase was washed with water (200 ml) and dried (Magnesium sulfate). The solvent was removed in vacuo to afford 13.5 g of (2R)-2-(N-tert-Butoxycarbonyl-N-methylamino)-3-(2-naphthyl)propionic acid.

H-NMR (CDCl₃) δ (mixture of rotameres) 1.30, 1.47 (two s, 9H); 15 2.66, 2.78 (two s, 3H); 3.21, 3.38 (two dd, 1H); 3.48, 3.51 (two d, 1H); 4.75, 4.83 (two dd, 1H); 7.31-7.82 (7 arom. H).


((1R)-2-(2-Naphthyl)-1-thiocarbamoylethyl)carbamic acid
tert-butyl ester.



(2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionic acid amide
5 (1.058 g; 3.36 mmol) and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-
diphosphetane-2,4-disulfide (Lawesson's reagent) (0.71 g; 1.76
mmol) were dissolved in dioxane (6 ml). The reaction mixture was
heated 30 min at 60°C and stirred 12 hours at room temperature.
The solvent was removed in vacuo and to the residue was added a
10 mixture of water/sodium hydrogencarbonate (1:1; 15ml) and stirred
30 min at room temperature. The mixture was filtered. The solid
was washed with water (2 x 5 ml) and chromatographed on silica (2
x 15cm) using ethyl acetate/heptane (2:1) to afford 0.914 g of
((1R)-2-(2-naphthyl)-1-thiocarbamoylethyl)carbamic acid
15 tert-butylester.

H-NMR (CDCl₃) δ 1.44 (s, 9H); 3.28 (m, 2H); 4.74 (dd, 1H); 4.94
(d(br), 1H); 7.35-7.79 (7 arom. H).

(2R) 2-Amino-3-(2-naphthyl)propionthioamide.




((1R)-2-(2-Naphthyl)-1-thiocarbamoylethyl)carbamic acid
tert-butyl-

ester (0.45 g; 1.36 mmol) was dissolved in methylene chloride (1.5 ml) and trifluoroacetic acid (1.5 ml) was added. The reaction mixture was stirred for 40 min at room temperature. The solvent was removed in vacuo and the residue was dissolved in methylene chloride. Aqueous sodium hydrogencarbonate was added until basic reaction and the aqueous phase was extracted with methylene
10 chloride (3 x 15 ml). The combined organic phases were dried (MgSO₄) and the solvent was removed in vacuo to afford 0.311 g of (2R)-2-amino-3-(2-naphthyl)propionthioamide.

¹H-NMR (CDCl₃) δ 2.36 (dd, 1H); 3.79 (dd, 1H); 4.19 (dd, 1H); 7.40-7.85 (7 arom. H).


N-Methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-thiocarbamoylethylcarbamoyl)ethyl)carbamic acid tert-butylester.



(2R)-2-Amino-3-(2-naphthyl)propionthioamide (0.290 g; 1.2 mmol),
 5 (2R)-2-(N-tert-butoxycarbonyl-N-methylamino)-3-(2-naphthyl)-
 propionic acid (0.436 g; 1.3mmol), HOBT (0.176 g; 1.3 mmol) and
 EDAC (0.267 g; 1.4 mmol) were dissolved in methylene chloride (20
 ml) and stirred 12 hours at RT. Methylene chloride (40 ml) was
 added and the organic phase was washed with aqueous sodium
 10 hydrogensulfate (10%; 40ml), aqueous sodium hydrogencarbonate
 (satd.; 40ml) and dried (Magnesium sulfate). The solvent was
 removed in vacuo to afford 0,53 g of N-methyl-N-((1R)-2-(2-
 naphthyl)-1-((1R)-2-(2-naphthyl)-1-thiocarbamoylethylcarbamoyl)-
 ethyl)carbamic acid tert-butylester.

15 H-NMR (CDCl₃) δ (mixture of rotamers, selected peaks) 1.28 (s,
 9H); 2.45, 2.51 (two s, 3H); 4.90 (m, 1H); 5.12, 5.20 (two m, 1H).


(2R)-2-Methylamino-3-(2-naphthyl)-N-((1R)-2-(2-naphthyl)-1-thiocarbamoylethyl)propionamide



N-Methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-
 5 thiocarbamoylethylcarbamoyl)ethyl)carbamic acid tert-butylester
 (0.25 g; 0.462 mmol) was dissolved in methylene chloride (1.5ml)
 and trifluoroacetic acid (1.5 ml) was added. The reaction mixture
 was stirred 1 h at RT. The solvent was removed in vacuo and the
 residue was dissolved in methylene chloride (5 ml) and washed with
 10 aqueous sodium hydrogencarbonate (5 ml). The organic phase was
 dried (Magnesium sulfate) and the solvent was removed in vacuo to
 afford 0.201 g of (2R)-2-methylamino-3-(2-naphthyl)-N-((1R)-
 2-(2-naphthyl)-1-thiocarbamoylethyl)propionamide.

H-NMR (CDCl₃) δ 2.16 (s, 3H); 2.46 (dd, 1H); 3.07 (dd, 1H); 3.20-
 15 3.41 (m, 4H); 5.09 (dd, 1H); 7.12-8.13 (m, 16H)

4-(N-Methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-thiocarbamoyl)ethyl)carbamoyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butylester.



5 N-tert-Butyloxycarbonylpiperidin-4-carboxylic acid (97 mg; 0.424 mmol) was dissolved in methylene chloride (2 ml). HOAt (58 mg; 0.424 mmol) and EDAC (85 mg; 0.444 mmol) were added. The reaction mixture was stirred 15 min at RT. (2R)-2-Methyl-amino-3-(2-naphthyl)-N-((1R)-2-(2-naphthyl)-1-thiocarbamoyl)-ethyl)propionamide (17 mg; 0.386 mmol) was dissolved in methylene chloride (2 ml) and added. Diisopropylethylamine (0.073 ml; 0.424 mmol) was added and the reaction mixture was stirred 12 hours at room temperature. Tert-butylmethylether (25 ml) was added and the reaction mixture was washed with water (25 ml), aqueous sodium hydrogencarbonate (15 ml), aqueous sodiumhydrogensulfate (10%; 15 ml), water (15 ml) and dried (magnesium sulfate). The solvent was removed in vacuo and the residue was chromatographed on silica (3.5 x 30cm) using gradient elution, starting with ethyl acetate/heptane (1:1) increasing to ethyl acetate/heptane (2:1) to afford 0.190 g of 4-(N-methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-

2 - (2 - n a p h t h y l) - 1 - t h i o -
carbamoylethylcarbamoyl)ethyl)carbamoyl)piperidine-1-carboxylic
acid tert-butylester.

H-NMR (CDCl₃) δ (mixture of rotamers, selected peaks): 1.40, 1.42
5 (two s, 9H); 2.49, 2.70 (two s, 3H); 3.10 (dd, 1H); 3.48 (dd, 1H);
5.00, 5.09 (two dd, 1H)


4-(N-Methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-
1-thiocarbamoylethylcarbamoyl)ethyl)carbamoyl)piperidine-1-car-
boxylic acid tert-butylester (0.190 g; 0.291 mmol) was dissolved
10 in methylene chloride (5 ml). Trifluoroacetic acid (5 ml) was
added and the reaction mixture was stirred 15 min at RT. The
solvent was removed in vacuo and the residue was dissolved in
methylene chloride and evaporated (2 x 5 ml). The residue was
chromatographed on silica (2 x 30 cm) using 25 % aqueous
15 ammonia/ethanol/methylene chloride (1:9:90) as eluent to afford
57 mg of the title compound.

ESMS: (M+H)⁺: 553.2

HPLC (A1): R_t = 29.4 min.


Example 27:

Piperidine-4-carboxylic acid ((1R)-1-((1R)-1-(4-carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethyl)amide.



5

2-Amino-3-oxo-3-phenylpropionic acid methylester.




Dry tetrahydrofuran (250 ml) was cooled to -78°C . Potassium tert-10 butoxide (6.37 g; 56.72 mmol) was dissolved in dry tetrahydrofuran (100 ml) and added. (Benzhydrylideneamino)acetic acid methyl ester (14.35 g; 56.72 mmol) was added and the reaction mixture was

stirred 30 min at -78°C . Benzoyl chloride (6.59 g; 56.72 mmol) was added dropwise and the reaction mixture was stirred 30 min at -78°C . Hydrochloric acid (1.0 M; 175 ml) was added dropwise. The reaction mixture was heated to room temperature and 2/3 of the solvent was removed in vacuo. Water (700 ml) was added and the reaction mixture was washed with diethyl ether (400 ml). The aqueous phase was evaporated in vacuo and the residue was dissolved in methanol and evaporated (2 x 150 ml). Methanol (80 ml) was added. The mixture was filtrated and the filtrate was evaporated in vacuo. The residue was recrystallised from tetrahydrofuran/diethyl ether to afford 8.86 g of 2-amino-3-oxo-3-phenylpropionic acid methylester as a hydrochloride.

H-NMR (DMSO) δ 3.66 (s, 3H); 6.25 (s, 1H); 7.57-8.17 (5 arom. H); 9.20 (s(br); 3H).

2-((2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionylamino)-3-oxo-3-phenylpropionic acid methylester.




(2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionic acid (5.49 g; 17.42 mmol) was dissolved in dry tetrahydrofuran (200 ml) and N-methylmorpholine (1.92 ml; 17.42 mmol) was added. The reaction

mixture was cooled to -20°C and stirred 15 min. Isobutyl chloroformate (2.27 ml; 17.42 mmol) was dissolved in dry tetrahydrofuran (3 ml) and added dropwise to the reaction mixture at -20°C. N-methylmorpholine (1.92 ml; 17.42 mmol) and 5 2-amino-3-oxo-3-phenylpropionic acid methylester (4.0 g; 17.42 mmol) were added and the mixture was stirred 30 min at -20°C. The reaction mixture was heated to room temperature and the solvent was removed in vacuo. The residue was dissolved in methylene chloride (200 ml), washed with water (200 ml) and dried 10 (magnesium sulfate). The solvent was removed in vacuo and the residue was chromatographed on silica (5 x 45 cm) using heptane/ethyl acetate/methylene chloride (2:1:1) as eluent to afford 6.19 g of a diastereomeric mixture of 2-((2R)-2-tert-butoxycarbonylamino-3-(2-naphthyl)propionylamino)-3-oxo-3-15 phenylpropionic acid methylester.

H-NMR (CDCl₃) δ 1.48 (s, 9H); 3.28 (m, 2H); 3.59, 3.67 (two s, 3H); 4.58 (s(br), 1H); 5.00, 5.03 (two m, 1H); 6.13, 6.17 (two d, 1H); 7.28-8.12 (m, 13 H).


2-((1R)-1-tert-Butoxycarbonylamino-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid methylester.



2-((2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionyl-5 amino)-3-oxo-3-phenylpropionic acid methylester (2.2 g; 4.069 mmol) and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent) (4.1 g; 10.17 mmol) were refluxed 6 hours in 50 ml tetrahydrofuran. The solvent was removed in vacuo and the residue was chromatographed on silica; (4 x 40 10 cm) using ethyl acetate/heptane (1:1) as eluent and the residue was recrystallised from ethyl acetate/heptane (1:1; 50 ml) to afford 1.45 g of 2-((1R)-1-(tert-butoxycarbonylamino)-2-(2-naphthyl)-ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid methylester.

¹H-NMR (CDCl₃) δ 1.39 (s, 9H); 3.48 (dd(br), 1H); 3.55 (dd, 1H); 3.85 (s, 3H); 5.26 (s(br), 1H); 5.38 (m, 1H); 7.24-7.81 (12 arom H).


2-((1R)-1-(1-tert-Butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid.



2-((1R)-1-(tert-Butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid methylester (0.35 g; 0.716 mmol) was dissolved in ethanol (99 %; 40 ml) and lithium hydroxide (0.112 g; 4.654 mmol) was added. The reaction mixture was stirred 12 hours at room temperature. The solvent was removed in vacuo and the residue was dissolved in water (50 ml) and diethyl ether (50 ml). The solution was made acidic with sodium hydrogensulfate (10 %), and the organic phase was dried (magnesium sulfate). The solvent was removed in vacuo to afford 0.185 g of 2-((1R)-1-(tert-butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid.

¹H-NMR (DMSO) δ 1.24 (s, 9H); 3.20 (dd, 1H); 3.55 (dd, 1H); 5.11 (m, 1H); 7.48-7.93 (12 arom. H)


2-((1R)-1-(tert-Butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide:



2-((1R)-1-(tert-Butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid (0.17 g; 0.362 mmol) was dissolved in methylene chloride (8 ml). 1-Hydroxybenzotriazole (0.049 g; 0.362 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.083 g; 0.434 mmol) were added. The reaction mixture was stirred 15 min at room temperature. 10 Ammonium hydrogencarbonate (0.057 g; 0.724 mmol) was added and the reaction mixture was stirred 12 h at room temperature. Methylene chloride (20 ml) was added and the reaction mixture was washed with sodium hydrogencarbonate (10%; 10 ml), sodium hydrogensulfate (5 %; 2 x 10 ml) and dried (magnesium sulfate). The solvent was 15 removed in vacuo and the residue was chromatographed on silica (2 x 15 cm) using ethyl acetate/heptane (1:1) as eluent to afford 0.155 g of 2-((1R)-1-(tert-butoxycarbonylamino)-2-(2-naphthyl)-ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide.

$^1\text{H-NMR}$ (CDCl_3) δ 1.38 (s, 9H); 3.39–3.52 (m, 2H); 5.17 (d(br), 1H); 5.35 (m, 1H); 5.52 (s(br); 1H); 7.15 (s(br); 1H); 7.22–7.82 (12 arom. H).


2-((1R)-1-Amino-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide:



2-((1R)-1-(tert-Butoxycarbonylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide (0.155 g; 0.327 mmol) was dissolved in methylene chloride (4 ml) and 10 trifluoroacetic acid (4 ml) was added. The reaction mixture was stirred 1 hour at room temperature and the solvent was removed in vacuo. The residue was dissolved in methylene chloride and evaporated (2 x 2 ml). The residue was dissolved in diethyl ether (2 ml). Hydrochloric acid (1 N; 3 ml) and methanol (10 ml) were 15 added. The solvent was removed in vacuo to afford 0.106 g of 2-((1R)-1-amino-2-(2-naphthyl)-ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide.

$^1\text{H-NMR}$ (CDCl_3) (selected peaks) δ 3.45–3.60 (m, 2H); 5.28 (m, 1H).

((1R)-1-((1R)-1-(4-Carbamoyl-5-phenyl-1,3-thiazole-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butylester.




5 (2R)-2-tert-Butoxycarbonylamino-3-(2-naphthyl)propionic acid
(0.107 g; 0.341 mmol) was dissolved in methylene chloride/dimethyl
formamide (5:1; 20 ml). 1-Hydroxybenzotriazole (0.046 g; 0.341
mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydro-
chloride (0.071 g; 0.369 mmol) were added. The reaction mixture
10 was stirred 15 min at room temperature and 2-((1R)-1-amino-2-(2-
naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide
(0.106 g; 0.284 mmol) was added. The reaction mixture was stirred
12 hours at room temperature. The reaction mixture was washed with
water (20 ml), sodium hydrogensulfate (10 %; 20 ml), sodium
15 hydrogencarbonate (satd; 20 ml), water (20 ml) and dried
(magnesium sulfate). The solvent was removed in vacuo and the
residue was chromatographed on silica (2 x 15 cm) using ethyl
acetate/heptane (2:1) as eluent to afford 0.22 g of ((1R)-1-((1R)-
1-(4-carbamoyl-5-phenyl-1,3-thiazole-2-yl)-2-(2-naphthyl))-

ethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester.

¹H-NMR (CDCl₃) (selected peaks) δ 1.32 (s, 9H); 3.13-3.41 (m, 4H); 4.42 (dd, 1H); 5.56 (dd, 1H).

5 2-((1R)-1-((2R)-2-Amino-3-(2-naphthyl)propionylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide.




((1R)-1-((1R)-1-(4-Carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamic acid
 10 tert-butylester (0.22 g; 0.328 mmol) was dissolved in methylene chloride (2.5 ml) and trifluoroacetic acid (2.5 ml) was added. The reaction mixture was stirred 1 h at room temperature and the solvent was removed in vacuo. The residue was dissolved in methylene chloride and evaporated (2 x 5 ml). The residue was
 15 dissolved in methylene chloride (10 ml) and washed with sodium hydrogencarbonate (satd; 10 ml), water (10 ml) and dried (magnesium sulfate). The solvent was removed in vacuo to afford

0.155 g of 2-((1R)-1-((2R)-2-amino-3-(2-naphthyl)propionylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide.

¹H-NMR (CDCl₃) δ 2.55 (dd, 1H); 3.22 (dd, 1H); 3.40 (dd, 1H); 3.52 (dd, 1H); 3.69 (dd, 1H); 5.53 (s(br), 1H); 5.67 (dd, 1H); 7.13-8.12 (m, 22H).

4-(((1R)-1-((1R)-1-(4-Carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethylcarbamoyl)pipe-ridine-1-carboxylic acid tert-butylester.



10

N-tert-Butyloxycarbonylpiperidine-4-carboxylic acid (0.140 g; 0.612 mmol) was dissolved in methylene chloride (5 ml) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.058 g; 0.306 mmol) was added. The reaction mixture was stirred 15 min at room temperature. 2-((1R)-1-((2R)-2-(Amino-3-(2-naphthyl)-propionylamino)-2-(2-naphthyl)ethyl)-5-phenyl-1,3-thiazole-4-carboxylic acid amide (0.155 g; 0.278 mmol) was dissolved in methylene chloride (10 ml) and added to the reaction mixture. The reaction mixture was stirred 8 hours at room temperature and washed with water (20 ml), sodium hydrogencarbonate (satd, 20 ml)

and dried (magnesium sulfate). The solvent was removed in vacuo and the residue was chromatographed on silica (2.5 x 30 cm) using ethyl acetate to afford 0.171 g of 4-(((1R)-1-((1R)-1-(4-carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethyl-5 carbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butylester.

¹H-NMR (CDCl₃) (selected peaks) δ 1.44 (s, 9H); 2.81 (t, 1H); 3.12 (m, 2H); 3.42 (dd, 1H); 3.85-4.02 (m, 4H); 4.88 (dd, 1H); 5.52 (dd, 1H);

10 4-(((1R)-1-((1R)-1-(4-Carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethyl)carbamoyl)piperidine-1-carboxylic acid tert-butylester (0.171 g; 0.219 mmol) was dissolved in methylene chloride/trifluoroacetic acid (1:1; 10 ml) and stirred 20 min at room temperature. The solvent was removed
15 in vacuo and the residue was dissolved in methylene chloride and evaporated in vacuo three times (3 x 5 ml) to afford 0.175 g of the title compound.


¹H-NMR (CDCl₃) (selected peaks) δ 3.37 (m, 2H); 3.44 (dd; 1H); 4.80 (m, 1H); 5.55 (dd, 1H).

20 ESMS: (M+H)⁺: 682.4

HPLC: (method B): R_t = 35.08 min.


The following compound may be prepared using the same method as in example 21 using methylamine instead of benzylamine:

(2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methyl-5 carbamoyl]-2-(2-naphthyl)ethyl)amide:




The following compound may be prepared using the same method as in example 21 using dimethylmethylamine instead of benzylamine:

(2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-dimethylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methyl-carbamoyl]-2-(2-naphthyl)ethyl)amide:




The following compound may be prepared according to method K, analogously to example 23, using (2E)-5-tert-butoxycarbonylamino-5-methylhex-2-onic acid instead of 3-tert-butoxycarbonylaminomethylbenzoic acid.

5 (2E)-5-Amino-5-methyl-N-((1R)-1-(N-((1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylhex-2-enoic acid amide:




The following compound may be prepared analogously to example 23, using methylmagnesium bromide instead of lithium boronhydride and (2E)-5-tert-butoxycarbonylamino-5-methylhex-2-onic acid instead of 3-tert-butoxycarbonylaminomethylbenzoic acid.

(2E)-5-Amino-5-methyl-N-((1R)-1-(N-((1R)-1-(2-hydroxy-2-methylpropoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylhex-2-enoic acid



CLAIMS:

1. A compound of general formula I



I

5 Wherein






n is 0 or 1;

m is 1 or 2;


p is 0, 1 or 2;

A is

10



or




wherein R¹ is hydrogen or C₁₋₆-alkyl,

W is =O or =S;



201

B is




wherein R^2 is hydrogen or C_{1-6} -alkyl,
 W' is $=\text{O}$ or $=\text{S}$;

5 D is



wherein R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

- 10 R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(\text{CH}_2)_i-\text{U}-(\text{CH}_2)_j-$, wherein i and j independently are 1 or 2, and U is $-\text{O}-$, $-\text{S}-$ or a valence bond;
 M is $-\text{O}-$, $-\text{S}-$, $-\text{CH}=\text{CH}-$,





optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

o, r and t are independently 0, 1, 2, 3 or 4;


q and s are independently 0 or 1;

5 and r+s+t is 1, 2, 3 or 4;

E is hydrogen,




or




wherein L is hydrogen, -OR⁹, -CONR⁹R¹⁰, C₁₋₆-alkyl optionally substituted with hydroxy or C₁₋₆-alkoxy,

10 or L is



or



wherein R⁹ and R¹⁰ are independently hydrogen, C₁₋₆-alkyl or together form -(CH₂)_k-U'-(CH₂)_l-,

wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5 or 6,

U' is -O-, -S- or a valence bond;

X is -N(R¹¹)-, -O- or -S-,

V is -C(R¹²)= or -N=,


Y is -C(R¹³)= or -N=,

20 Z is -C(R¹⁴)= or -N=,

R¹², R¹³ and R¹⁴ independently are hydrogen, -COOR¹⁵, -CONR¹⁶R¹⁷, -(CH₂)_vNR¹⁶R¹⁷, -(CH₂)_uOR¹⁵, halogen, hydroxy, C₁₋₆-alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is hydrogen or



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(CH_2)_{k'}-Z-(CH_2)_{l'}-$ where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;

Z is $-O-$, $-S-$ or a valence bond;

b is 0 or 1;


a and d are independently 0, 1, 2, 3 or 4;

and $a+b$ is 1 to 4;

15 Q is $>CR^{22}-$ or $>N-$,

wherein R^{22} is hydrogen or C_{1-6} -alkyl,


F is



wherein R^{23} is hydrogen or C_{1-6} -alkyl,


20 W' is $=O$ or $=S$;

G is hydrogen,



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

5 J is




optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

or a pharmaceutically acceptable salt thereof, and the compounds
 10 of formula I comprise any optical isomers thereof, in the form of
 separated, pure or partially purified optical isomers or racemic
 mixtures thereof.

205

2. A compound of general formula I



I


Wherein

n is 0 or 1;

m is 1 or 2;

p is 0, 1 or 2;

A is




10 wherein R¹ is hydrogen or C₁₋₆-alkyl,

W is =O or =S;



with the proviso that when n is 1 and A is a secondary or tertiary amide or a secondary or tertiary amine, B or F is not an amide or an amine;

B is



wherein R^2 is hydrogen or C_{1-6} -alkyl,
 W' is $=O$ or $=S$;


5 D is



wherein R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

10 R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and U is $-O-$, $-S-$ or a valence bond;

M is -O-, -S-, -CH=CH-,




optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

5 o, r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;


and r+s+t is 1, 2, 3 or 4;

E is hydrogen,



10 wherein L is hydrogen, -OR⁹, -CONR⁹R¹⁰, C₁₋₆-alkyl optionally substituted with hydroxy or C₁₋₆-alkoxy,

or L is



wherein R⁹ and R¹⁰ are independently hydrogen, C₁₋₆-alkyl or
15 together form -(CH₂)_k-U'-(CH₂)_l-,

wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5 or 6,

U' is -O-, -S- or a valence bond;

X is -N(R¹¹)-, -O- or -S-,

20 V is -C(R¹²)= or -N=,


Y is $-C(R^{13})=$ or $-N=$,

Z is $-C(R^{14})=$ or $-N=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$, $-(CH_2)_vNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is hydrogen or



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(CH_2)_{k'}-Z-(CH_2)_{l'}-$ where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;

Z is $-O-$, $-S-$ or a valence bond;

b is 0 or 1;


a and d are independently 0, 1, 2, 3 or 4;

and $a+b$ is 1 to 4;

20 Q is $>CR^{22}-$ or $>N-$,


wherein R^{22} is hydrogen or C_{1-6} -alkyl,

F is



wherein R^{23} is hydrogen or C_{1-6} -alkyl,
 W' is $=\text{O}$ or $=\text{S}$;


5 G is hydrogen,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or
 C_{1-6} -alkoxy;

210


J is



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

5 or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

3. A compound of general formula I



10

I


Wherein

n is 0 or 1;

m is 1 or 2;

15 p is 0, 1 or 2;

A is




wherein R^1 is hydrogen C_{1-6} -alkyl,

W is =O or =S;

5 with the proviso that when A contains a secondary or tertiary amide or a secondary or tertiary amine, either B or F do not contain a secondary or tertiary amide or a secondary or tertiary amine;

B is





10

wherein R^2 is hydrogen or C_{1-6} -alkyl,

W' is =O or =S;


D is



wherein R³, R⁴, R⁵, R⁶, R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy or 5 aryl;

R⁵ and R⁶, R⁶ and R⁷, R⁵ and R⁸ or R⁷ and R⁸ optionally forming -(CH₂)_i-U-(CH₂)_j-, wherein i and j independently are 1 or 2, and U is -O-, -S- or a valence bond;

M is -O-, -S-, -CH=CH-,





optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

o, r and t are independently 0, 1, 2, 3 or 4;


q and s are independently 0 or 1;

15 and $r+s+t$ is 1, 2, 3 or 4;


E is hydrogen,




or



wherein L is hydrogen, $-\text{OR}^9$, $-\text{CONR}^9\text{R}^{10}$, C_{1-6} -alkyl optionally substituted with hydroxy or C_{1-6} -alkoxy,
5 or L is



or



wherein R^9 and R^{10} are independently hydrogen, C_{1-6} -alkyl or together form $-(\text{CH}_2)_k-\text{U}'-(\text{CH}_2)_l-$,
wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5
10 or 6,

U' is $-\text{O}-$, $-\text{S}-$ or a valence bond;

X is $-\text{N}(\text{R}^{11})-$, $-\text{O}-$ or $-\text{S}-$,

V is $-\text{C}(\text{R}^{12})=$ or $-\text{N}=$,


Y is $-\text{C}(\text{R}^{13})=$ or $-\text{N}=$,

15 Z is $-\text{C}(\text{R}^{14})=$ or $-\text{N}=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-\text{COOR}^{15}$, $-\text{CONR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_u\text{NR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_v\text{OR}^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl
20 optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is hydrogen or



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, 5 hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(\text{CH}_2)_{k'}-\text{Z}-(\text{CH}_2)_{l'}$ -where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;

Z is $-\text{O}-$, $-\text{S}-$ or a valence bond;

b is 0 or 1;






10 a and d are independently 0, 1, 2, 3 or 4;

and $a+b$ is 1 to 4;


Q is $>\text{CR}^{22}-$ or $>\text{N}-$,

wherein R^{22} is hydrogen or C_{1-6} -alkyl,

F is



or




15

wherein R^{23} is hydrogen or C_{1-6} -alkyl,


W' is $=\text{O}$ or $=\text{S}$;

G is hydrogen,



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

5 J is




optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

or a pharmaceutically acceptable salt thereof, and the compounds
10 of formula I comprise any optical isomers thereof, in the form of
separated, pure or partially purified optical isomers or racemic
mixtures thereof.


4. A compound of formula I according to any one of claims 1-3
wherein m and p are independently 1 or 2;

G is



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and A, B, D, J, E, F and n are defined as in the 5 preceding claims.

5. A compound of formula I according to any one of the preceding claims
wherein A is




10 wherein R¹ is hydrogen or C₁₋₆-alkyl,

W is =O or =S; and

B, D, G, J, E, F, n, m and p are defined as in the preceding claims.

6. A compound of formula I according to any one of the preceding 15 claims
wherein D is



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

o, r and t are independently 0, 1, 2, 3 or 4;


q and s are independently 0 or 1;

5 and r+s+t is 1, 2, 3 or 4;

and A, B, G, J, E, F, n, m and p are defined as in the preceding claims.

7. A compound of formula I according to any one of the preceding claims


10 wherein G and J independently are



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and A, B, D, E, F, n, m and p are defined as in the preceding claims.

15 8. A compound of formula I according to any one of the preceding claims

wherein D is



wherein R⁵, R⁶, R⁷ and R⁸ independently are hydrogen or


20 C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R⁵ and R⁶, R⁶ and R⁷, R⁵ and R⁸ or R⁷ and R⁸ optionally forming

—(CH₂)_i—U—(CH₂)_j—, wherein i and j independently are 1 or 2, and

U is —O—, —S— or a valence bond;

25 M is —O—, —S—, —CH=CH—, or



optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;


o, r and t are independently 0, 1, 2, 3 or 4;

5 q and s are independently 0 or 1;

and r+s+t is 1, 2, 3 or 4;

and A, B, G, J, E, F, n, m and p are defined as in the preceding claims.


9. A compound of formula I according to any one of the preceding
10 claims
wherein D is



wherein R⁵, R⁶, R⁷ and R⁸ independently are hydrogen or
C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy or
15 aryl;

R⁵ and R⁶, R⁶ and R⁷, R⁵ and R⁸ or R⁷ and R⁸ optionally forming
-(CH₂)_i-U-(CH₂)_j-, wherein i and j independently are 1 or 2, and
U is -O-, -S- or a valence bond;

M is -O-, -S-, -CH=CH-, or



20

optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

o, r and t are independently 0, 1, 2, 3 or 4;

q is 1;

s is 0 or 1;



and r+s+t is 1, 2, 3 or 4;

and A, B, G, J, E, F, n, m and p are defined as in the preceding 5 claims.


10. A compound of formula I according to any one of the preceding claims

wherein E is


10 E is hydrogen,




or



wherein L is hydrogen, $-\text{OR}^9$, $-\text{CONR}^9\text{R}^{10}$, C_{1-6} -alkyl optionally substituted with hydroxy or C_{1-6} -alkoxy



or



15 wherein R^9 and R^{10} are independently hydrogen, C_{1-6} -alkyl or together form $-(\text{CH}_2)_k-\text{U}'-(\text{CH}_2)_l-$,

wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5 or 6,

U' is $-\text{O}-$, $-\text{S}-$ or a valence bond;

20 X is $-\text{N}(\text{R}^{11})-$, $-\text{O}-$ or $-\text{S}-$,

V is $-\text{C}(\text{R}^{12})=$ or $-\text{N}=$,

Y is $-\text{C}(\text{R}^{13})=$ or $-\text{N}=$,


Z is $-\text{C}(\text{R}^{14})=$ or $-\text{N}=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-\text{COOR}^{15}$, $-\text{CONR}^{16}\text{R}^{17}$,

25 $-(\text{CH}_2)_v\text{NR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_v\text{OR}^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(CH_2)_{k'}-Z-(CH_2)_{l'}$ -where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;

Z is $-O-$, $-S-$ or a valence bond;

b is 0 or 1;


a and d are independently 0, 1, 2, 3 or 4;

and $a+b$ is 1 to 4;

15 and A , B , D , G , J , F , n , m and p are defined as the preceding claims.

11. A compound of formula I according to any one of the preceding claims

wherein E is



wherein

X is $-N(R^{11})-$, $-O-$ or $-S-$,

V is $-C(R^{12})=$ or $-N=$,

Y is $-C(R^{13})=$ or $-N=$,

Z is $-C(R^{14})=$ or $-N=$,


R^{12} , R^{13} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$, $-(CH_2)_uNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

5 R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;


and A, B, D, G, J, F, n, m and p are defined as in the preceding claims.

10 12. A compound of formula I according to any one of the preceding claims,

wherein E is



or



wherein

15 X is $-N(R^{11})-$ or $-O-$,

V is $-C(R^{12})=$ or $-N=$,

Y is $-N=$,

Z is $-C(R^{14})=$ or $-N=$,

R^{12} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$,


20 $-(CH_2)_uNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

25 and A, B, D, G, J, F, n, m and p are defined as in the preceding claims;

13. A compound of formula I according to any one of the preceding claims

wherein E is



5 wherein

X is $-N(R^{11})-$ or $-O-$,

V is $-C(R^{12})=$,

Y is $-N=$,

Z is $-C(R^{14})=$ or $-N=$,

10 R^{12} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$, $-(CH_2)_uNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl, R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

and A, B, D, G, J, F, n, m and p are defined as in the preceding claims;

14. A compound of formula I according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 selected from the group consisting of

20 (3R) Piperidine-3-carboxylic acid ((1R,2E)-4-hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)amide,

3-Aminomethyl-N-((1R,2E)-4-hydroxymethyl-1-(2-naphthyl)methyl-5-phenylpent-2-enyl)benzamide,

25 Piperidine-4-carboxylic acid (1-([1-(3-carbamoyl-

[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)amide,

5-((1R)-1-[(2R)-2-(Piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester,

5-(1-[2-(3-Aminomethylbenzoyl)-3-(2-naphthyl)propionyl-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazol-3-carboxylic acid ethylester,

5-((1R)-1-[(2R)-2-(3-Aminomethylbenzoylamino)-3-(2-naphthyl)propionylamino]-2-phenylethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester, or the trifluoroacetic acid salt thereof,

Piperidine 4-carboxylic acid [(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]amide,

3-Aminomethyl-N-[(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]benzamide,

4-Amino-4-methyl-pent-2-enoic acid [(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]amide,

(3R)-Piperidine 3-carboxylic acid [(1R)-1-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenylethylcarbamoyl)-2-(2-naphthyl)ethyl]amide,

3-Aminomethyl-N-((1R, 2E; 4S)-4-carbamoyl-5-(2-naphthyl)-1-(2-naphthyl)methylpent-2-enyl)benzamide,

Piperidine-4-carboxylic acid ((1R,2E,4S)-4-carbamoyl-5-(2-naphthyl)-1-(2-naphthyl)methylpent-2-enyl)amide,

N-((1R)-1-(((1R)-1-(((1S)-5-Amino-1-(dimethylcarbamoyl)pentylcarbamoyl)-2-phenylethoxy)methyl)-2-(2-naphthyl)ethyl)-3-aminomethylbenzamide,

N-((1R,4S)-4-(((1S)-5-Amino-1-(dimethylcarbamoyl)pentyl)carbamoyl)-1-((2-naphthyl)methyl)-2-oxo-5-phenylpentyl)-3-aminomethylbenzamide,

N-((1R,2R,4S)-4-(((1S)-5-Amino-1-(dimethylcarbamoyl)pentyl)carbamoyl)-2-hydroxy-1-(2-naphthyl)methyl-5-phenylpentyl)-3-aminomethylbenzamide,

Piperidine-3-carboxylic acid ((1R, 2R, 4S)-4-(((1S)-5-amino-1-(dimethyl-carbamoyl)pentyl)carbamoyl)-2-hydroxy-1-(2-naphthyl)methyl)-5-phenylpentyl)amide,

15 5-((1R)-1-(N-Methyl-N-((2R)-3-(2-naphthyl)-2-(piperidin-4-yl-carbonylamino)propionyl)amino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester,

5-((1R)-1-(N-((2R)-2-(3-Aminomethylbenzoylamino)-3-(2-naphthyl)propionyl)-N-methylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethylester,

5-((1R)-1-(N-((2R)-2-(3-Aminomethylbenzoylamino)-3-(2-naphthyl)propionyl)-N-methylamino)-2-phenylethyl)-[1,3,4]oxadiazole-2-carboxylic acid amide,

(2E)-5-Amino-5-methylhex-2-enoic acid ((1R)-1-[N-methyl-N-((1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)-ethyl)carbamoyl]-2-(2-naphthyl)ethyl)amide,

4-Amino-4-methylpent-2-enoic acid N-[(1R)-1-(N-methyl-N-[(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]-N-methylamide,

(2E)-4-Amino-4-methylpent-2-enoic acid N-[(1R)-1-(N-methyl-N-5 [(1R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl]amide,

3-Aminomethyl-N-[(1R)-1-(N-[(1R)-1-(((dimethylcarbamoyl)methoxy)methyl)-2-phenylethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl]-N-methylbenzamide,

10 5-[(1R)-1-(((2R)-2-(((2E)-4-Amino-4-methylpent-2-enoyl)methylamino)-3-(2-naphthyl)propionyl)methylamino)-2-phenylethyl]-[1,3,4]-oxadiazole-2-carboxylic acid amide

Piperidine-4-carboxylic acid N-methyl-N-(1-(methyl-[1-(3-methyl-[1,2,4]oxadiazole-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-15 (2-naphthyl)ethyl)amide,

Piperidine-4-carboxylic acid N-(1-(N-[methyl-N-[1-(3-methyl-[1,2,4]oxadiazole-5-yl)-2-(2-naphthyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)amide,

5-(1-[N-2-(piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl]-N-methylamino)-2-(2-naphthyl)ethyl)-20 [1,2,4]oxadiazole-3-carboxylic acid (2-propyl)ester,

5-(1-[N-(2-(Piperidine-4-carbonylamino)-3-(2-naphthyl)propionyl)-N-methylamino]-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid, trifluoro acetic acid,

25 Piperidine-4-carboxylic acid (1-(N-[1-(3-methylcarbamoyl-

[1,2,4]oxadiazol-5-yl)-2-(2-naphthyl)ethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)amide,

(2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-benzylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methyl-5 carbamoyl]-2-(2-naphthyl)ethyl)amide,

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-[N-((1R)-1-benzyl-2,5-dihydroxypentyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl)-N-methylamide,

3-Aminomethyl-N-((1R)-1-(N-[(1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylbenzamide,

Piperidine-4-carboxylic acid ((1R,2E)-4-hydroxymethyl-5-(2-naphthyl)-1-((2-naphthyl)methyl)pent-2-enyl)amide,

Piperidine-4-carboxylic acid ((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-(1-phenethyl-1H-tetrazol-5-yl)ethylcarbamoyl)ethyl)amide,

Piperidine-4-carboxylic acid N-methyl-N-((1R)-2-(2-naphthyl)-1-((1R)-2-(2-naphthyl)-1-thiocarbamoylethylcarbamoyl)ethyl)amide,

Piperidine-4-carboxylic acid ((1R)-1-((1R)-1-(4-carbamoyl-5-phenyl-1,3-thiazol-2-yl)-2-(2-naphthyl)ethylcarbamoyl)-2-(2-naphthyl)ethyl)amide,

(2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-methylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl)amide,

25 (2E)-5-Amino-5-methylhex-2-enoic acid (1-[N-(1-(3-


dimethylcarbamoyl-[1,2,4]oxadiazol-5-yl)-2-phenylethyl)-N-methylcarbamoyl]-2-(2-naphthyl)ethyl)amide,

(2E)-5-Amino-5-methyl-N-((1R)-1-(N-((1R)-1-(2-hydroxyethoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylhex-2-enoic acid amide,

(2E)-5-Amino-5-methyl-N-((1R)-1-(N-((1R)-1-(2-hydroxy-2-methylpropoxymethyl)-2-phenylethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylhex-2-enoic acid,

or a pharmaceutically acceptable salt thereof or all possible optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof.


15. The compound of the general formula



wherein D, G and J are as defined in claim 1;
or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

16. The compound according to claim 15, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;


o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;

and $r+s+t$ is 1, 2, 3 or 4.


17. The compound according to any one of claims 15 or 16, wherein

15 J is




18. The compound according to any one of claims 15, 16 or 17, wherein

G is



19. The compound of the general formula




wherein D, J, G, E, m and p are as defined in claim 1;

5 or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

20. The compound according to claim 19, wherein

10 D is




wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or

C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R⁵ and R⁶, R⁶ and R⁷, R⁵ and R⁸ or R⁷ and R⁸ optionally forming
 -(CH₂)_i-U-(CH₂)_j-, wherein i and j independently are 1 or 2, and
 5 U is -O-, -S- or a valence bond;

M is -O-, -S-, -CH=CH-,




optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy;

10 o, r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;


and r+s+t is 1, 2, 3 or 4.

21. The compound according to any one of claims 19 or 20, wherein J is




22. The compound according to any one of claims 19, 20 or 21, wherein

G is




23. The compound according to any one of claims 19, 20, 21 or 22, wherein

5 E is hydrogen,



wherein L is hydrogen, $-OR^9$, $-CONR^9R^{10}$, C_{1-6} -alkyl optionally substituted with hydroxy or C_{1-6} -alkoxy



10 wherein R^9 and R^{10} are independently hydrogen, C_{1-6} -alkyl or together form $-(CH_2)_k-U'-(CH_2)_l-$,

wherein k and l independently are 1, 2 or 3, and k+l is 3, 4, 5 or 6,

U' is $-O-$, $-S-$ or a valence bond;

15 X is $-N(R^{11})-$, $-O-$ or $-S-$,

V is $-C(R^{12})=$ or $-N=$,


Y is $-C(R^{13})=$ or $-N=$,

Z is $-C(R^{14})=$ or $-N=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$, $-(CH_2)_vNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

5 R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is



10 wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(CH_2)_{k'}-Z-(CH_2)_{l'}$, where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;


15 Z is $-O-$, $-S-$ or a valence bond;

b is 0 or 1;

a and d are independently 0, 1, 2, 3 or 4;

and $a+b$ is 1 to 4.

24. The compounds of the general formula




20 wherein D, J, G, E, m and p are as defined in claim 1;

or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

5 25. The compound according to claim 24, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or
10 aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

o , r and t are independently 0, 1, 2, 3 or 4;


q and s are independently 0 or 1;

20 and $r+s+t$ is 1, 2, 3 or 4.

26. The compound according to any one of claims 24 or 25, wherein


234

J is




27. The compound according to any one of claims 24, 25 or 26, wherein

5 G is




28. The compound according to any one of claims 24, 25, 26 or 27, wherein

E is hydrogen,



wherein L is hydrogen, $-OR^9$, $-CONR^9R^{10}$, C_{1-6} -alkyl optionally substituted with hydroxy or C_{1-6} -alkoxy



wherein R^9 and R^{10} are independently hydrogen, C_{1-6} -alkyl or together form $-(CH_2)_k-U'-(CH_2)_l-$,

wherein k and l independently are 1, 2 or 3, and $k+l$ is 3, 4, 5 or 6,

U' is $-O-$, $-S-$ or a valence bond;

X is $-N(R^{11})-$, $-O-$ or $-S-$,

V is $-C(R^{12})=$ or $-N=$,


Y is $-C(R^{13})=$ or $-N=$,

10 Z is $-C(R^{14})=$ or $-N=$,

R^{12} , R^{13} and R^{14} independently are hydrogen, $-COOR^{15}$, $-CONR^{16}R^{17}$, $-(CH_2)_vNR^{16}R^{17}$, $-(CH_2)_uOR^{15}$, halogen, hydroxy, C_{1-6} -alkyl, phenyl, oxazol-5-yl, 5-methyl-[1,2,4]oxadiazol-3-yl,

R^{11} , R^{15} , R^{16} and R^{17} independently are hydrogen or C_{1-6} -alkyl optionally substituted with aryl, and u and v are independently 0 or 1, 2, 3, 4, 5 or 6;

K is



wherein R^{18} , R^{19} , R^{20} and R^{21} are independently hydrogen, C_{1-6} -alkyl optionally substituted with halogen, amino, C_{1-6} -alkylamino, hydroxy or aryl; R^{18} and R^{19} , R^{18} and R^{21} , R^{19} and R^{20} or R^{20} and R^{21} optionally forming $-(CH_2)_{k'}-Z-(CH_2)_{l'}-$ where k' and l' independently are 1, 2 or 3, and $k'+l'$ are 3, 4, 5 or 6;


Z is $-O-$, $-S-$ or a valence bond;

25 b is 0 or 1;

a and d are independently 0, 1, 2, 3 or 4;


and a+b is 1 to 4.

29. The compounds of the general formula



wherein D, J, G, E, m and p are as defined in claim 1;
or a pharmaceutically acceptable salt thereof, and the compounds
5 of formula I comprise any optical isomers thereof, in the form of
separated, pure or partially purified optical isomers or racemic
mixtures thereof.


30. The compounds of the general formula



wherein D, J, R¹, G, and R¹² are as defined in claim 1;
10 or a pharmaceutically acceptable salt thereof, and the compounds
of formula I comprise any optical isomers thereof, in the form of
separated, pure or partially purified optical isomers or racemic
mixtures thereof.

31. The compound according to claim 30, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;


o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;

15 and $r+s+t$ is 1, 2, 3 or 4.


32. The compound according to any one of claims 30 or 31, wherein

J is




33. The compound according to any of claims 30, 31 or 32, wherein

G is



34. The compounds of the general formula




5 wherein D, J, R⁴ and m are as defined in claim 1;

or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof,

10 35. The compound according to claim 34, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming
 5 $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and
 U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or
 10 C_{1-6} -alkoxy;


o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;


and $r+s+t$ is 1, 2, 3 or 4.

36. The compound according to any one of claims 34 or 35, wherein

15 J is



37. The compound of the general formula




wherein D , R^2 , J , R^1 , G , R^9 , R^{10} and p are as defined in claim 1;

or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

5 38. The compound according to claim 37, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or
10 aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming $-(\text{CH}_2)_i-\text{U}-(\text{CH}_2)_j-$, wherein i and j independently are 1 or 2, and U is $-\text{O}-$, $-\text{S}-$ or a valence bond;

M is $-\text{O}-$, $-\text{S}-$, $-\text{CH}=\text{CH}-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;


o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;

20 and $r+s+t$ is 1, 2, 3 or 4.


39. The compound according to any one of claims 37 or 38, wherein

J is




40. The compound according to any of claims 37, 38 or 39, wherein

G is




41. The compound of the general formula



wherein D, R^2 , J, R^1 , G, and p are as defined in claim 1;
 or a pharmaceutically acceptable salt thereof, and the compounds
 of formula I comprise any optical isomers thereof, in the form of
 10 separated, pure or partially purified optical isomers or racemic
 mixtures thereof.

42. The compound according to claim 41, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or
5 C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming
- $(CH_2)_i$ -U- $(CH_2)_j$ -, wherein i and j independently are 1 or 2, and
U is -O-, -S- or a valence bond;

10 M is -O-, -S-, -CH=CH-,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or
 C_{1-6} -alkoxy;


o, r and t are independently 0, 1, 2, 3 or 4;

15 q and s are independently 0 or 1;

and $r+s+t$ is 1, 2, 3 or 4.


43. The compound according to any one of claims 41 or 42, wherein

J is




44. The compound according to any one of claims 41, 42 or 43, wherein

G is




5 45. The compound of the general formula



wherein D, R², J, R¹, G, and p are as defined in claim 1;
or a pharmaceutically acceptable salt thereof, and the compounds
of formula I comprise any optical isomers thereof, in the form of
separated, pure or partially purified optical isomers or racemic
10 mixtures thereof.

46. The compound according to claim 45, wherein


D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming
5 $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and
U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,




optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or
10 C_{1-6} -alkoxy;

o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;


and $r+s+t$ is 1, 2, 3 or 4.

47. The compound according to any one of claims 45 or 46, wherein
15 J is




48. The compound according to any of claims 45, 46 or 47, wherein

G is hydrogen,



49. The compound of the general formula




wherein D, R², J, R¹, G, and p are as defined in claim 1;

5 or a pharmaceutically acceptable salt thereof, and the compounds of formula I comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

50. The compound according to claim 49, wherein


10 D is



wherein R^5 , R^6 , R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl optionally substituted with halogen, amino, hydroxy or aryl;

R^5 and R^6 , R^6 and R^7 , R^5 and R^8 or R^7 and R^8 optionally forming
 5 $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently are 1 or 2, and
 U is $-O-$, $-S-$ or a valence bond;

M is $-O-$, $-S-$, $-CH=CH-$,



optionally substituted with halogen, amino, hydroxy, C_{1-6} -alkyl or
 10 C_{1-6} -alkoxy;


o , r and t are independently 0, 1, 2, 3 or 4;

q and s are independently 0 or 1;

and $r+s+t$ is 1, 2, 3 or 4.


51. The compound according to any one of claims 49 or 50, wherein

15 J is



52. The compound according to any one of claims 49, 50 or 51,
 wherein

G is



53. A pharmaceutical composition comprising, as an active ingredient, a compound of the general formula I according to any one of claims 1-52 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

54. A composition according to claim 53 in unit dosage form, comprising from about 10 to about 200 mg of the compound of the general formula I or a pharmaceutically acceptable salt thereof.

55. A pharmaceutical composition for stimulating the release of growth hormone from the pituitary, the composition comprising, as an active ingredient, a compound of the general formula I according to any one of claims 1-52 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

56. A method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula I according to any one of claims 1-52 or a pharmaceutically acceptable salt thereof.

57. A method of increasing the rate and extent of growth, the milk and wool production, or for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula I according to any one 5 of claims 1-52 or a pharmaceutically acceptable salt thereof.

58. A method according to claim 56 or 57, wherein the effective amount of the compound of the general formula I or pharmaceutically acceptable salt or ester thereof is in the range of from about 0.0001 to about 100 mg/kg body weight per day, 10 preferably from about 0.001 to about 50 mg/kg body weight per day.

59. Use of a compound of the general formula I according to any one of claims 1-52 or a pharmaceutically acceptable salt thereof for the preparation of a medicament.

60. Use of a compound of the general formula I according to any 15 one of claims 1-52 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulating the release of growth hormone from the pituitary.

61. Use of a compound of the general formula I according to any one of claims 1-52 or a pharmaceutically acceptable salt thereof 20 for the preparation of a medicament for administration to animals to increase their rate and extent of growth, to increase their milk and wool production, or for the treatment of ailments.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00045

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 5/02, A61K 38/05, A61K 38/06 // C07K 14/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9517423 A1 (NOVO NORDISK A/S), 29 June 1995 (29.06.95) --	1-13,53-55, 59-61
P,X	Proc. Natl. Acad. Sci., Volume 92, November 1995, (USA), R.S. McDowell et al., "Growth hormone secretagogues: Characterization, efficacy, and minimal bioactive conformation", pages 11165-11169 --	1-13,37-40, 49-52,53-55, 59-61
P,X	Endocrinology, Volume 136, No 12, 1995, K.A. Elias et al., "In Vitro Characterization of Four Novel Classes of Growth Hormone-Releasing Peptide" page 5694 - page 5699 -- -----	1-13,37-40, 49-52,53-55, 59-61

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 April 1996

Date of mailing of the international search report

30 -04- 1996

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Teddy Ercégovic

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00045

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 56-58
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☒ Claims Nos.: 1-4 in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The formulation of claims 1-4 is so complicated because of the long lists of cascading substituents that it does not comply with Article 6 PCT prescribing that claims shall be clear and concise. For this reason the search has mainly been limited to the examples.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

01/04/96

PCT/DK 96/00045

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)